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Summary 
Peptide-based drug delivery systems and therapeutics have gained an enormous attention during 
the last ten years. Progress in this field will lead to site specific delivery, improved receptor 
affinities, efficient cellular uptake and/or nuclear targeting. Thus, in this research project, metal 
conjugates of some bioactive peptides were synthesized and biologically tested in order to evaluate 
the effects of these metal moieties on the biological activities such as the cellular uptake, nuclear 
targeting and binding affinity, of these selected peptides. 
 
In this study, the two redox active metallocenes, ferrocene and cobaltocenium and in addition the 
cytotoxic platinum were chosen as metal labels. The investigated peptides were the Simian Virus 40 
nuclear localisation signal (NLS), the HIV transactivator of transcription (TAT) peptide and the 
small regulatory peptide, the neurotensin (NT). Metal conjugates of these bioactive peptides were 
successfully synthesized by solid phase peptide synthesis (SPPS) which was used not only for the 
covalent bonding of the metallocenes to the peptides but also for the complexation of platinum to the 
peptides and fluorescence labelling with FITC. Comprehensive characterisation of the synthesized 
bioconjugates was carried out by various techniques such as NMR, RP-HPLC, MS and 
electrochemistry. 
 
The cellular uptake and nuclear localisation of the metallocene-NLS and -TAT bioconjugates was 
monitored by fluorescence microscopy in living liver cancer cells (Hep G2). The metallocene-NLS 
conjugates were efficiently internalized by the cells and were localised in the nuclei of the Hep G2 
cells. The metallocene moiety is responsible for the enhanced cellular uptake of these bioconjugates 
and the NLS transports the organometallic species into the nuclei. This is the first example of the 
directed nuclear delivery of ferrocene and the cobaltocenium cation, by conjugation to the NLS 
peptide. The use of the scrambled NLS sequence (NLSscr) abolishes the nuclear targeting property of 
the conjugates. All metallocene-NLS bioconjugates were found to be non-toxic in concentrations up 
to 1mM in the WST-1 proliferation assay.  
 
In case of the metallocene-TAT bioconjugates, the ferrocene moiety plays a role in the escape of 
the conjugate from the endosomes, which is an advantage because the utility of TAT peptide as a 
vector for cellular delivery is limited by its inability to escape from the endosomes. Moreover, these 
peptides are toxic in higher concentration due to cell membrane perturbation. This was also 
demonstrated in the present study using the WST-1 proliferation assay. 
 
In the last part of the project, metal conjugates of wild type NT(8-13) and the modified 
Pseudoneurotensin (pNT) were synthesized and tested for their binding affinity to the NTR1 
receptors in the HT 29 adenocarcinoma cell line. Replacement of Arg8-Arg9 with Lysines in pNT led 
to a significant decrease in the binding affinity. The metal-NT bioconjugates showed good receptor 
affinity especially the cobaltocenium-NT conjugate (IC50=2.3nM). In this case, the lipophilicity of 
the metallocene bioconjugate may facilitate the crossing of the blood brain barrier which is a 
limiting factor in any centrally intended therapy. The Pt-NT bioconjugate also showed good affinity 
(IC50=6.8nM) for the receptors. Thus, such bioconjugates may be specifically and selectively 
delivered to the tumour tissues that overexpress the neurotensin receptors.  
 
In conclusion, the optimised synthesis procedures for the studied metals and the peptides were 
established. The biological studies demonstrate a great potential of these metals for the improvement 
of the biological functions of the tested peptides especially for use as vectors for cellular uptake and 
targeted nuclear delivery. This represents a novel application of bioorganometallic chemistry in 
biological systems. 
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Zusammenfassung 
Peptid-basierten Wirkstoff-Transportsystemen und Therapeutika  wurde in den letzten zehn Jahren 
große Aufmerksamkeit gewidmet. Fortschritte auf diesem Gebiet versprechen gezielten Transport, 
erhöhte Rezeptor-Affinitäten, effiziente zelluläre Aufnahme und/oder Aufnahme in den Zellkern. 
Dementsprechend wurden in dieser Arbeit Metallkonjugate einiger biologisch aktiver Peptide 
synthetisiert und auf ihre biologische Wirksamkeit getestet. Ziel war es, die Effekte der Metall-
Struktureinheiten auf die biologische Aktivität wie Aufnahme in die Zelle bzw. den Zellkern sowie 
die Bindungsaffinität der Peptide zu untersuchen. 
 
In dieser Arbeit wurden die redox-aktiven Metallocene Ferrocen und Cobaltocen sowie das 
cytotoxische Platin als Metall-Komponenten ausgewählt. Untersuchte Peptide waren das 
Kernlokalisierungssignal (NLS) des viralen Antigens SV 40 T, das HIV-TAT-Peptid (transactivator 
of transcpition) und das kleine regulatorische Peptid Neurotensin (NT). Metallkonjugate dieser 
biologisch aktiven Peptide wurden mit Hilfe der Festphasen-Peptidsynthese (SPPS) erhalten. Diese 
Methode wurde nicht nur Knüpfung der kovalenten Bindung zwischen Peptid und Metallocen 
verwendet, sondern auch zur Komplexierung des Platins durch die Peptide und zur Fluoreszenz-
Markierung mittels FITC. Die synthetisierten Biokonjugate wurden mit unterschiedlichen Techniken 
wie NMR, RP-HPLC, MS und elektrochemischen Verfahren umfassend charakterisiert. 
 
Die Aufnahme der Metallocen-NLS- und –TAT-Biokonjugate in die Zelle und den Zellkern wurde 
durch Fluoreszenzmikroskopie in lebenden Leberkrebszellen (Hep G2) verfolgt. Die Metallocen-
NLS-Konjugate wurden effizient in die Zellen aufgenommen und waren in den Zellkernen der Hep 
G2-Zellen lokalisiert. Die Metallocen-Struktureinheit ist verantwortlich für die erhöhte Aufnahme 
dieser Biokonjugate in die Zelle wohingegen die NLS-Einheit den Transport der organometallischen 
Spezies in den Zellkern ermöglicht. Dies ist das erste Beispiel eines gezielten Transportes von 
Ferrocen und des Cobaltocenium-Kations in den Zellkern durch Konjugation mit dem NLS-Peptid. 
Die Verwendung einer intern vertauschten NLS-Sequenz (NLSscr) unterbindet die zielgerichtete 
Aufnahme in den Zellkern. Alle NLS-Biokonjugate waren im WST-1 Proliferations-Assay nicht 
toxisch. 
 
Im Fall der Metall-TAT-Biokonjugate spielt die Ferrocen-Einheit eine Rolle beim Verlassen der 
Endosome durch Konjugate, was insofern vorteilhaft ist, als daß die Wirksamkeit von TAT als 
Vektor für den zellulären Transport durch seine Unfähigkeit, die Endosomen zu verlassen, 
eingeschränkt ist. Darüberhinaus sind diese Peptide in höherer Konzentration toxisch aufgrund einer 
Störung der Struktur der Zellmembran. Auch dies wurde in der vorliegenden Arbeit mit Hilfe des 
WST-1 Proliferations-Assay nachgewiesen. 
 
Im letzten Teil des Projektes wurden Metall-Konjugate vom Wildtyp NT(8-13) sowie vom 
modifizierten Pseudoneurotensin (pNT) synthetisiert und bezüglich ihrer Bindungsaffinität zu 
NTR1-Rezeptoren in der HT 29 Ardenokarzinomzelllinie getestet. Substitution in pNT von Arg8-
Arg9 durch Lysine führte zu einer signifikanten Erniedrigung der Bindungsaffinität. Die Metall-NT-
Biokonjugate zeigten eine hohe Rezeptoraffinität, insbesondere das Cobaltocenium-NT-Konjugat 
(IC50=2.3nM). In diesem Fall könnte die Lipophilie der Metallocen-Biokonjugate eine Überwindung 
der Blut-Hirn-Schranke ermöglichen, die einen limitierenden Faktor in jeder auf das ZNS zielenden 
Therapie darstellt. Das Pt-NT-Biokonjugat zeigte ebenso eine hohe Affinität (IC50=6.8nM) für die 
Rezeptoren. Dementsprechend könnten solche Biokonjugate insbesondere und selektiv in 
Tumorgewebe transportiert werden, in denen Neurotensin-Rezeptoren überexprimiert sind. 
 
In dieser Arbeit wurden die optimierte Synthesemethoden für die Konjugate der untersuchten 
Metalle und Peptide etabliert. Die biologischen Untersuchungen zeigen das große Potential dieser 
Metalle für die Verbesserung der biologischen Wirkungen der untersuchten Peptide insbesondere für 
die Verwendung als Vektoren für die zelluläre und die gerichtete Aufnahme in den Zellkern. Dies 
stellt eine neue Anwendung der Bioorganometallchemie in biologischen Systemen dar. 
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 Introduction 
Drug discovery nowadays is a multidisciplinary effort linking various fields of science 
together. Fields like Inorganic and organometallic chemistry that were once thought to be 
incompatible with biology have found evergrowing relevance in biological systems. This 
has resulted in certain hybrid fields of science such as the Bioorganometallic chemistry. 
 
Last 50 years have seen Bioorganometallic chemistry emerging as an established field of 
science[1-5] and in very simple terms it deals with biologically significant organometallic 
species with at least one direct metal-carbon (M-C) bond. Bioorganometallic chemistry has 
integrated the classical organometallic chemistry to biology, biochemistry, medicine and 
biotechnology to a remarkable extent.[1, 2, 7-10] Recent advances in fields such as human 
genetics especially the discovery of genetic basis of various pathological conditions,[11-14] 
the 3-D structural analysis by X-ray crystallography[15] and other sophisticated 
spectroscopic techniques have, no doubt, brought the implication of metals in biological 
systems to the forefront of drug discovery for diagnostic as well as therapeutic purposes. 
This has in turn fuelled the enthusiasm of the bioorganometallic scientists to apply their 
expertise to the field of biology. In this regard, the development and improvement of 
synthetic methods, the efficiency of synthesis achieved by combinatorial synthesis and the 
possibility to synthesize biological material artificially have played very important roles. 
Inorganic and organometallic moieties can now be easily incorporated in a variety of 
biomolecules thereby allowing diverse structural and functional studies under physiological 
conditions.[10, 16-23] Bioorganometallic derivatives of amino acids and peptides have been 
comprehensively reviewed.[16, 24] One elegant way to incorporate an organometallic moiety 
in biomolecules such as amino acids and peptides is through covalent bonding.[24-32] This 
usually involves the most reactive nucleophilic functions of peptides or proteins such as the 
free N-termini of peptides, the primary amino groups of lysine residues and the thiol groups 
of cysteine residues.[33] The lysine residues are particularly interesting since they are 
generally abundant and due to their hydrophilic character are usually located on the surface 
of proteins.[34]  
 
Many organometallic compounds exhibit high stability in aerobic aqueous media and 
therefore, can be applied as novel applications in biology and medicine. The unique 
properties of the organometallic moiety bound to biomolecules can be exploited in a number 
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 of ways such as the sensitive detection of the biomolecule,[35]  biomolecular sensing and 
switching devices,[36, 37]  other detection  techniques such as  atomic absorption 
spectroscopy[38, 39] and electrochemistry,[40, 41] various diagnostic tools,[19, 20, 42-44] nuclear 
medicine and radiopharmaceuticals.[45] 
 
To review all the organometallic moieties and their applications in biological systems is 
beyond the scope of this thesis. The discovery and elucidation of the structure of 
ferrocene,[46] a metallocene, is considered as the starting point for modern organometallic 
chemistry.[47] Therefore later descriptions are limited to the metallocenes specially ferrocene 
and cobaltocenium derivatives and in addition, to platinum analogues which are also a 
subject of research presented in this thesis. 
 
Metallocenes 
In simple terms, metallocenes are a class of compounds in which a transition metal ion in 
the +2 valence state is sandwiched between two cyclopentadienyl rings (scheme 1.1). They 
are electrically neutral compounds soluble in organic solvents and insoluble in water. It is 
important to mention here the metallocene dihalides that contain the transition metal ion in 
the +4 valence state with two cyclopentadienyl ligands and two halide or pseudohalide 
ligands. The metallocene dihalides slowly undergo hydrolysis in water with the release of 
one or both halide ions.  
 
M M
X
X
(1) (2)  
Scheme 1.1: Structure of Metallocene (1) and Metallocene dihalide (2), where M indicates the metal. 
 
Metallocenes are small, rigid and hydrophobic molecules that, in principle, can easily 
cross cellular membranes. Even when derivatized with polar substituents, the metallocenes 
can still cross the cell membrane.[48] The cyclopentadienyl rings, though resembling simple 
aromatic rings, are rather thick being as thick as they are wide.[48] In this way they may 
mimic the binding of aromatic compounds but can block the active site due to their bulk. 
However the most remarkable characterising feature of the metallocenes is the fact that the 
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 metal atom is so tightly bound to the cyclopentadienyl rings that it cannot be dislodged 
without destroying the whole structure of the metallocene. Metallocenes of transition metals 
have been extensively studied especially in the field of catalysis.[49, 50] One special area of 
interest is the study of the electronic properties of the metallocenes and their derivatives.[51, 
52] The metallocenes have also found interesting applications in physical and material 
chemistry. 
 
However, as remarked earlier, the biggest challenge and special interest of the 
bioorganometallic chemist is to exploit the potential of these unique compounds in the 
domain of biology. This field is still in its infancy where not all the molecular mechanisms 
are well understood. This has resulted in a diversity of biological applications in order to 
assess the true potential in each field of study. A great deal of research is still required to 
properly understand the various activities and their mechanisms at molecular and cellular 
level.  
Applications of Metallocenes in Biological Systems 
This will be a brief account of the most documented and exploited applications of the 
metallocenes and their derivatives in biology. We can broadly divide these applications into 
following major themes: 
1. Radiopharmaceuticals and Nuclear Medicine 
A recent review by Schubiger and Schibli[45] has very well outlined the current use and the 
future potential of organometallic radiopharmaceuticals. Radioactive metallocenes have 
found diagnostic and therapeutic applications in nuclear medicine.  
 
The synthesis and use of Ruthenocene derivatives containing 97Ru or 103Ru that even 
impart organ specificity has been described as early as the late 1970s.[53-55] Examples of half 
sandwiched complexes with a radioactive metal centre coordinated with carbonyl ligands 
are already available in the literature. The cyclopentadienyl metal core is highly lipophilic 
and has a great potential for functionalisation to incorporate certain therapeutics that require 
passage through the blood brain barrier such as the steroids and analogues of the 
neuropeptides. Wenzel et al. reported for the first time the synthesis of cyclopentadienyl 
derivative of 99mTc.[56] Recently, Alberto et al. reported a unique aqueous based synthesis of 
this  compound[57]  and thus enabled the  handling of such compounds in aqueous media at a  
3 
 physiological pH for the functionalisation of biomolecules.  
 
R
99mTc
OC CO
CO  
Scheme 1.2: Half sandwich compound with 99mTc as reported by Wenzel and Alberto. 
 
The labelling of small receptor targeting molecules such as those for neuroreceptors, with 
99mTc has been the focus of research.[58] Some of these compounds have been used for 
dopamine receptor imaging.[59, 60] Katzenellenbogen et al. have recently reported the 
potential of η5-cyclopentadienyltricarbonyl rhenium and technetium derivatives of tropane 
for Dopamine transporter (DAT) imaging.[61] Other classes of targeted receptors include the 
serotonergic receptors[62] and the steroid receptors for progestrone and oestrogen.[63-71] In 
addition, the potential of 103Ru-ruthenocene-glycine derivatives as surrogate for 123I-
hippuran has been described.[72] 
 
M
O
N CO2CH3
R
O
O O
Re
OC CO
CO
(1) (2)
OC
OC CO
 
Scheme 1.3: Organometallic derivative of tropane for DAT (1) and of progesterone (2). 
 
2. Detectors and Biosensors 
Metallocenes exhibit characteristic physicochemical properties that can be used as detection 
and analytical tools by the use of various techniques like spectroscopy such as IR and 
electrochemistry. 
 
In this regard, ferrocene can be definitely singled out due to its stability and reversible 
redox activity.  
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Fe (II) Fe (III)
- e
+ e
ferrocene                              ferrocenium  
Scheme 1.3: Redox behaviour of ferrocene.  
 
It is used as a chemical sensor for cations and anions.[73-75] Ferrocene mediated electron 
transfer in glucose oxidase has led to its use in the monitoring of the glucose levels in the 
blood.[23, 42, 76, 77] Ferrocene has also been employed for selective recognition of nucleotides 
and DNA for use in DNA sensors[78-82] on the basis of its electrochemical properties. 
Various applications of ferrocene labelled DNA oligomers as gene sensors have been 
reviewed in detail.[47] 
 
Using the IR spectroscopy, Jaouen’s group has developed the technique of 
carbonylmetalloimmunoassay (CMIA) for the quantification of antiepileptic drugs.[83, 84] It 
is a nonradioactive immunoanalytical method in which a metal carbonyl probe is chemically 
attached to the hapten to form a tracer. This tracer competes with the analyte for specific 
antibody binding in a liquid phase immunoassay. The remaining free tracer is extracted and 
quantified with FTIR spectroscopy on the basis of the strong absorption bands of the 
carbonyl ligands. Recently, an improved version of the CMIA which is solvent free, 
biocompatible and more sensitive has been reported.[85] 
3. Anticancer therapy 
The metallocenes are considered as a new class of antitumour organometallic compounds 
since they are structurally and chemically unrelated to the well known platinum based 
anticancer drugs. The antitumour metallocenes can be, in a very broad sense, further divided 
into metallocene dihalides and metallocene derivatives of ferrocene.  
 
Metallocene dihalides (see scheme 1.1 (2), where M= Ti, V, Mo, Nb) have exhibited a 
wide spectrum of activity against a range of tumours in experimental models.[86-89] 
Titanocene dichloride has been most extensively studied and is the only metallocene 
dihalide to have entered clinical trials.[90-92] Unfortunately, the efficacy of Cp2TiCl2 in 
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 advanced renal cell carcinoma or metastatic breast cancer was too low to be pursued 
further.[93] Although, interactions with DNA are postulated mechanism of action for these 
compounds,[94-98] the different  chemical stabilities at  physiological pH[97, 99] and  the 
different  coordination chemistries[95, 98, 100, 101] of these metallocenes indicate significantly 
different modes of action for  each metallocene.[101] Recent studies on these compounds 
with proteins such as transferrin,[102, 103] human serum albumin,[104] protein kinase C,[88] 
topoisomerase II[88, 105] and glutathione[106] have confirmed that the interaction with proteins 
and amino acids play a role in the anticancer activity of the metallocene dihalides. Active 
research is still going on in this area. 
 
Conflicting reports exist in literature about the cytotoxicity of ferrocene compounds. 
Köpf-Maier, in 1984,[107] demonstrated for the first time the antitumour activity of some 
ferrocenium complexes. Although much speculation exists, until now, the mechanism of 
action remains an ambiguity. In this regard, the chemistry of ferrocene/ferrocenium 
complexes should not be overlooked.  
 
The early reports on the antineoplastic activity of ferrocene[108-110] describe ferrocene 
derivatives with organic moieties that themselves are most probably responsible for the 
effects observed. It is interesting to note that nitrogen mustard ferrocenes had a stimulatory 
effect on tumour growth.[109]Other studies suggesting specified targets such as DNA 
cleavage[111] and Topoisomerase inhibition[112] are ex-vivo studies. Polymeric ferrocene 
conjugates with antiproliferative activity have also been reported.[113]  
 
It was shown that the antitumour effects of ferrocene were dependent on the unstability 
of the ferrocenium cation[114] and that stabilizing substituents lead to a decrease in the 
antitumour activity. More recently, Osella et al., have demonstrated that only the 
ferrocenium species (FeIII) are able to inhibit the growth of Ehrlich ascites tumour cells in-
vivo. This inhibitory activity is independent of the redox potentials of the tested compounds. 
This report confirmed the early reports that Fe(II) bearing ferrocenes are unable to inhibit 
cell growth.[115-117] The ferrocenium salts induce DNA damage. However the cytotoxicity of 
ferrocenium salts is not due to direct linkage to DNA but their ability to generate oxygen 
active species which induce oxidative DNA damage. The possibility of intercalation is ruled 
out. Osella showed that ferrocenium salts in physiological solutions generate OH. radicals. 
A direct relation between generation of OH. radicals and DNA damage could not be 
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 established by these independent tests. The in-vivo cytotoxicity could be caused by an 
immediate attack on the cell membranes carried out by OH. radicals generated in 
extracellular fluid by ferrocenium salts. The same group has recently reported the generation 
of hydroxy radicals upon degradation of the ferrocenium derivative (DEMFc+) (scheme 1.4) 
in cells. The iron ions liberated during this decomposition had a synergistic effect on the 
activity of bleomycin.[118] 
 
Fe BF4
 
Scheme 1.4: Decamethylferrocenium tetrafluoroborate. 
 
A recent study has indicated a non-apoptotic pathway for the action of ferrocene 
derivatives.[119] Another study has attributed the antitumour activity of ferrocene to its 
immune-stimulatory effect that is mediated by redox active signalling.[120] Indeed a very 
recent observation by Kraatz shows that as the redox potential increased, the toxicity of 
ferrocene pyrazole conjugates decreased.[121] 
 
All these diverse studies lead to the conclusion that complex mechanisms are involved in 
the antitumour activity of ferrocene derivatives and which are highly dependent on the 
chemical properties of the conjugates. The neutral ferrocene has to undergo some kind of 
activation before an antitumour effect is elicited. 
 
4. Functional and Structural mimetics of proteins 
The earliest amino acid derivatives of ferrocene were reported by Schlögel et al.[122] Since 
then attempts have been made not only to make different derivatives from chemical point of 
view but also in order to employ the unusual characteristics of the metallocenes to mimic 
the structural features of peptides.[30, 31] One of the first examples was the substitution of the 
phenylalanine residue with either ferrocenylalanine or with cymantrenylalanine moieties 
(scheme 1.5) in peptides such as enkephalin,[123, 124] substance P,[125] bradykinin[125] and 
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 angiotensin.[126, 127] However in most cases this substitution resulted in decreased activities 
or lower affinity indicating that although ferrocene does resemble the aromatic system but 
interacts poorly with the receptors. 
 
Fe
H2
C
COOH
NH2
H2
C
Mn
OC CO
CO
COOH
NH2
(1) (2)  
Scheme 1.5: Ferrocenylalanine (Fer) 1 and Cymantrenylalanine (Cym) 2. 
 
Many enzymatic reactions involve oxidation or reduction of bound substrates and are 
dependent on electron transfer processes. Modified metalloproteins have been used to get a 
better understanding of these processes.[128, 129] The electron transfer is dependent upon the 
structure of the proteins. The β-sheets allow easier electron transfer than the α-helical 
peptides.[130] The secondary and tertiary structure of the protein as well as the hydrogen 
bonding[131] influences the rate of electron transfer. Ferrocene can be used as a sensitive 
electrochemical probe to detect small structural changes.[132] An extensive description on the 
redox behaviour of ferrocenoylpeptides has been reported by Kraatz.[133] 
 
Protein scaffolds play an important role in the biological function[134] and are usually 
involved in the recognition of the protein by its receptor and subsequent conformational 
changes that enable the binding and elicitation of a physiological response. These scaffolds 
include the α-helices, β-turns and β-sheets which constitute the secondary structural 
elements of the peptide.[135] Structural features of ferrocene amino acids and peptides has 
been extensively studied.[31, 136-138] Ferrocenes are recognized as organometallic 
scaffolds[139] for molecular receptors. Hirao et al. have reported dipeptide podand 
derivatives of ferrocene that exhibited helical molecular arrangement in the crystal packing 
of those molecules with intramolecular hydrogen bonds.[137, 140-142] Oligoproline derivatives 
of ferrocene that have a helical structure have also been reported and their redox behaviour 
studied.[138] 
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 β-turns are responsible for the proper folding of the protein which in turn is essential for 
the biological function. β-turns align the β-strands in either parallel manner (usually called 
the α/β barrel arrangement) for example in Triosephosphate isomerase or in the antiparallel 
manner such as in staphylococcal nuclease. Pyruvate kinase has both parallel and 
antiparallel β-sheet arrangement.  
 
 
                 (A)                                                                     (B) 
Scheme 1.6: Parallel (A) and antiparallel (B) arrangement of β-sheets. The β-strands are indicated by 
green arrows and the orange rectangles indicate the α-helices.  
 
Due to their important structural function, the β-turns have been extensively studied. 
Artificial β-turn mimetics have been reported.[139, 143, 144] In this regard the metallocenes are 
very good candidates since the two Cp rings could be functionalised and the whole 
metallocene structure could then serve as a turn mimetic. 
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Scheme 1.7: Metallocene β-turn mimetics. 
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 Bioorganometallic chemists have realised this potential of metallocenes and some reports 
of β-turn mimetics appeared in the literature recently.[145-147] This may allow not only an 
understanding of the folding of peptides but may ultimately be used as peptidic sensors e.g. 
based on the redox behaviour of ferrocene. 
 
5. Miscellaneous applications in Biochemistry, Microbiology and Medicine 
Metallocenes especially ferrocene have been tested in-vivo in man and other species.[148-150] 
Due to their lipophilicity they have been valuable tools in the study of absorption, 
distribution and utilization of iron. Compounds have been reported[151, 152] which upon oral 
administration are metabolized and the Fe+2 is stored in the liver. 
 
Metallocene derivatives have been shown to inhibit certain metabolizing enzymes and 
thus they may allow the study of the enzyme active site as well as the receptor site. β-
Ferrocenylalanine is an inhibitor of phenylalanine hydroxylase and phenylalanine 
decarboxylase.[153, 154] Another derivative, ferrocenylcholine inhibits the hydrolysis of 
butyrylcholine by horse serum butyrylcholinestrase.[155]  
 
Another unusual application of metallocenes has been their use for histochemical and 
immunological analyses. A dextran derivative of ferrocene has been employed in the 
indirect identification of lectin receptors via electron microscopy.[156] Cais and co-workers 
have developed the non-isotopic metalloimmunoassays for the quantification of antigens 
and antibodies.[157, 158] 
 
Metallocenes can be used to modify antibiotics in order to address the problem of 
resistance. A series of ferrocenylpenicillins and ferrocenyl cephalosporins have been 
reported.[159, 160] In addition a ferrocene derivative bearing both penicillin and cephalosporin 
rings has also exhibited antibiotic activity. Various other ferrocene derivatives have shown 
antimicrobial activity against some bacteria, yeasts and fungi. More recently, the 
antibacterial activity of some ferrocenyl and cobaltocenium peptide bioconjugates has been 
studied.[161] 
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 Cobaltocenium derivatives 
Though much research had been consecrated to ferrocene and its derivatives as well as the 
radioactive metallocenes and the antitumour metallocene dihalides, not many reports about 
the cobaltocenium derivatives and their application in biological systems could be found in 
literature. Cobaltocenium derivatives are isostructural with ferrocene although naturally 
bearing a positive charge.[162] 
 
Co PF6
 
Scheme 1.8: Cobaltocene usually isolated as hexafluorophosphate salt.  
 
Incorporation of metals in dendritic structures has led to new compounds with novel 
magnetic, electronic, photophysical or catalytic properties.[163-166] Ferrocene is the most 
widely used redox active moiety incorporated in dendrimeric structures.[165, 167, 168] These 
dendrimeric structures can be employed as electrode surface modifiers,[169] as 
electrochemical biosensors,[170] as multisite guests for supramolecular assemblies[171] and as 
sensors for anions.[172] Cobaltocenium is a good candidate for incorporation or 
functionalization of dendritic structures by the virtue of its excellent stability and reversible 
one electron reduction to give the neutral cobaltocene. In fact, the synthesis and the redox 
properties of cobaltocenium dendrimers have been reported.[169, 173] 
 
Cobaltocenium salts are highly resistant to oxidation even in the presence of strong 
oxidizing agents like fuming nitric acid, potassium permanganate and ozone.[174] Due to 
their stability and robustness the cobaltocenium salts could be used as models for the 
synthesis and application of derivatives of other metallocenes especially those of ferrocene. 
As noted earlier, ferrocene derivatives act as potent haptens[175] but they undergo enzymatic 
degradation. Therefore, the use of stable cobaltocenium salts has been proposed. In addition, 
the cobaltocenium derivatives could also be used in biological systems as electron dense 
markers in electron microscopy and X-ray crystallography and as carriers of 60Co in 
radiotherapy. Recently some cobaltocenium derivatives have been reported as anion 
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 sensors.[176] Cobaltocenium has also been used for reference potential calibration in 
microdisk electrodes.[177] 
 
Platinum derivatives 
The antitumour properties of Cisplatin were reported by Rosenberg and co-workers in 
1969.[178, 179] Cisplatin is one of the rare curative drugs. Other analogues of platinum that are 
now in use for the treatment of various solid tumours are carboplatin and oxaliplatin.  
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Scheme 1.9: Clinically used platinum drugs, Cisplatin (1), Carboplatin (2) and Oxaliplatin (3). 
 
These platinum compounds exert their anticancer activity by covalently modifying 
cellular DNA.[180, 181] Cisplatin and carboplatin form similar adducts with DNA covalently 
coordinating with two adjacent guanines on the same strand forming an intrastrand cross 
link.[182] This in turn bends the DNA resulting in local distortion that triggers a chain of 
cellular events that ultimately cause the death of the cell.[183] The severe side effects of these 
drugs include nephrotoxicity, ototoxicity, neurotoxicity and myelosuppression. In addition, 
poor solubility also limits the effectiveness of cisplatin. As such, some lipophilic Pt (IV) 
complexes have been reported as prodrugs yielding Pt (II) on reduction in-vivo by 
endogenous biomolecules such as glutathione and ascorbate.[184] 
 
One more major problem encountered in therapy with cisplatin is the resistance of the 
cancer cells to the drug due to reduced cellular accumulation, increased production of 
intracellular platinophiles such as glutathione and metalothionein as detoxifiers, enhanced 
DNA repair and increased tolerance of DNA to platination.[185-187] 
 
One interesting approach has been recently reported in which carboplatin analogues were 
conjugated through a polyethyleneglycol linker to the nuclear localisation signal in order to 
facilitate nuclear targeting.[188] Though nuclearly localised, the conjugates were less active 
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 than the free drug forming less Pt-DNA adducts. The study supported the hypothesis that 
carboplatin, unlike cisplatin, require cytosolic activation prior to its binding to DNA. An 
excellent review by Lippard explains the cellular processing of the platinum anticancer 
drugs.[189] 
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Scheme 1.10: An NLS-PEG analogue of carboplatin.[189] 
 
Recently, peptide conjugates of platinum (II) complexes have been synthesized on the solid 
support and characterized.[190-193] Some platinum-PNA bioconjugates have also been 
reported[194] as potential antisense agents.  
 
From the above description the biological potential of organometallic compounds is evident. 
To incorporate various organometallics in bioactive peptides for either discovery of novel 
bioactivity or modulation of a biological activity is an extremely tempting objective. 
However, for targeted drug design, the understanding of the mechanisms by which the 
organometallics exert their effects is fundamentally important. Many of the underlying 
mechanisms of activity for most organometallics are far from being fully understood, 
emphasizing the need for an effort at a molecular and cellular level. Although the site of 
action of most of the antitumour organometallics especially those of ferrocene derivatives 
has been suggested to be intranuclear, the passage of these compounds through various 
biological membranes such as the cell membrane and the nuclear membrane has not been 
thoroughly investigated. Passage through these biomembranes in intact cells is a 
prerequisite for any non-receptor mediated biological action. Similarly, bioselectivity is 
highly desired especially in case of anticancer agents. Lack of selectivity is often a limiting 
factor in the use of chemotherapeutics. 
 
Following description shall concentrate on the peptides that play a role in cellular uptake 
and nuclear localisation such as the TAT and NLS peptides. Finally a brief account of small 
regulatory peptides especially neurotensin shall be presented. All these peptides i.e. nuclear 
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 localisation signal (NLS), transactivator of transcription (TAT) and neurotensin (NT) are the 
project of research presented in this thesis. 
  
 
Transport across biological membranes 
Biological membranes are natural barriers and they ensure compartmentalisation in living 
systems. They control the influx and efflux of solutes from cells and from cell organelles. 
The basic structural unit of these biological membranes is the phospholipid bilayer.  
 
 
Scheme 1.11: Lipid bilayer cell membrane showing polar heads and non-polar tails. 
 
The delivery of any compound across a given membrane is a challenge. The passage of 
drugs and gene therapy agents (DNAs or plasmids) through various biological barriers such 
as the cell or nuclear membrane still poses a problem, especially when a large population of 
cells is targeted. To effect cellular entry, various transfection agents like PEI 
(polyethyleneimine) or cell permeablising agents like digitonin or direct injections into the 
cytoplasm are commonly used. Low molecular weight compounds, including many drugs, 
may enter cells by passive diffusion. However, P-glycoproteins usually pump them out of 
the cells before they gain access to the nucleus. Enhanced cellular, but not nuclear, uptake 
of radio-metals has been achieved by conjugation to peptides for receptor-mediated 
uptake.[195-198] In gene therapy, the transport of the therapeutic DNA from cytoplasm to the 
nucleus is an additional complication because it is inefficient in most cases and it is 
considered as major limiting step in non-dividing cells. Physical methods that facilitate 
transport into the nuclei include microinjection, liposome fusion or electroporation of 
conjugates containing an NLS and a drug.[199-202]  
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 Transport across the cell membrane 
One of the main constraints in the design of drugs whose interaction targets are located 
within the host cells is cell membrane permeability. Only compounds with a narrow range 
of molecular size, net charge and polarity are able to diffuse through the lipid bilayers of the 
cell membranes and thus reach their pharmacological target.[203] 
 
There are two major pathways by which macromolecules gain cellular entry namely 
endocytosis (scheme 1.12) and direct translocation through the membrane by a mechanism 
described as penetration.[204] 
 
 
Scheme 1.12: The process of endocytosis with self sealing property of the cell membrane. 
 
Endocytosis is an energy dependent mechanism that involves the adsorption of the 
macromolecule on the surface of the membrane or membrane associated receptors followed 
by vesicle formation. The vesicular machinery then directs the internalised molecules to 
appropriate compartments for either destruction or recycling. Delivery of molecules via the 
endocytosis pathway is often limited by insufficient endosomal escape, restricted diffusion, 
degradation or lack of nuclear entry.  The second mode of entry into the cells is not well 
understood but appears to occur through an energy independent mechanism. Both endocytic 
and non-endocytic modes of uptake have been observed.[205] 
 
Short peptides derived from the protein-transduction domains can be internalized in most 
cell types and are usually known as the cell penetrating peptides (CPP).[204, 206] These CPPs 
are either basic segments of RNA or DNA-binding proteins[207-209] such as pAntp(43-58) 
and TAT (48-60) or artificial peptides such as transportan,[210] model amphipathic peptide 
(MAP)[211] or other sequence based constructs[212, 213] such as oligoarginines. These peptides 
can act as cytosolic delivery vectors for both low and high molecular weight cargos like 
FITC,[208] proteins,[214-216] oligonucleotides,[217] peptide nucleic acids,[204] liposomes[218] and 
even particulates.[219]  
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 Transactivator of Transcription (TAT peptide)  
The transactivator of transcription (TAT) is an 86 residue protein derived from the human 
immunodeficiency virus (HIV). TAT trans-activates certain viral genes and is essential to 
viral replication. Independent studies using bacterially expressed[220] and chemically 
synthesized[221] TAT protein, respectively, showed that this protein can enter cells when 
added to the growth medium of cells in culture. The domain necessary for translocation 
across the membrane was determined to be the basic domain of the TAT protein.[208] The 
shortest sequence that is essential for internalisation is shown to be TAT (48-57) which has 
a sequence GRKKRRQRRR. The positively charged arginine residues are essential to the 
membrane penetration ability. This has been further confirmed by the fact that TAT-peptide 
mimetic composed of seven arginine residues[222] is able to gain entry into the cells. It has 
been concluded that the cationic guanidine moiety on arginine side chains confers the 
membrane translocating properties that are not observed in peptides containing similar 
amino acids such as lysine, ornithine or histidine.[223] The detailed mechanism of cellular 
internalisation of TAT peptide still remains to be determined.[224] Recent studies indicate an 
energy dependent endocytosis as the major mode of entry for TAT peptides.[225-228] However 
in addition to endocytosis, other mechanisms might exist as well.[229, 230] Although TAT 
allows efficient cellular uptake of molecules, the limiting factors are the inability of these 
conjugates to escape the endosomes and their subsequent lysosomal degradation. 
 
Transport across the nuclear membrane 
The eukaryotic nucleus is surrounded by the nuclear envelope that is composed of the inner 
and the outer membranes. The outer membrane is continuous with the endoplasmic 
reticulum (ER). Primarily, the nuclear membrane separates the DNA and the genetic 
machinery from the cytoplasm. The nuclear membrane is studded with large numbers of 
pores of huge size and elaborate construction.[231] Each nucleus has several thousand pores 
forming channels between the cytoplasm and the nucleoplasm for the trafficking of 
macromolecules in and out of the nucleus. These pores are usually referred as the nuclear 
pore complexs (NPC). Small molecules like ions diffuse freely through the central aqueous 
channel of the NPC in an energy independent way. Macromolecules are usually actively 
transported across the NPCs in a temperature sensitive and energy dependent manner. 
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 Recent work has led to a better understanding of the mechanisms involved in the 
transport of proteins and RNA in and out of the nuclei.[232, 233] This transport involves 
nuclear localisation signals (NLSs) or export signals that bind to nuclear transport proteins 
(e.g Karyopherins α and β), which mediate their movement in or out of the nucleus through 
the nuclear pore complexes. 
 
The nuclear transport across the NPC is a complex process and has been actively 
investigated[234] (see review articles[231, 235, 236]). There are a number of pathways available 
for nuclear import. Görlich recently reported on the kinetics of the translocation though the 
NPC.[237] A recent study by Read et al. showed that non-viral gene transfer based on NLS 
depends on the type of the NLS peptide, morphology of the DNA and the method of 
incorporation of the NLS peptide to the DNA.[238] 
 
Nuclear Localisation Signal (NLS) 
Selective nuclear import is mediated by nuclear localisation signals. The simian virus 40 
(SV 40) large T antigen peptide was the first nuclear localisation signal that was 
identified[239] and was actively investigated by Feldherr.[240] Since then a large number of 
NLSs have been identified and they all include a stretch of basic amino acids. The SV 40 
large T antigen NLS has one short cluster of basic amino acids and is therefore called the 
monopartite sequence. There are bipartite such as nucleoplasmin[241] and tripartite such as 
the PrnA NLSs[242] that contain two or three clusters of basic amino acids respectively. 
 
The shortest functional sequence of the SV 40 large T antigen NLS is a heptapeptide 
with the sequence PKKKRKV and has a wide range of cargo import functions.[243] This 
NLS(126-132) binds to the Karyopherin α/β1 heterodimer, also known as importin α/β.[244] 
The karyopherin-α provides the NLS binding site[236] whereas the karyopherin-β, docks the 
heterotrimeric complex through the nuclear pore complex [245] and is subsequently 
translocated into the nucleus through the pore by an energy dependent mechanism that 
involves Ran.[246] (scheme 1.13).  
 
17 
  
Scheme 1.13: Nuclear transport of NLS with a cargo through the nuclear pore complex. 
 
The nuclear localisation signals have been used for gene delivery,[247] anti-gene PNA,[248] 
oligonucleotides,[249, 250] photosentisizers,[251] gold nanoparticles[252, 253] and radiolabelled 
intercalator.[254] To function properly, the NLS conjugate has to be located in the 
cytoplasm.[237] NLS conjugates, however, are not readily incorporated into the cells. 
Inefficient entry into the cells[255] or inability to escape endosomes[252] has been reported. 
More complicated conjugates have been devised to circumvent the problem of cellular 
uptake, for example NLS conjugates with lipophilic membrane anchoring peptide domains 
or Au clusters.[243, 251]  
 
Small Regulatory Peptides 
A number of human tumour tissues overexpress certain types of high affinity receptors on 
their surface. These receptors can be exploited for in-vivo imaging and therapy by the use of 
the so-called tumour affine peptides and their derivatives. These are small regulatory 
peptides and have been a continuous focus of attention since the last decade. These peptides 
can be used to localise tumours in-vivo and more recently to treat cancer with peptide 
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 receptor radiation therapy (PRRT). The regulatory peptide receptors are overexpressed in 
various neuroendocrine tumours, breast, prostrate, gastrointestinal tract, pancrease and brain 
tumours. An excellent review appeared recently which highlights the tumours that 
overexpress the regulatory peptide receptors and the various regulatory/tumour affine 
peptides such as the gastrin releasing peptide, somatostatin, cholecystokinin-2, neurotensin, 
neuropeptide Y, bombesin, vasoactive intestinal peptide (VIP), substance P and the 
glucagon-like peptide.[256] 
 
These regulatory peptides are usually small peptides (between 1 to 15 kDa). Due to their 
low molecular weight they can better penetrate into tumour tissues and can be rapidly 
cleared from the normal tissue and circulation. As such they lead to better tumour-to-
background ratios than higher molecular weight compounds like monoclonal antibodies and 
their constructs. Therefore, radiolabelled neuropeptides can be used for imaging and therapy 
purposes.[257] The application of radiolabelled somatostatin and vasoactive intestinal peptide 
analogues for successful imaging of neuropeptide postive receptors has been reported.[258, 
259] In addition, the development of further small regulatory peptides such as bombesin, 
cholecystokinin, neurotensin and substance P[260, 261] as potential imaging agents is actively 
pursued.  
 
Of special interest are the gut peptides that function in an endocrine, paracrine and 
autocrine fashion. The gut peptides (gastrin, vasoactive intestinal peptide, neurotensin and 
bombesin) regulate, the growth, in-vivo and in-vitro, of some cancers in the gastrointestinal 
tract and pancreas.[263] Moreover, neurotensin plays important role in the central nervous 
system such as in nociception, pathophysiology of schizophrenia and in the mechanisms of 
action of antipsychotic drugs. 
Neurotensin (NT) 
Neurotensin is a brain and gastrointestinal peptide that carries out important central and 
peripheral functions in the organism. It is a 13 amino acid peptide (ELYGNKPRRPYIL) 
and was first isolated from bovine hypothalamus.[264] It has dual functions of a 
neurotransmitter/neuromodulator in the central nervous system and of a local hormone in 
the periphery. At central level, it is a neuromodulator of dopamine transmission[265] and 
anterior pituitary hormone secretion. It also has potent hypothermic and analgesic effects in 
the brain.[266, 267] In the periphery, neurotensin exerts paracrine and endocrine modulation of 
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 the gastrointestinal tract and of the cardiovascular system.[268] Neurotensin has been shown 
to influence growth in a number of cancerous and non-cancerous cells by enhancing the 
proliferative effects of growth factors without itself inducing proliferation. Neurotensin for 
example, can potentiate the proliferative effects of insulin on human fibroblasts.[269] 
  
In the brain, NT is exclusively found in nerve cells, fibers and terminals. Whereas in the 
periphery, it is mostly found in the endocrine N-cells of the intestinal mucosa.[264] Most of 
the actions of neurotensin are mediated through its interaction with the cell surface 
receptors. These receptors include the NTR1, NTR2 and the recently discovered NTR3 
receptors.[270] The NTR1 and NTR2 receptors belong to the family of G-protein coupled 
receptors[271-273] with 7 transmembrane domains. The NTR3 receptor is different from these 
two receptors and has a single transmembrane domain.[274, 275] The NTR1 and NTR2 
receptors have been studied in detail by radioligand-binding assays.[276] NTR1 receptor has a 
high binding affinity and a low capacity whereas the NTR2 receptors show low affinity and 
high capacity.[277, 278] 
 
The structure activity studies have shown that the hexapeptide, NT(8-13) is equipotent or 
even more potent than the wild type NT in binding to the neurotensin receptors while 
maintaining its biological and pharmacological functions.[279] Point mutations have shown 
that the two guanidio groups of Arginines, the hydroxyphenyl group of tyrosine and the side 
chains of the isoleucine and leucine as well as the free carboxylic group at the C-terminal 
are necessary for the activity of NT.[280]  
 
 
Scheme 1.14: A 3-D model of Neurotensin (8-13) and NTR1 complex.[281] 
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 The activation of the NT receptors by binding of NT leads to the production of cGMP 
and cAMP or activation of the phosphatidylinositol pathway and calcium mobilisation.[282] 
The NT receptor is internalised by endocytosis after its interaction with the peptide and is 
destroyed.[270] In prostrate cancer cell lines, NT is metabolised by endogenous proteases.[283] 
The peptide bonds between Arg-Arg, Pro-Tyr and Tyr-Ile are the usual sites of cleavage by 
various endopeptidases.[284, 285] In human plasma the NT is rapidly degraded despite its high 
affinity.[286] 
 
Over the years a large number of neurotensin analogues have been prepared and tested 
for various purposes in therapy as well as in tumour and receptor imaging. Neurotensin 
derivatives can serve as potent analgesics and antipsychotics especially in treatment of 
Parkinson’s disease and Schizophrenia.[287, 288] A number of NT derivatives have been 
investigated for their use in the detection, localisation and treatment of malignant human 
tumours.[289-293] However the rapid degradation of NT derivatives and their inability to cross 
the blood brain barrier are major limiting factors.[264] Non-peptidic analogues have been 
reported.[294] In addition, various stabilised derivatives of the peptide have also been actively 
investigated.[295-298] 
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 Objectives of present study 
There is a huge potential of organometallic compounds in biology. Various bioactive 
peptides seem attractive targets. Incorporation of biologically functional organometallics in 
the exploitation of these targets will result in novel compounds with specific applications in 
detection, diagnosis and therapy or in lead compounds for further research. 
 
The main objectives of the present research are: 
• Solid phase peptide syntheses of various metal-peptide bioconjugates which include the 
metallocene (ferrocene and cobaltocenium carboxylic acids) bioconjugates of the SV 40 
T antigen nuclear localisation signal peptide (NLS), Transactivator of transcription 
(TAT) and Neurotensin (NT) peptides. In addition, to carry out the solid phase syntheses 
of Platinum bioconjugates of NLS and NT. 
 
• Optimization of syntheses procedures for metal as well as fluorescence labelling. 
 
• Comprehensive characterization of the synthesized bioconjugates by means of NMR, 
HPLC, mass spectrometry and electrochemistry. 
 
• Cellular uptake and nuclear localisation studies on the metallocene-NLS bioconjugates 
in human liver cancer cell line (Hep G2) and determination of their cytotoxic effects (if 
any).  
 
• Cellular uptake and nuclear localisation studies on metallocene-TAT bioconjugates in 
Hep G2 cell line and study of their cytotoxicity. 
 
• Determination of the cytotoxicity of Platinum-NLS bioconjugates in Hep G2 cell line. 
 
• Receptor binding studies on various metal-neurotensin bioconjugates with NTR1 
receptors in human adenocarcinoma (HT 29) cell line. 
 
• Evaluation of the cytotoxic and genotoxic potential of various metal-peptide 
bioconjugates in a preliminary yeast assay. 
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Experimental Details 
2.1 Syntheses and Characterisation 
2.1.1 Materials and Apparatus 
The compounds were synthesized using routine methods of solid phase peptide synthesis on 
Eppendorf automatic synthesizers. DMF for peptide synthesis was purchased from Roth 
Chemicals. All other solvents were reagent grade unless otherwise specified. All amino 
acids and resin were purchased from Novabiochem, Laufelfingen, Switzerland. Other 
reagents and chemicals were purchased from Aldrich-Sigma GmbH and used as received. 
FITC was purchased from Fluka Chemicals. 
 
Mass spectra, MALDI-TOF were recorded on a Bruker Biflex Instrument and the ESI 
spectra (neg./pos.) on a Finnigan TSQ 700 at 4.5 kV, at the Institute of Organic Chemistry, 
University of Heidelberg. Only characteristic fragments are given with possible 
composition. 
 
NMR spectra were measured at room temperature on a Bruker DRX 300 (1H at 300.1316 
MHz), Bruker AM (1H at 366.1316 MHz), Bruker DRX (1H at 500.1300 MHz) and Varian 
Unity Instruments (1H at 399.896 MHz). The chemical shifts are reported in δ (ppm) 
referenced to TMS, using residual protio signals of deuterated solvents as internal standards. 
Coupling constants (J) are given in Hz. The peaks are identified as singlets (s), doublets (d), 
triplets (t) or multiplets (m). Depending upon the solubility of compounds, D2O or CD3OD 
were used as solvents. 
 
Cyclic and square wave voltammograms were obtained with a three electrode cell on a 
Princeton Applied Research Basic Electrochemical System potentiostat. A Ag/AgCl (0.01 
M AgCl in MeCN) reference electrode, a glassy carbon working electrode and a Pt wire 
auxiliary electrode in MeCN containing 0.1 M TBAPF6 as supporting electrolyte were used.  
Ferrocene was used as an internal standard at a scan rate of 60 Hz. 
 
Analytical HPLC was carried out on a Varian Prostar Instument using a Reverse Phase 
Varian Dynamax analytical column (C18 microsorb 60Å, diameter 4.5 mm, 250 mm length) 
with water and acetonitrile, both containing 0.1 % TFA, as eluents using a linear gradient, 5 
to 95% acetonitrile, for 20 minutes. Purifications were done on a Varian Dynamax 
preparative column (C18 microsorb 60Å, diameter 21.4 mm, 250 mm length). 
 2.1.2 Methods and Analytical data 
2.1.2.1   NLS(126-132) Bioconjugates 
Solid Phase Peptide Synthesis  
All NLS(126-132) bioconjugates were snythesized using standard SPPS methods using 
Fmoc strategy. Wang resin preloaded with Fmoc-Val-OH (0.63 mmol/g) was used. The 
resin was swelled in DMF for 1 h. Fmoc groups were cleaved using 20% piperidine in DMF 
for 10 minutes followed by 3x washing with DMF.  3 eq. of  Fmoc-Lys(Boc)-OH, Fmoc-
Arg(Pbf)-OH and  Fmoc-Pro-OH along with equimolar quantities TBTU and HOBt as 
coupling reagents and DIPEA (8eq.) as base were used to synthesize the NLS part of the 
bioconjugates. The activation time was one minute and the coupling time for the amino 
acids was 35 minutes. The arginine and the lysine following the proline were coupled for 
one hour. The synthesized NLS has asequence of PKKKRKV. The terminal amino group of 
the peptide was used to carry the metallocene moiety, which was coupled using the standard 
method on solid phase (using 3 eq. cobaltocenium carboxylic acid or ferrocene carboxylic 
acid, 3 eq of TBTU and 3 eq. of HOBt with a longer activation time of 10 minutes). 
 
For compounds 1 and 2, the metallocene carboxylic acids were coupled on the resin to 
the N-terminal proline of the peptide. In case of compound 3, Fmoc-Lys(mca)-OH which is 
commercially available was used in the second step of coupling. For Pt-bioconjugates 4 and 
5, the complexation was carried out with 6 eq. of K2PtCl4 in a 1:9 H2O/DMF mixture. 
Aminoethyglycine (BB) and diaminopropionic acid (DAP) were used as ligands for 
platination. The complexation was carried out for 3 days. Upon successful complexation of 
the metal to the peptide, the resin changed colour from off white to brown. BB denotes the 
backbone (aminoethylglycine) and DAP the diaminopropionic acid ligands respectively.  
 
For compounds 6-11, after the NLS(126-132) sequence, another lysine, Fmoc-Lys(Mtt)-
OH, was used as a linker and carrier of the fluorescent label. The metallocene carboxylic 
acid was then added to the N-terminal of the peptide and upon successful coupling of the 
metal complex to the peptide, the resin changed colour from off white to yellow or orange.  
For all compounds, the metallocene carboxylic acid was coupled to the free N-terminal of 
the peptide chain on the resin prior to labelling with the fluorescence marker. The side chain 
of the linker lysine was used for labelling with Fluorescein isothiocyanate (FITC). 
Compounds 12 and 13 are the truncated peptide-metallocene conjugates containing a lysine 
which is labelled with FITC.  
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 The fluorescent label was added manually in the lab. The resin was washed with DMF to 
remove impurities. The resin carrying the bioconjugate had to be shrinked using MeOH  for 
efficient removal of the methyltrityl (Mtt) protecting group. The side chain Mtt group was 
removed with 1% TFA in CH2Cl2 (using 5% TIS in the cleavage mixture). The resin was 
treated with 2 ml of the cleavage mixture for 2 min and this step is repeated 5 times. 
Afterwards the resin was washed with CH2Cl2 and again swelled for in DMF for 30 
minutes. The resin was then shaken in the dark for 3 to 4 hours with a solution of FITC in 
DMF and 10 eq. of DIPEA.  
 
At the end of the synthesis, the bioconjugates were washed repeatedly with DMF, 
CH2Cl2 and shrinked with MeOH. The resin was thoroughly dried over KOH under vaccum 
overnight prior to cleavage of the bioconjugate. Cleavage from the resin was achieved with 
95 % TFA, 2.5 % TIS and 2.5 % H2O for 3 h for all compounds except those containing 
ferrocene carboxylic acid as the metal moiety. For ferrocene containing compounds, the 
cleavage mixture consisted of 85% TFA, 10% phenol and 5% TIS. Whereas for Pt-
bioconjugates, the cleavage mixture consisted of wet TFA containing 5 % H2O. 
 
The cleaved peptides were collected by filtration. The bioconjugates were precipitated 
from the filtrate upon addition of cold diethylether (-20 °C). The crude product was dried 
and lyophilized. Crude yield was quantitative in all cases. Purification was achieved by 
preparative HPLC. 
 
HPLC conditions: 
Analytical HPLC at 25°C 
Method A Linear gradient, 5 to 95% Acetonitrile in 20 minutes with water and 
acetonitrile both containing 0.1% TFA as eluents. 
Method B Linear gradient, 5 to 95% Methanol in 30 minutes with water 
containing 0.1% TFA and methanol as eluents. 
Method C Linear gradient, 5 to 95% Acetonitrile in 30 minutes with water and 
acetonitrile both containing 0.1% TFA as eluents. 
Preparative HPLC at RT  
Preparative HPLC was carried out using isocratic gradient with eluent concentrations 
ranging from 40 % to 55 % acetonitrile containing 0.1 % TFA. In case where methanol was 
used as an eluent, the purification was carried out at 70% methanol isocratic gradient.  
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 Analytical data 
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1: CcC(O)-NLS 
Pale yellow solid, soluble in water and ethanol 
C51H86Co+N14O9 (1097.6 g/mol)  
Rt = 6.9 minutes (Analytical HPLC;  Method A) 
ESI : m/z 366.9 [M+3H]3+  549.6 [M+2H]2+
SWV: E1/2 =  -1.076 V vs. FcH / FcH+ 
1H-NMR (366 MHz, CD3OD): δH  6.29 (s, 1H, substituted Cp) 6.24 (s, 1H, substituted  Cp) 
5.90 (pseudo t, 2H, substituted Cp) 5.87 (s, 5H, unsubstituted Cp) 4.50-4.60 (m, 1H, Hα,Val) 
4.23-4.42 (m, 7H, Hα) 3.72-3.79 (m, 2H, Hδ, Pro) 3.20 (t, J=6.6 Hz, 2H, Hδ, Arg) 2.91- 3.01 
(m, 8H, Hε, Lys) 2.38-2.32 (m, 1H, Hβ,Val) 2.05-1.99 (m, 2H, Hβ, Pro) 1.93-1.82 (m, 2H, Hγ, Pro) 
1.79-1.64 (m, 20H, Hβ, δ, Lys, Hβ, γ, Arg)   1.61-1.37 (m, 8H, Hγ, Lys)   0.98 (d, J=6 Hz, 6H, 
CH3-Val) 
 
2: FcC(O)-NLS 
Orange solid, soluble in water and ethanol 
C51H86FeN14O9 (1094.61 g/mol) 
Rt = 9.91 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1094.8 [M]+ 1134.8 [M+K]+  
SWV: E1/2 =  247 vs. FcH / FcH+
1H-NMR (400 MHz, CD3OD): δH 4.72 (broad s, 2H, Hα) 4.41 (broad s, 3H, substituted Cp, 
Hα) 4.34-4.22 (m, 4H, substituted Cp, Hα) 4.18 (s, 7H, unsubstituted Cp, Hα) 4.04-3.86 (m, 
1H, Hδ, Pro) 3.88-3.80 (m, 1H, Hδ, Pro) 3.11 (pseudo t, 2H, Hδ, Arg) 2.89-2.79 (m, 8H, Hε, Lys) 
2.27-2.19 (m, 1H,  Hβ, Val) 2.12-2.06 (m, 1H, Hβ, Pro) 1.98-1.75 (m, 3H,  Hβ, γ, Pro)  1.70-1.56 
(m, 20H, Hβ, δ, Lys, Hβ, γ, Arg) 1.48-1.33 (m, 8H, Hγ, Lys) 0.89 (d, J=6.6 Hz, 6H, CH3-Val) 
26 
  
 
OH
H
N
N
H
H
N
O
O
HN
O
NH
NH2
HN
N
H
H
N
N
H O
O
O
H2N
H2N
H2N
N
OO
Co+
O OCH3O
O
c
b
a
d
 
 
 
3: CcC(O)-NLSmca
Light yellow solid, soluble in water and ethanol 
C63H94Co+N14O13 (1313.65 g/mol) 
Rt = 11.14 minutes (Analytical HPLC; Method A) 
ESI : m/z 438.9 [M+3H]3+   657.6 [M+2H]2+   
SWV: E1/2 =  -1.162V vs. FcH / FcH+
1H-NMR (300 MHz, D2O): δH 7.50 (d, J=8.8 Hz, 1H, Ha, mca) 6.87 (d, J=8.7 Hz, 1H,Hc, mca) 
6.80 (s, 1H, Hb, mca) 6.18-6.10 (m, 3H, Hd, mca, substituted Cp) 5.82 (pseudo t, 2H, substituted 
Cp) 5.75 (s, 5H, unsubstituted Cp) 4.48 (pseudo t, 1H, Hα) 4.14-4.28 (m, 6H, Hα) 3.85 (s, 
3H, OCH3-mca)  3.65 ( broad s, 2H, Hδ, Pro)  3.35 (pseudo t, 2H, Hδ, Arg)  3.20-3.06 (m, 2H, 
Hα, mca) 3.00-2.89 (broad s, 8H, Hε, Lys) 2.45-2.30 (m, 1H, Hβ, Val) 2.19-1.95 (m, 4H, Hβ, γ, Pro) 
1.81-1.59 (m, 20H, Hβ, δ, Lys, Hβ, γ, Arg)  1.45-1.20 (m, 8H, Hγ, Lys)  0.86 (d, J=6.7 Hz, 6H, 
CH3-Val) 
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4: Pt(II)-BB-NLS 
Silvery brown solid, soluble in water 
C44H86Cl2N16O9Pt  (1248.59 g/mol)
Rt = 9.4 minutes (Analytical HPLC; Method C)  
MALDI-TOF: m/z 1248.7 [M]+ 1288.7 [M+H+K]+
1H-NMR (400 MHz, D2O): δH 4.35-4.28 (m, 1H, Hα, Val) 4.28-4.17 (m, 6H, Hα) 3.56-3.40 
(m, 2H, Hδ, Pro) 3.07 (pseudo t, 2H, Hδ, Arg) 2.95-2.82 (m, 11H, Hb,c, BB Hε, Lys) 2.64-2.49 
(broad s, 2H, Ha, BB) 2.20-2.15 (m, 1H, Hβ, Val) 2.10-2.03 (m, 1H, Hβ, Pro) 1.92-1.83 (m, 3H, 
Hβ, γ, Pro) 1.77-1.47 (m, 20H, Hβ, δ, Lys, Hβ, γ, Arg) 1.36-1.22 (m, 8H, Hγ, Lys) 0.83 (d, J=7 Hz, 
6H, CH3-Val) 
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5: Pt(II)-DAP-NLS 
Light brown solid, soluble in water 
C43H84Cl2N16O9Pt  (1233.56 g/mol)
Rt = 7.8 minutes (Analytical HPLC;  Method C)  
MALDI-TOF: m/z 1235.8 [M+2H]+ 1275.8 [M+2H+K]+  
1H-NMR (400 MHz, D2O): δH 4.41-4.39 (m, 1H, Hα, Val) 4.35-4.25 (m, 6H, Hα ) 4.04-4.93 
(m, 3H, Ha, DAP,  Hδ, Pro) 3.78-3.72 (m, 1H, Hδ, Pro) 3.60-3.55 (m, 2H, Hb, DAP) 3.19 (pseudo t, 
2H, Hδ, Arg) 3.05-2.96 (m, 8H, Hε, Lys) 2.70-2.64 (m, 1H, Hβ, Val) 2.35-2.25 (m, 1H, Hβ, Pro) 
2.12-1.99 (m, 3H, Hβ, γ, Pro) 1.88-1.65 (m, 20H, Hβ, δ, Lys, Hβ, γ, Arg) 1.54-1.38 (m, 8H, Hγ, Lys) 
0.93-0.82 (m, 6H, CH3-Val) 
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6: H-Lys-NLS 
White solid, soluble in water and ethanol 
C46H90N16O9  (1010.71 g/mol) 
Rt = 6.98 minutes (Analytical HPLC;  Method A)  
MALDI-TOF: m/z 1011 [M+H]+ 1032.9 [M+Na]+
1H-NMR (300 MHz, D2O): δH  4.52 (pseudo t, 1H, Hα, Val)  4.40-4.25 (m, 6H, Hα)  4.16 (d, 
J=6 Hz, 1H,  Hα, Lys terminal) 3.83-3.74 (m, 1H, Hδ, Pro) 3.67-3.58 (m, 1H, Hδ, Pro) 3.22 (pseudo 
t, 2H, Hδ, Arg) 3.09-2.99 (m, 10H, Hε, Lys) 2.42-2.31 (m, 1H, Hβ, Val) 2.19-1.99 (m, 1H, Hγ, Pro) 
2.03-1.95 (m, 3H, Hγ, Hβ, Pro)   1.90-1.67 (m, 24 H, Hβ, δ, Lys, Hβ, γ, Arg)   1.58-1.39 (m, 10H, 
Hγ, Lys) 0.95 (2 overlapping d, J=6.8 Hz, 6H, CH3-Val) 
 
7: H-Lys(FITC)-NLS 
Bright yellow solid, soluble in water and ethanol 
C67H101N17O14S+ (1399.74 g/mol) 
Rt = 10.58 minutes (Analytical HPLC;  Method A) 
MALDI-TOF: m/z 1401.9 [M+2H]+, 1442 [M+2H+K]+  
1H-NMR (300 MHz, D2O) δH 8.20 (s. 1H, FITC) 7.90 (s, 1H, FITC) 7.33-7.29 (m, Hz, 1H, 
FITC) 7.25-7.20 (m, 2H, FITC) 6.95 (s, 2H, FITC) 6.89 (d, J=8.2 Hz, 1H, FITC) 6.85-6.79 
(m, 1H, FITC) 4.48-4.41 (m, 1H, Hα ) 4.35-4.16 (m, 6H, Hα) 4.07-4.01 (m, 1H, Hα) 3.87-
3.73 (m, 1H, Hδ, Pro) 3.63-3.55 (m, 1H, Hδ, Pro) 3.16-3.05 (m, 2H, Hδ, Arg) 2.98-2.80 (m, 10H, 
Hε, Lys) 2.30-2.22 (m, 1H, Hβ, Val) 2.06-2.01 (m, 1H, Hβ, Pro) 1.97-1.88 (m, 2H, Hγ, Pro) 1.79-
1.55 (m, 24H, Hβ, δ, Lys, Hβ, γ, Arg ) 1.43-1.22 (m, 10H, Hγ, δ, Lys) 0.88-0.80 (m, 6H, CH3-Val) 
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8: CcC(O)-Lys-NLS    
Pale yellow solid, soluble in water and ethanol 
C57H98Co+N16O10 (1225.7 g/mol) 
Rt = 8.14 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1226.5 [M+H]+ 1266.5 [M+K]+
SWV: E1/2 = -1.38 V vs. FcH / FcH+
1H-NMR (400 MHz, D2O) δH 6.25 (s, 1H, substituted Cp) 6.18 (s, 1H, substituted  Cp) 5.82 
(pseudo t, 2H, substituted Cp) 5.73 (s, 5H, unsubstituted Cp) 4.39 (pseudo t, 1H, Hα) 4.30-
4.19 (m, 7H, Hα) 3.91-3.80 (m, 1H, Hδ, Pro)  3.62-3.55 (m, 1H, Hδ, Pro)  3.14 (pseudo t, 2H, 
Hδ, Arg) 2.98-2.84 (m, 10H, Hε, Lys)  2.31-2.20 (m, 1H, Hβ, Val) 2.18-2.05 (m, 1H, Hγ, Pro) 2.01-
1.90 (m, 2H, Hβ, γ, Pro)   1.82-1.48  (m, 25 H, Hγ, Pro, Hβ, δ, Lys, Hβ, γ, Arg)  1.39-1.25 (m, 10H, 
Hγ, Lys) 0.84 (d, J=7 Hz, 6H, CH3-Val) 
 
9: FcC(O)-Lys-NLS 
Yellow solid, soluble in water and ethanol 
C57H98FeN16O10 (1222.7 g/mol) 
Rt = 9.7 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1223.5 [M+H]+ 1246.6 [M+Na]+ 
SWV: E1/2 = 239 vs. FcH / FcH+
1H-NMR (400 MHz, D2O): δH  4.50 (s, 2H, substituted Cp) 4.45-4.35 (m, 1H, Hα, Val) 4.15 
(broad s, 9H, unsubstituted Cp, Hα) 3.99-3.94 (m, 2H, Hα) 3.92-3.88 (m, 1H, Hα, Lys terminal) 
3.79-3.50 (m, 2H, Hδ, Pro) 3.15 (pseudo t, 2H, Hδ, Arg)  2.99-2.88 (broad s, 10H, Hε, Lys)  2.30-
2.24  (m, 1H, Hβ, Val)   1.95-2.10  (m, 3H, Hβ, γ, Pro)   1.90-1.60  (m, 25 H, Hγ, Pro, Hβ, δ, Lys,  
Hβ, γ, Arg)  1.50-1.30 (m, 10H,  Hγ, Lys) 0.85 (2 overlapping d, J=6 Hz, 6H, CH3-Val) 
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10: CcC(O)-Lys(FITC)-NLS     
Bright orangish yellow solid, soluble in water and ethanol 
C78H109Co+N17O15S (1614.73 g/mol) 
Rt = 11.21 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1616.3 [M+H]+
SWV: E1/2 = -1.37 V vs. FcH / FcH+
1H-NMR (300 MHz, D2O): δH 7.95 (s, 1H, FITC) 7.60 (d, J=6.8 Hz,1H, FITC) 7.30 (d, 
J=7.8 Hz,1H, FITC) 7.20 (d, J=8.6 Hz, 2H, FITC) 7.03 (s, 2H, FITC) 6.84 (d, J=6.8 Hz, 2H, 
FITC) 6.20 (pseudo t, 1H, substituted Cp) 6.17 (pseudo t, 1H, substituted Cp) 5.78 (s, 2H, 
substituted Cp) 5.73 (s, 5H, unsubstituted Cp) 4.40-4.32 (m, 1H, Hα) 4.25-4.10 (m, 6H, Hα) 
4.05 (d, J=6 Hz, Hα, Lys) 3.90-3.78 (m, 1H, Hδ, Pro) 3.69-3.55 (m, 1H, Hδ, Pro) 3.15-3.02 (m, 
2H, Hδ, Arg) 2.91-2.82 (m, 10H, Hε, Lys)  2.05-1.79 (m, 5H, Hβ, γ, Pro, Hβ, Val) 1.71-1.42 (m, 
24H, Hβ, δ,  Lys, Hβ, γ,  Arg ) 1.35-1.20 (m, 10H, Hγ, Lys) 0.86 (d, J=6 Hz, 6H, CH3-Val)  
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11: FcC(O)-Lys(FITC)-NLS 
Bright orange solid, soluble in water and ethanol  
C78H109FeN17O15S (1611.74 g/mol)  
Rt = 12.23 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1614.2 [M+2H]+  1636.2 [M+H+Na]+
SWV: E1/2 =  166 mV vs. FcH / FcH+
1H-NMR (400MHz, CD3OD): δH 8.29 (s, 1H, FITC) 7.75 (d, J=8.6 Hz, 1H, FITC) 7.39-7.31 
(m, 1H, FITC) 7.22-7.17 (m, 1H, FITC)  6.76-6.68 (m, 3H, FITC) 6.58 (dd, J=6.2 Hz, 2H, 
FITC) 4.77-4.69 (pseudo t, 1H, Hα, Val) 4.49-4.43 (m, 3H, Hα) 4.42 (s, 2H, substituted Cp) 
4.38-4.31 (m, 4H, Hα)  4.29 (s, 2H, substituted Cp)  4.24 (s, 5H, unsubstituted Cp)  4.04-
3.98 (m, 1H, Hδ, Pro) 3.85-3.76 (m, 1H, Hδ, Pro) 3.26-3.16 (m, 2H, Hδ, Arg) 3.05-2.89 (m, 10H, 
Hε, Lys) 2.34-2.26 (m, 1H, Hβ, Val)  2.23-2.18 (m, 1H, Hγ, Pro) 2.06-1.98 (m, 2H, Hβ, γ, Pro)  
1.96-1.65 (m, 25 H, Hβ, Pro, Hβ, δ, Lys, Hβ, γ, Arg) 1.60-1.45 (m, 10H, Hγ, Lys) 1.00 (d, J=6.2 Hz, 
6H, CH3-Val) 
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12: CcC(O)-Lys(FITC)-Val-OH   
Bright orangish yellow solid, partially soluble in water and methanol, soluble in DMSO 
C43H42Co+N4O9S (849.20 g/mol) 
Rt = 13.75 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 849.3 [M]+
SWV: E1/2 = -1.23 V vs. FcH / FcH+
1H-NMR (300 MHz, CD3OD): δH 8.20 (s. 1H, FITC) 7.75 (d, J=7 Hz, 1H, FITC) 7.09 (dd, 
J=7.8 Hz, 1H, FITC) 6.65 (d, J= 8.7 Hz, 2H, FITC) 6.52 (s, 2H, FITC) 6.50 (d, J=7 Hz, 
2H, FITC) 6.48 (pseudo t, 1H, substituted Cp) 6.28 (pseudo t, 1H, substituted Cp) 5.90 
(pseudo t, 2H, substituted Cp)   5.85 (s, 5H, unsubstituted Cp)  4.38-4.34 (m, 2H, Hα)  3.70-
3.61 (m, 2Hε, Lys)  2.32-2.25 (m, 1H, Hβ, Val)  2.08-1.95 (m, 2H, Hβ, Lys)  1.87-1.75 (m, 2H, 
Hδ, Lys) 1.68-1.57 (m, 2H, Hγ, Lys) 1.00 (d, J=6 Hz, 6H, CH3-Val) 
 
13: FcC(O)-Lys(FITC)-Val-OH 
Dark orange solid, soluble in DMSO and methanol, sparingly soluble in water 
C43H42FeN4O9S (846.2 g/mol) 
Rt = 21.8 minutes (Analytical HPLC; Method B) 
MALDI-TOF: m/z 847.5 [M+H]+ 869.5 [M+Na]+   885.5 [M+K]+   
SWV: E1/2 =  258 mV vs. FcH / FcH+
1H-NMR (400MHz, CD3OD): δH 8.18 (s, 1H, FITC) 7.79 (d, J=8.2 Hz, 1H, FITC) 7.17 (d, 
J=8.2 Hz, 1H, FITC) 6.83-6.75 (m, 4H, FITC) 6.64 (d, J=8.2 Hz, 2H, FITC) 4.67 (pseudo t, 
1H, Hα, Val) 4.45-4.39 (m, 3H, substituted Cp, Hα, Lys)  4.23 (s, 5H, unsubstituted Cp) 3.70 
(broad s, 2H, Hε, Lys) 2.29-2.19 (m, 1H, Hβ, Val) 2.01-1.89 (m, 2H, Hβ, Lys) 1.81-1.75 (m, 2H, 
Hδ, Lys) 1.66-1.51 (m, 2H, Hγ, Lys) 1.03 (d, J=6.6 Hz, 6H, CH3-Val) 
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2.1.2.2  NLSscr (Scrambled sequence) Bioconjugates 
 
Solid Phase Peptide Synthesis  
 
The bioconjugates were synthesized using the routine methods of SPPS described in section 
2.1.2.1. Wang resin preloaded with Fmoc-Arg-OH (0.58 mmol/g) was used. The NLSscr has 
a sequence of KKVKPKR. Another Lysine was added at the N-terminal and its side chain 
was used as a carrier for the fluorescent label. Cobaltocenium and Ferrocene carboxylic 
acids were used as metal labels.  
 
After the steps of synthesis, shrinking and cleavage from the resin, the crude products 
obtained in quantitative yields were dried and lyophilized. Purification was achieved by 
preparative HPLC. 
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14: NLSscr
White solid, soluble in water and ethanol 
C40H78N14O8 (882.6 g/mol) 
Rt = 7.4 minutes (Analytical HPLC; Method A) 
 MALDI-TOF: m/z 883.6 [M+H]+
1H-NMR (400 MHz, D2O): δH 4.62-4.54 (m, 1H, Hα, Val) 4.48-4.38 (m, 3H, Hα, Lys) 4.30-
4.20 (m, 1H, Hα, Arg) 4.15-4.08 (m, 1H, Hα, Pro) 4.05 (t, J=6.6 Hz, 1H, Hα, terminal Lys) 3.92-
3.82 (m, 1H, Hδ, Pro) 3.70-3.60 (m, 1H, Hδ, Pro) 3.21 (pseudo t, 2H, Hδ, Arg) 3.05-2.95 (m, 8H, 
Hε, Lys)   2.35-2.25 (m,1H, Hβ, Val)   2.08-1.99 (m, 3H, Hβ, γ, Pro)   1.92-1.56 (m, 21H, Hγ, Pro, 
Hβ, γ, Lys, Hβ, γ, Arg) 1.55-1.37 (m, 8H, Hδ, Lys) 0.90 (t, J=7.0  Hz, 6H, CH3-Val) 
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15: CcC(O)-NLSscr 
Pale yellow solid, soluble in water and ethanol 
C51H86Co+N14O9 (1097.6 g/mol) 
Rt = 7.34 minutes (Analytical HPLC; Method A)  
MALDI-TOF : m/z 1099 [M+H]+ 1121 [M+Na]+
SWV: E1/2 = -1.09 V vs. FcH / FcH+
1H-NMR (400 MHz, D2O): δH 6.29 (s, 1H, substituted Cp) 6.25 (s, 1H, substituted Cp) 5.89 
(s, 2H, substituted Cp) 5.80 (s, 5H, unsubstituted Cp) 4.62-4.57 (m, 1H, Hα,Val) 4.43-4.36 
(m, 5H, Hα) 4.26 (pseudo t, 1H, Hα) 4.13-4.08 (m, 1H, Hα) 3.90-3.84 (m, 1H, Hδ, Pro) 3.68-
3.60 (m, 1H, Hδ, Pro) 3.20 (pseudo t, 2H, Hδ, Arg) 3.01-2.95 (m, 8H, Hε, Lys) 2.34-2.23 (m, 1H, 
Hβ,Val) 2.03-1.98 (m, 3H, Hβ, γ Pro)  1.92-1.63 (m, 21H, Hβ, Pro, Hβ, γ, Lys, Hβ, γ, Arg)  1.51-1.38 
(m, 8H, Hδ, Lys) 0.92-0.89 (m, 6H, CH3-val) 
 
16: FcC(O)-NLSscr
Yellow solid, soluble in water and ethanol 
C51H86FeN14O9 (1094.61 g/mol) 
Rt = 9.5 minutes (Analytical HPLC; Method A)  
MALDI-TOF: m/z 1096.5 [M+2H]+ 1117.7 [M+Na]+  
SWV: E1/2 = 252 mV vs. FcH / FcH+
1H-NMR (400MHz, CD3OD): δH 4.65-4.60 (pseudo t, 1H, Hα,Val) 4.55-4.44 (m, 6H, Hα, 
substituted Cp ) 4.40-4.36 (m, 1H, Hα) 4.26 (s, 5H, unsubstituted Cp) 4.20 (d, J=7.03 Hz, 
1H, Hα) 3.96-3.87 (m, 1H, Hδ, Pro) 3.74-3.34 (m, 1H, Hδ, Pro) 3.28-3.19 (m, 2H, Hδ, Arg) 2.97 
(d, J=7.0 Hz, 8H, Hε, Lys) 2.32-2.23 (m, 1H, Hβ, Val) 2.16-1.90 (m, 3H, Hβ, γ, Pro) 1.80-1.64 (m, 
21H, Hβ, Pro, Hβ, γ, Lys, Hβ, γ, Arg) 1.63-1.47 (m, 8H, Hδ, Lys) 0.97 (d, J=6.6 Hz, 6H, CH3-Val) 
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17: H-Lys-NLSscr
White solid, soluble in water and ethanol 
C46H90N16O9 (1010.71 g/mol)  
Rt = 6.7 minutes (Analytical HPLC, Method A)  
MALDI-TOF: m/z 1011.8 [M+H]+  1033.8 [M+Na]+
1H-NMR (300MHz, D2O): δH 4.63-4.56 (m, 1H, Hα, Val) 4.47-4.41 (m, 1H, Hα, Lys) 4.37-4.29 
(m, 2H, Hα, Lys) 4.28-4.22 (m, 2H, Hα) 4.14 (d, J=7.3 Hz, 1H, Hα) 4.06-3.92 (pseudo t, 1H, 
Hα) 3.92-3.83 (m, 1H, Hδ, Pro) 3.71-3.62 (m, 1H, Hδ, Pro) 3.21 (t, J=7 Hz, 2H, Hδ, Arg) 3.05-
2.93 (m, 10H, Hε, Lys)  2.36-2.24 (m, 1H, Hβ, Val)  2.08-1.98 (m, 2H, Hβ, γ, Pro) 1.93-1.58 (m, 
26H, Hγ, β, Pro, Hβ, δ, Lys, Hβ, γ, Arg)    1.53-1.33 (m, 10H, Hγ, Lys)   0.92 (dd, J=6.2 Hz, 6H, 
CH3-Val) 
 
18: H-Lys(FITC)-NLSscr
Bright yellow solid, soluble in water and ethanol 
C67H101N17O14S+ (1399.74 g/mol) 
Rt = 10.14 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1402.2 [M+2H]+, 1424.1 [M+Na]+
1H-NMR (400 MHz, D2O) δH 8.06 (s. 1H, FITC) 7.69 (d, J=8.9 Hz, 1H, FITC) 7.42 (pseudo 
t, 1H, FITC) 7.37-7.27 (m, 1H, FITC) 7.20 (pseudo t, 1H, FITC) 7.01 (s, 2H, FITC) 6.86 (d, 
J=8.9 Hz, 2H, FITC) 4.40-4.25 (m, 7H, Hα) 4.15-4.05 (m, 1H, Hα) 3.90-3.82 (m, 1H, Hδ, Pro) 
3.70-3.65 (m, 1H, Hδ, Pro) 3.58-3.51 (m, 2H, Hδ, Arg) 3.05-2.90 (m, 10H, Hε, Lys) 2.35-2.21 (m, 
1H, Hβ, Val) 1.95-1.86 (m, 3H, Hβ, γ, Pro) 1.80-1.55 (m, 25H, Hβ, Pro, Hβ, δ, Lys, Hβ, γ, Arg) 1.49-
1.31 (m, 10H, Hγ, Lys) 0.91 (d, J=6.6 Hz, 6H, CH3-Val) 
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19: CcC(O)-Lys-NLSscr
Pale yellow solid, soluble in water and ethanol 
C57H98Co+N16O10 (1225.7 g/mol) 
Rt = 7.40 minutes (Analytical HPLC; Method A)  
MALDI-TOF: m/z 1226.9 [M+H]+ 1248.9 [M+Na]+ 1282.9 [M+K]+
SWV: E1/2 = -1.38 V vs. FcH / FcH+
1H-NMR (400MHz, D2O) δH 6.20 (s, 1H, substituted Cp) 6.18 (s, 1H, substituted Cp) 5.80 
(s, 2H, substituted Cp) 5.70 (s, 5H, unsubstituted Cp) 4.51-4.44 (pseudo t, 1H, Hα, Val) 4.35-
4.28 (m, 2H, Hα) 4.26-4.19 (m, 3H, Hα) 4.18-4.13 (m, 1H, Hα) 3.99 (d, J=7.8 Hz, 1H, Hα) 
3.80-3.78 (m, 1H, Hδ, Pro) 3.61-3.58 (m, 1H, Hδ, Pro) 3.09 (pseudo t, 2H, Hδ, Arg) 2.93-2.83 (m, 
10H, Hε, Lys) 2.23-2.18 (m, 1H, Hβ, Val) 1.98-1.90 (m, 3H, Hβ, γ, Pro) 1.70-1.45 (m, 25 H, Hβ, Pro 
Hβ, γ, Lys, Hβ, γ, Arg ) 1.38-1.18 (m, 10H, Hγ, Lys) 0.93 (d, J=7 Hz, 6H, CH3-Val) 
 
20: FcC(O)-Lys-NLSscr
Yellow solid, soluble in water and ethanol 
C57H98FeN16O10 (1222.7 g/mol)  
Rt = 9.11 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1224.1 [M+2H]+ 1246.6 [M+Na]+ 
SWV: E1/2 =  279 mV vs. FcH / FcH+
1H-NMR (300 MHz, D2O): δH 4.53-4.60 (m, 2H, Hα) 4.34-4.38 (m, 2H, Hα) 4.17-4.30 (m, 
7H, Hα, unsubstituted Cp) 4.05 (d, J=7.7 Hz, 2H, Hα) 3.87-3.76 (m, 1H, Hδ, Pro)  3.64-3.55 
(m, 1H, Hδ, Pro) 3.15 (t, J=6.7 Hz, 2H, Hδ, Arg) 3.00-2.80 (m, 10H, Hε, Lys) 2.30-2.20 (m, 1H, 
Hβ, Val) 2.08-1.92 (m, 4H, Hβ, γ,  Pro) 1.90-1.52 (m, 24 H, Hβ, δ, Lys, Hβ, γ, Arg) 1.50-1.30 (m, 
10H, Hγ, Lys) 0.91 (d, J=6.2 Hz, 6H, CH3-Val) 
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21: CcC(O)-Lys(FITC)-NLSscr
Bright yellow solid, soluble in water and ethanol 
C78H109Co+N17O15S (1614.73 g/mol)  
Rt = 10.71 minutes (Analytical HPLC; Method A)  
MALDI-TOF: m/z 1615.9 [M+H]+ 1637.8 [M+Na]+
SWV: E1/2 = -1.35 mV vs. FcH / FcH+
1H-NMR (300MHz, D2O): δH 7.93 (s, 1H, FITC) 7.60-7.53 (d, J=8.1, 1H, FITC) 7.32 (d, 
J=8 Hz,1H, FITC) 7.22-7.16 (m, 2H, FITC) 6.95 (s, 2H, FITC) 6.80 (dd, J=8.4 Hz, 2H, 
FITC) 6.20-6.15 (m, 2H, substituted Cp) 5.79 (pseudo t, 2H, substituted Cp) 5.72 (s, 5H, 
unsubstituted Cp) 4.50-4.00 (m, 7H, Hα) 3.80-3.37 (m, 2H, Hδ, Pro) 3.15-3.04 (pseudo t, 2H, 
Hδ, Arg) 3.00-2.89 (m, 10H, Hε, Lys) 2.00-1.85 (m, 9H, Hβ, γ, Pro, Hβ, Val, Hβ, γ, Arg) 1.84-1.56 (m, 
20H, Hβ, δ , Lys) 1.50-1.38 (m, 10H, Hγ, Lys) 0.85 (d, J=6.9 Hz, 6H, CH3-Val) 
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22: FcC(O)-Lys(FITC)-NLSscr
Bright orange solid, soluble in water and ethanol  
C78H109FeN17O15S (1611.74 g/mol)  
Rt = 12.01 minutes (Analytical HPLC; Method A)  
MALDI-TOF: m/z 1614.0 [M+2H]+ 1637.2 [M+H]+
SWV: E1/2 = 279 mV vs. FcH / FcH+
1H-NMR (400 MHz, CD3OD): δH 8.29 (s, 1H, FITC) 7.70 (d, J=8.2 Hz, 1H, FITC) 7.39-
7.30 (m, 1H, FITC) 7.17 (d, J=8.2 Hz, 1H, FITC) 6.75-6.66 (m, 3H, FITC) 6.57 (dd, J=6.4 
Hz, 2H, FITC) 4.62 (pseudo t, 1H, Hα,val) 4.50-4.34 (m, 10H, substituted Cp, Hα) 4.24 (s, 
5H, unsubstituted Cp)  4.20 (d, J=7.4 Hz, 1H, Hα)  3.95-3.85 (m, 1H, Hδ, Pro)  3.71-3.65 (m, 
1H, Hδ, Pro)   3.27-3.19 (m, 2H, Hδ, Arg)  2.98 (broad s, 10H, Hε, Lys)  2.32-2.21 (m, 1H, Hβ, Val)  
2.11-1.94 (m, 3H, Hβ, γ, Pro) 1.85-1.65 (m, 25H, Hβ, Pro, Hβ, δ, Lys, Hβ, γ, Arg) 1.62-1.45 (m, 10H, 
Hγ, Lys) 0.98 (dd, J=6.2 Hz, 6H, CH3-Val) 
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2.1.2.3   TAT (48-57) bioconjugates 
Solid Phase Peptide Synthesis  
 
All TAT bioconjugates were synthesized using the routine method of SPPS described in 
section 2.1.2.1. Wang resin preloaded with Fmoc-Arg(Pbf)-OH (0.35 mmol/g) was used. 
The synthesized TAT(48-57) peptide has a sequence of GRKKRRQRRR. Another Lysine 
was added at the N-terminal as a carrier of fluorescent label on its side chain. 
Cobaltocenium and ferrocene carboxylc acids were used as metal labels.  
 
After the steps of synthesis, shrinking and cleavage from the resin, the crude products 
obtained in quantitative yields were dried and lyophilized. Purification was achieved by 
preparative HPLC. 
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23: H-K-TAT 
White solid, soluble in water and ethanol 
C61H121N33O13 (1523.98 g/mol) 
Rt = 7.73 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1525.6 [M+H]+
1H-NMR (D2O): δH   4.34-4.24 (m, 9H, Hα) 4.09 (pseudo t, 1H, Hα, Arg)  4.02 (d, J=7.4 Hz, 
2H, Hα, Gly) 3.20-3.14 (m, 12H, Hδ, Arg) 3.03-2.96 (m, 6H, Hε, Lys) 2.35 (pseudo t, 2H, Hγ, Gln) 
2.10-2.03  (m, 2H, Hβ, Gln)  1.98-1.70  (m, 18H, Hβ, Lys, Hβ,  Arg)  1.71-1.55  (m, 18 H, Hδ, Lys, 
Hγ, Arg) 1.51-1.33 (m, 6H, Hγ, Lys) 
 
24: H-K(FITC)-TAT 
Bright dark yellow solid, soluble in water and ethanol 
C82H132N34O18S (1913.02 g/mol)  
Rt =10.36 minutes (Analytical HPLC; Method A)  
ESI (pos.): m/z 383.9 [M+5H]5+ 704.6 [M+TFA+2Na+K+H]3+
1H-NMR (D2O): δH 8.06 (s, 1H, FITC) 7.66 (broad d, J=8.2 Hz, 2H, FITC) 7.22 (d, J=7.8 
Hz, 2H, FITC) 7.02 (s, 2H, FITC) 6.86 (d, J=8.2 Hz, 2H, FITC) 4.26-4.10 (m, 9H, Hα) 4.04-
3.90 (m, 3H, Hα, Arg, Hα, Gly)  3.10-2.98 (m, 12H, Hδ, Arg)  2.90- 2.82 (m, 6H,  Hε, Lys) 2.23 
(pseudo t, 2H, Hγ, Gln) 1.90-1.80 (m, 2H, Hβ, Gln) 1.75-1.60 (m, 18H, Hβ, Lys, Hβ, Arg) 1.55-1.40 
(m, 18 H, Hδ, Lys, Hγ, Arg ) 1.33-1.23 (m, 6H, Hγ, Lys) 
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25: CcC(O)-K-TAT 
Light yellow solid, soluble in water and ethanol 
C72H129Co+N33O14 (1738.97 g/mol) 
Rt =7.26 minutes (Analytical HPLC; Method A)  
MALDI-TOF: m/z 1740.2 [M+H]+
SWV: E1/2 = -1.32 V vs. FcH / FcH+
1H-NMR (D2O): δH 6.30 (broad s, 2H, substituted Cp) 5.90 (pseudo t, 2H, substituted Cp) 
5.81 (s, 5H, unsubstituted Cp) 4.49 (pseudo t, 1H, Hα) 4.34-4.25 (m, 9H, Hα)  4.02 (broad d, 
J=7.2 Hz, 2H, Hα, Gly) 3.23-3.13 (m, 12H, Hδ, Arg) 3.03-2.95 (m, 6H, Hε, Lys) 2.35 (pseudo t, 
2H, Hγ, Gln) 1.96-1.90 (m, 2H, Hβ, Gln) 1.85-1.72 (m, 18H, Hβ, Lys, Hβ, Arg) 1.70-1.58 (m, 18 H, 
Hδ, Lys, Hγ, Arg ) 1.48- 1.38 (m, 6H, Hγ, Lys) 
 
26: FcC(O)-K-TAT 
Yellow solid, soluble in water and ethanol 
C72H129FeN33O14 (1735.97 g/mol) 
Rt = 9.24 minutes (Analytical HPLC; Method A)  
MALDI-TOF: m/z 1736.8 [M+H]+  
SWV: E1/2 = 199 mV vs. FcH / FcH+
1H-NMR (D2O): δH 4.38 (pseudo t, 2H, substituted Cp) 4.26-4.21 (m, 9H, substituted Cp, 
Hα)  4.15 (s, 5H, unsubstituted Cp)  4.12-4.05 (m, 3H, Hα, Gly, Hα, Lys) 3.15-3.07 (m, 12H, 
Hδ, Arg) 2.91-2.81 (m, 6H, Hε, Lys) 2.36-2.25 (m, 2H, Hγ, Gln) 2.06-1.97 (m, 2H, Hβ, Gln) 1.90-
1.75 (m, 18H, Hβ, Lys, Hβ, Arg) 1.71-1.54 (m, 18 H, Hδ, Lys, Hγ, Arg ) 1.49-1.42 (m, 6H, Hγ, Lys) 
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27: CcC(O)-K(FITC)-TAT 
Bright orange yellow solid, soluble in water and ethanol 
C93H140Co+N34O19S (2128.01 g/mol) 
Rt = 10.74 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 582.1 [M+2Na+K+TFA]4+  557.6 [M+H+Na+2K]4+  426.7 [M+5H]5+  
355.8 [M+6H]6+   
SWV: E1/2 = -1.38 V vs. FcH / FcH+
1H-NMR (D2O): δH 8.12 (s, 1H, FITC) 7.90-7.88 (m, 2H, FITC) 7.24-7.21 (m, 1H, FITC)  
7.19-7.12 (m, 1H, FITC) 6.93 (s, 2H, FITC) 6.77 (d, J=8.4 Hz, 2H, FITC) 6.17 (pseudo t, 
2H, substituted Cp) 5.76 (pseudo t, 2H, substituted Cp) 5.69 (s, 5H, unsubstituted Cp) 4.23-
4.10 (m, 10H, Hα)  3.90-3.85 (m, 2H, Hα, Gly) 3.11-2.97 (m, 12H, Hδ, Arg) 2.89-2.81 (m, 6H, 
Hε, Lys)  2.21  (pseudo t, 2H, Hγ, Gln)  1.94-1.83 (m, 2H, Hβ, Gln)  1.73-1.58 (m, 18H, Hβ, Lys, 
Hβ,  Arg) 1.55-1.40 (m, 18 H, Hδ, Lys, Hγ, Arg ) 1.34-1.17 (m, 6H, Hγ, Lys) 
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 28: FcC(O)-K(FITC)-TAT 
Bright orange yellow solid, soluble in water and ethanol 
C93H140FeN34O19S (2125.01 g/mol) 
Rt = 12.15 minutes (Analytical HPLC; Method A) 
ESI (pos): m/z  532.6 [M+4H]4+ 709.9 [M+3H]3+  
SWV: E1/2 = 237 mV vs. FcH / FcH+
1H-NMR (D2O): δH 8.16 (s, 1H, FITC) 7.66 (dd, J=8.2 Hz, 2H, FITC) 7.29-7.18 (m, 1H, 
FITC) 7.11-7.03 (m, 1H, FITC)  6.61 (s, 2H, FITC) 6.46 (d, J=7.03 Hz, 2H, FITC) 4.37-
4.22 (m, 12H, substituted Cp, Hα) 4.13 (s, 5H, unsubstituted Cp) 4.10-4.07 (m, 2H, Hα, Gly) 
3.16-3.05 (m, 12H, Hδ, Arg) 2.90-2.83 (m, 6H, Hε, Lys) 2.40-2.22 (m, 2H, Hγ, Gln) 2.07-1.99 (m, 
2H, Hβ, Gln) 1.91-1.72 (m, 18H, Hβ, Lys, Hβ, Arg) 1.70-1.52 (m, 18 H, Hδ, Lys, Hγ, Arg) 1.40-1.32 
(m, 6H, Hγ, Lys) 
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2.1.2.4   NT(8-13) bioconjugates 
Solid Phase Peptide Synthesis  
 
All NT bioconjugates were snythesized using standard SPPS methods with Fmoc strategy. 
Wang resin preloaded with Fmoc-Ileu-OH (0.67 mmol/g) was used. The resin was swelled 
in DMF for 1 h. Fmoc groups were cleaved using 20% piperidine in DMF for 10 minutes.  3 
eq. of  Fmoc-protected amino acids along with 3 eq. TBTU and HOBt as coupling reagents 
and 8 eq. of DIPEA were used to synthesize the NT(8-13) with sequence (RRPWIL) or 
pseudo-NT (KKPWIL) part of the bioconjugates.  
 
The terminal amino group was used to carry the metallocene moiety, coupled using the 
standard method on solid phase (using 3 eq. cobaltocenium or ferrocene carboxylic acid, 3 
eq of TBTU and 3 eq. of HOBt and 8 eq. of DIPEA).  
 
For Pt-bioconjugates, aminoethylglycine (BB) and diaminopropionic acid (DAP) were 
used as ligands for platination. The complexation was carried out with 6 eq. of K2PtCl4 in a 
1:9 H2O/DMF mixture for 3 days. Upon successful complexation of the metal complex to 
the peptide, the resin changed colour from off white to brown or biege. 
 
At the end of the synthesis, the bioconjugates were washed repeatedly with DMF, 
CH2Cl2 and shrinked with MeOH. The resin was thoroughly dried over KOH under vaccum 
overnight prior to cleavage of the bioconjugate. Cleavage from the resin was achieved with 
95 % TFA, 2.5 % TIS and 2.5 % H2O for 3 h in case of cobaltocenium and non-metal 
bioconjugates. In case of ferrocene containing bioconjugates 10% phenol was added in a 
TFA/TIS mixture. Whereas, for Pt-bioconjugates, the cleavage mixture consisted of 
95% TFA with 5% H2O. After filtration, the bioconjugates were precipitated from the 
filtrate upon addition of cold diethylether (-20°C). The crude products in quantitative yields 
were dried and lyophilized. Purification was carried out by preparative HPLC. 
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29: pNT(8-13, Lys8-Lys9)  
White solid, soluble in water and ethanol 
C38H64N8O8 (760.48g/mol) 
Rt = 10.68 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 761.4 [M+H]+ 799.3 [M+K]+
1H-NMR (300 MHz, D2O) δH  7.05 (d, J=7.7 Hz, 2H, Hortho, Tyr)  6.75  (d, J=8.2 Hz,  2H, 
Hmeta, Tyr)   4.60-4.50 (m, 2H, Hα, Ile, Hα, Lys)   4.36-4.31 (m,1H, Hα, Leu)  4.42-4.21 (m, 1H, 
Hα, Pro)   4.07-4.04 (m, 1H, Hα, Lys)   3.98-3.73 (m, 1H, Hδ, Pro) 3.61-3.56 (m, 1H, Hδ, Pro) 
2.96-2.91 (m, 7H, Hβ, Tyr, Hε, Lys, Hβ, Pro)  2.22-2.15 (m, 1H, Hβ, Tyr) 1.99-1.92 (m, 2H, Hβ, Ile, 
Hγ, Leu) 1.87-1.74 (m, 3H, Hβ, Leu, Hβ, Pro) 1.70-1.51 (m, 11H, Hβ, δ, Lys, Hγ, Pro, Hγ, Ile) 1.46-1.28 
(m, 4H, Hγ, Lys) 1.12-0.98 (m, 1H, Hγ, Pro) 0.88-0.76 (m, 12H, CH3-Leu, CH3-Ile) 
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30: FcC(O)-pNT 
Light yellow solid, soluble in water and ethanol 
C49H72FeN8O9 (972.48 g/mol) 
Rt = 12.8 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 973.4 [M+H]+ 995.4 [M+Na]+ 1012.4 [M+K]+
SWV: E1/2 = 218 mV vs. FcH / FcH+
1H-NMR (300 MHz, D2O): δH  7.05 (d, J=8.3 Hz, 2H, Hortho, Tyr)  6.76  (d, J=8.2 Hz, 2H, 
Hmeta, Tyr) 4.59-4.53 (m, 1H, Hα, Tyr) 4.50 (s, 2H, substituted Cp) 4.41 (pseudo t,1H, Hα, Leu) 
4.33-4.28 (m, 1H, Hα, Pro) 4.22 (s, 5H, unsubstituted Cp) 4.19-4.12 (m, 2H, Hα, Ile, Hα, Lys)  
4.06 (d, J=8 Hz, 1H, Hα, Lys) 3.80-3.74 (m, 1H, Hδ, Pro) 3.62-3.52 (m, 1H, Hδ, Pro) 2.99-2.88 
(m, 7H, Hβ, Tyr, Hε, Lys, Hβ, Pro) 2.22-2.10 (m, 1H, Hβ, Tyr) 1.98-1.88 (m, 2H, Hβ, Ile, Hγ, Leu) 
1.81-1.50 (m, 13H, Hβ, δ, Lys, Hγ, Ile, Hγ, β, Pro, Hβ, Leu) 1.48-1.27 (m, 4H, Hγ, Lys) 1.10-0.99 (m, 
1H, Hγ, Pro) 0.89-0.71 (m, 12H, CH3-Leu, CH3-Ile)  
 
31 :CcC(O)-pNT 
Light yellow solid, soluble in water and ethanol 
C49H72 Co+N8O9 (975.48 g/mol) 
Rt = 11.33 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 975.9 [M]+ 998.9 [M+Na]+   
SWV: E1/2 = -1.15 V vs. FcH / FcH+
1H-NMR (D2O) δH 7.05 (d, J=8.2 Hz, 2H, Hortho, Tyr) 6.76 (d, J=8.2 Hz, 2H, Hmeta, Tyr) 6.23 
(s, 1H, substituted Cp) 6.18 (s, 1H, substituted Cp) 5.84 (s, 2H, substituted Cp) 5.74 (s, 5H, 
unsubstituted Cp) 4.61-4.50 (m, 1H, Hα, Ile) 4.4-4.31 (m,2H, Hα, Lys, Hα, Leu) 4.28-4.20 (m, 
1H, Hα, Pro) 4.10-4.02 (m, 1H, Hα, Lys) 3.83-3.75 (m, 1H, Hδ, Pro) 3.65-3.56 (m, 1H, Hδ, Pro) 
3.01-2.88 (m, 7H, Hβ, Tyr, Hε, Lys, Hβ, Pro) 2.25-2.15 (m, 1H, Hβ, Tyr) 2.01-1.90 (m, 2H, Hβ, Ile, 
Hγ, Leu) 1.85-1.50 (m, 14H, Hβ, Leu, Hβ, Pro, Hβ, δ, Lys, Hγ, Pro, Hγ, Ile) 1.49-1.34 (m, 4H, Hγ, Lys) 
1.10-1.01 (m, 1H, Hγ, Pro) 0.90-0.72 (m, 12H, CH3-Leu, CH3-Ile) 
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32: Pt(II)-BB-pNT 
Dull yellow solid, soluble in water and ethanol 
C42H72Cl2N10O9Pt (1125.45 g/mol)  
Rt = 11.3 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1128.0 [M+2H]+ 1150.0 [M+H+Na]+ 1165.9 [M+K]+
195Pt-NMR (D2O) : δ -1774 (Ref. H2PtCl6 in D2O) 
1H-NMR  (500 MHz, D2O)  δH   7.12 (d, J=8 Hz, 2H, Hortho, Tyr)   6.84 (d, J= 8 Hz, 2H, 
Hmeta, Tyr)  4.60-4.59 (m, 2H, Hα, Ile, Hα, Lys)   4.43-4.38 (m,1H, Hα, Tyr)   4.34-4.28 (m, 2H, 
Hα, Pro, Hα, Leu) 4.16-4.11 (m, 1H, Hα, Lys) 3.82-3.78 (m, 2H, Hδ, Pro) 3.69-3.60 (m, 2H, Ha, BB) 
3.04-2.97 (m, 6H, Hβ, Tyr, Hε, Lys, Hβ, Ile) 2.90-2.85 (m, 1H, Hβ, Tyr) 2.70-2.60 (m, 2H, Hb, BB) 
2.03-2.24 (m, 1H, Hβ, Tyr) 2.09-1.99 (m, 2H, Hc, BB) 1.90-1.75 (m, 4H, Hβ, Lys)  1.77-1.65 (m, 
10H,  Hδ, Lys, Hβ, Pro, Hβ, Ile, Hβ, γ, Leu)    1.52-1.40 (m, 6H, Hγ, Lys, Hγ, Ile)   1.96-1.06 (m, 2H, 
Hγ, Pro)  0.96 (d, J=6 Hz, 3H, CH3-Leu)  0.92-0.83 (m, 9H, CH3-Leu, CH3-Ile) 
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33: NT (8-13)  
White solid, partially soluble in water and methanol, soluble in DMSO 
C38H64N12O8 (816.99 g/mol)  
Rt = 15.8 minutes (Analytical HPLC; Method B)  
MALDI-TOF: m/z 817.4 [M+H]+ 839.4 [M+Na]+  
1H-NMR (300 MHz, CD3OD): δH 7.03 (d, J=7.8 Hz, 2H, Hortho, Tyr) 6.68 (d, J=7.6 Hz, 2H, 
Hmeta, Tyr) 4.60-4.50 (m, 2H, Hα, Ile, Hα, Arg) 4.49-4.40 (m,2H, Hα, Leu, Hα, Pro) 4.30-4.26 (m, 
1H, Hα, Arg terminal)  3.83-3.79 (m, 1H, Hδ, Pro)  3.71-3.62 (m, 1H, Hδ, Pro)  3.28-3.14 (m, 4H, 
Hδ, Arg) 3.10-3.00 (m, 1H, Hβ, Tyr) 2.90-2.80 (m, 1H, Hβ, Tyr) 2.21-2.10 (m, 1H, Hβ, Pro) 1.52-
1.42 (m, 2H, Hγ, Ile) 2.08-1.56 (m, 15H, Hβ, γ, Arg, Hβ, Pro, Hβ, γ, Leu, Hβ, Ile) 1.58-1.33 (m, 4H, 
Hγ, Arg) 0.88-0.76 (m, 12H, CH3-Leu, CH3-Ile) 
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34: CcC(O)-NT 
Yellow solid, soluble in water and ethanol 
C49H72Co+N12O9 (1031.49 g/mol) 
Rt = 11.4 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1031.2 [M]+ 1070.1 [M+Na]+
SWV: E1/2 = -1.31 V vs. FcH / FcH+
1H-NMR (300 MHz, D2O): δH  7.05 (d, J=8.0 Hz, 2H, Hortho, Tyr)   6.75 (d, J=7.8 Hz, 2H, 
Hmeta, Tyr) 6.23 (s, 1H, substituted Cp) 6.18 (s, 1H, substituted Cp) 5.84 (s, 2H, substituted 
Cp) 5.73 (s, 5H, unsubstituted Cp) 4.54-4.49 (m, 1H, Hα, Arg) 4.41-4.36 (m, 1H, Hα, Ile)  4.33-
4.28 (m,1H, Hα, Leu) 4.20-4.18 (m, 1H, Hα, Pro)  4.05 (d, J=8.5 Hz, 1H, Hα, Arg) 3.80-3.74 (m, 
1H, Hδ, Pro)  3.65-3.58 (m, 1H, Hδ, Pro)  3.22-3.12 (m, 5H, Hδ, Arg, Hβ, Ile) 3.00-2.88 (m, 2H, 
Hβ, Tyr) 2.22-2.10 (m, 1H, Hβ, Pro) 1.80-1.50 (m, 12H, Hβ, γ, Arg, Hγ, β, Pro, Hγ, Leu) 1.58-1.48 (m, 
2H, Hβ, Leu) 1.29-1.24 (m, 2H, Hγ, Ile) 0.86-0.79 (m, 12H, CH3-Leu, CH3-Ile) 
 
35: FcC(O)-NT 
Yellow solid, soluble in water and ethanol 
C49H72FeN12O9 (1028.02 g/mol) 
Rt = 13.18 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1029.3 [M+H]+ 1067.2 [M+K]+  
SWV: E1/2 = 214 mV vs. FcH / FcH+
1H-NMR (400 MHz, CD3OD): δH 7.08 (d, J=8.2 Hz, 2H, Hortho, Tyr) 6.72 (d, J=8.2 Hz, 2H, 
Hmeta, Tyr) 4.54-4.58 (m, 1H, Hα, Tyr) 4.47 (s, 2H, substituted Cp) 4.45-4.42 (m,2H, Hα, Leu, 
Hα, Pro) 4.29-4.24 (m, 8H, unsubstituted Cp, Hα, Ile, Hα, Lys, Hα, Lys) 3.86-3.78 (m, 1H, Hδ, Pro) 
3.70-3.60 (m, 1H, Hδ, Pro) 3.30-3.20 (m, 5H, Hβ, Tyr, Hε, Lys) 3.10-3.00 (m, 1H, Hβ, Pro) 2.95-
2.85 (m, 1 H, Hβ, Pro) 2.24-2.14 (m, 1H, Hβ, Tyr)  2.10-1.51 (m, 19H, Hβ, Ile, Hγ, Leu, Hβ, δ, Lys, 
Hγ, Ile, Hγ, β, Pro, Hβ, Leu,  Hγ, Lys)   1.24-1.10 (m, 1H, Hγ, Pro)  1.04-0.84 (m, 12H, CH3-Leu, 
CH3-Ile) 
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36: Pt(II)-BB-NT 
Dull yellow solid, sparingly soluble in water and soluble in methanol 
C42H72Cl2N14O9Pt (1181.46 g/mol)  
Rt = 11.58 minutes (Analytical HPLC; Method A) 
MALDI-TOF: m/z 1183.9 [M+2H]+
195Pt-NMR (D2O) : δ -1865 (Ref. H2PtCl6 in D2O) 
1H-NMR (500 MHz, CD3OD): δH 7.77 (d, J=6.5 Hz, 2H, Hortho, Tyr) 7.41 (d, J=7.5 Hz, 2H, 
Hmeta, Tyr) 4.50-4.40 (m, 2H, Hα, Arg)  4.31-4.29 (m,1H, Hα, Tyr)   4.18-4.13 (m, 3H, Hα, Leu, 
Hα, Ile, Hα, Pro) 3.93-3.88 (m, 4H, Hδ, Arg) 3.70-3.60 (m, 2H, Hδ, Pro) 3.50-3.40 (m, 2H, Ha, BB) 
2.81-2.75 (m, 1H, Hβ, Tyr) 2.70-2.60 (m, 3H, Hβ, Ile, Hb, BB) 2.54-2.45 (m, 3H, Hβ, Tyr, Hc, BB) 
2.43-2.29 (m, 10H, Hβ, Arg, Hβ, Pro, Hγ, β, Leu, Hγ, Ile) 2.21-2.18 (m, 2H, Hγ, Pro) 1.89-1.85 (m, 
5H, Hγ, Arg, Hβ, Pro) 1.68 (d, J=6.5 Hz, 3H, CH3-Ile) 1.67-1.56 (m, 9H, CH3-Leu, CH3-Ile) 
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 2.1.2.5    Literature Syntheses 
1. Cobaltocenium carboxylic acid 
The cobaltocenium carboxylic acid was synthesized in two steps by a reported 
method.[299] The first step comprised of reaction of cyclopentadiene, methyl 
cyclopentadiene and cobalt (II) bromide in pyrrolidine. This yielded a mixture of mono 
and dimethyl cobaltocenium that was precipitated as hexafluorophosphate salt. The 
second step was the oxidation of the methyl group to acid using KMnO4. The 
cobaltocenium monocarboxylic was separated from the disubstituted cobaltocenium or 
the starting material by soxhlet’s extraction with acetone. 
 
2. Fmoc-t-butyl-N-2-aminoethyl glycinate  
The Fmoc-t-butyl-N-2-aminoethyl glycinate was synthesised by a reported method.[300] 
It was isolated as HCl salt. The other amino group was protected with Fmoc using the 
reported method.[190] The purification was carried out by flash chromatography and the 
yield was 71%. 
 
3. Fmoc- N-2-aminoethyl glycine (BB) 
Before reaction of the ligand to the peptide, the t-butyl group was removed by 90% TFA 
in CH2Cl2 at 0°C in 2 hours. The t-butyl alcohol and excess of TFA was removed by 
azeotropic distillation with toluene. The yield was 97%. 
 
4. Fmoc protected N,N-diaminopropionic acid 
Diaminopropionic acid is available commercially. The amino groups were protected 
according to a described method.[301] The purification was carried out by flash 
chromatography and yield was 30 %. 
 
5. Platination  
The platination was carried out as described by Roubillard.[190] Potassium 
tetrachloroplatinate was dissolved in a mixture of DMF/water (9:1 v/v) on an ultrasonic 
warm water bath (at 50°C) due to its poor solubility. The Fmoc groups of the BB and 
DAP ligands were removed by 20% piperidine. After washing, the resin was treated 
with the solution of K2PtCl2  for 40-72 hours in the dark with vigrous agitation. 
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2.2     Biological Studies 
Uptake Studies and Cytotoxicity  
Materials and Apparatus 
Cell line 
Human Hep G2 cell line   DSMZ, Braunschweig, Germany 
(Human liver cancer) 
 
Chemicals 
Gelatine      Merck, Darmstadt, Germany 
Paraformaldehyde    Riedel-de-Haën AG, Seelze, Germany  
DAKO® Fluorescent Mounting Medium DAKO Diagnostics GmbH, Hamburg,  
Germany 
Hoechst 33342 Dye    Molecular Probes, Göttingen, Germany 
FM 4-64 Marker    Molecular Probes, Göttingen, Germany 
Foetal Bovine Serum (FBS)   PAA Laboratories GmbH, Cölbe, Germany 
RPMI 1640 with L-Glutamine  Gibco, Invitrogen GmbH, Karlsruhe, Germany 
RPMI 1640 with L-Glutamine   Gibco, Invitrogen GmbH, Karlsruhe, Germany 
(Without phenol red)      
Penicillin/Streptomycin/Glutamine (100x) Invitrogen GmbH, Karlsruhe, Germany 
Dulbecco’s Phosphate buffered saline Sigma-Aldrich, Taufkirchen, Germany 
Trypsin-EDTA solution   Sigma-Aldrich, Taufkirchen, Germany 
Trypanblue solution    Serva Feinbiochemika, Heidelberg, Germany 
Triton x100     Serva Feinbiochemika, Heidelberg, Germany 
WST-1 reagent (4-[3-(4-iodopheny)- 
2-(4-nitrophenyl)-2H-5-tetrazolio]- 
1,3-benzene disulfonate)   Roche Diagnostics, Mannheim, Germany 
Crystal Violet  Merck, Darmstadt, Germany  
Sodium-n-dodecyl sulphate   Boehringer, Mannheim, Germany 
 
  
Cell culture media 
 
Medium A RPMI 1640 with L-Glutamine, 10% FBS not heat inactivated, 100 Units/ml 
Penicillin G, 100 µg/ml Streptomycin, 0.292 mg/ml L-Glutamine 
Medium B RPMI 1640 with L-Glutamine, 100 Units/ml Penicillin G, 100 µg/ml 
Streptomycin, 0.292 mg/ml L-Glutamine 
Medium C Phenol red free RPMI 1640 with L-Glutamine, 100 Units/ml Penicillin G, 
100 µg/ml Streptomycin, 0.292 mg/ml L-Glutamine 
 
 
Apparatus 
Cell culture flasks   Greiner bio-one, Frickenhausen, Germany. 
NunclonTMsurface 4-well plates Nunc Roskilde, Denmark. 
MicrotestTM96 plates   Becton Dickinson Labware, Franklin Lakes, NJ, USA. 
Incubator    Direct Heat CO2 Incubator Series 310, Forma  
     Scientific. 
Laminar Flow    Pretil® Laminarflow, Bemplingen, LaminAir®   
                                   HB2448, Heraeus Instruments.  
Centrifuge    Heraeus Multifuge 3S-R, Osterode. 
Microscope    Inverse microscope Nikon ECLIPSE TS 100/TS    
100-F, Nikon Europe B.V., Badhoevedorp, Holland. 
Leica® BioMed microscope. 
Fluorescence microscope Zeiss Axioplan-2 with  
AxioCam, Jena, Germany. 
Absorbance reader   Bio-Rad Microplate reader 550, Tokyo, Japan. 
 
Methods 
Cell Culture and Passaging 
Hep G2 cells were cultured in 25 cm2 or 75cm2 culture flasks (as needed) in Medium A in a 
humified incubator maintained at 37°C in an atmosphere containing 5% CO2. The cells were 
cultured at subconfluent numbers (65-70%) for three to four days.  
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 The cell mono layer was once washed with PBS without Mg2+/Ca,2+ thereafter Trypsin-
EDTA, 1ml per 25cm2 of surface area, was added directly onto the cells. The culture flasks 
were then incubated at 37 °C for exactly 1 minute 45 seconds. Swiftly, the trypsin was 
neutralised with 0.5 ml FBS (5 ml of medium A) for 25 cm2 culture flask. The cells were 
taken in a sterile plastic tube (blue cap). The culture flask rinsed 3 times with PBS and the 
volume was made up to 45 ml with sterile PBS. The blue cap tube was then centrifuged at 
250xg for 5 minutes. The supernatant was discarded and the pellet of cells was resuspended 
in 5 ml of Medium A.  The cell suspension was diluted to the required seeding density in a 
new labelled culture flask or plate containing pre-warmed medium for experiments. All the 
solutions for cell handling and passaging are kept at 37 °C during manipulations. 
 
Cell Counting  
Because a fixed number of cells were seeded for experiments,  the counting of the cells is an 
important step before the actual experiments. For this, after normal passaging, the cell pellet 
was resuspended in 2 ml of medium A. 20 µl of this cell suspension was diluted with 30 µl 
of PBS in a 1.5 ml eppendorf tube and 50µl of Trypan blue solution was added. The tube 
was gently agitated and left for one minute. 10µl of this suspension was then taken in a 
Neubauer cell counting chamber and the cells counted under a microscope. Only the 
unstained (live) cells were counted. 
 
For the calculation of the number of cells in one millilitre the following formula was 
used: 
Y = n /4 x 5 x 104 
 
Where, Y is the number of cells per millilitre of cell suspension under investigation, n is 
the total cell number in the 4 regions in the neubauer chamber in which the cells were 
counted, 5 is the dilution factor and 104 gives the number per millilitre.  
 
2.2.1  Cellular Uptake Monitoring and Microscopy 
The experiments were performed in 4-well plates. Each well was supplied with a glass cover 
slip which was coated with 0.2 % gelatine for 6 hours at 37°C. For experiments, 7.5 x 104 
cells per well were seeded and grown for two days in Medium A. Before incubation with the 
compounds, cells were starved for 1 hour in Medium B. Hep G2 cells were incubated with 
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 test compounds in a concentration range of 1mM to 10µM in medium B, for 24 h at 37 °C in 
a humified incubator (5 % CO2). 
  
Tested Concentrations 
NLS-bioconjugates   1mM, 500µM and 100µM 
TAT-bioconjugates   1mM, 500µM, 100µM and 50µM 
 
Experiments with Live cells 
After treatment, cells were washed twice with Medium A and once with phosphate buffered 
saline (PBS, 10mM). In case of the endosome marker, after the first washing with 
medium B, the cells were incubated in Medium B with 10 µM of FM 4-64 for 15 minutes. 
Afterwards, the cells were again washed twice with PBS. For nuclear staining, 100µl 
Hoechst 33342 dye (25µg/ml) was added for 1 minute to the cells and the cells were washed 
again with PBS three times for one minute each time.  
 
The viability of the cells was checked by incubation with propidium iodide (8µg/ml; 15 
minutes). The cover slips were mounted in a drop of PBS on a glass slide for microscopic 
observations. The cells were photographed within 5 minutes after mounting.  
 
Experiments with Fixed Cells  
The endosomal staining was carried out prior to the fixation of the cells. The cells were 
incubated in Medium B with 10 µM FM 4-64 for 15 minutes. After washing twice with 
PBS, the fixation was carried out by treating the cells with 2% paraformaldehyde for 20 
minutes. Afterwards the cells were washed three times with 5 minute intervals. In this case 
the nuclear staining was carried out with 40µl of Hoechst 33342 dye (25µg/ml) after 
fixation of the cells. Afterwards the cells were washed again three times with PBS with 3 
minute intervals. Finally, the cover slips were mounted upside down in DAKO’s fluorescent 
mounting medium. All the fixed cells were preserved in dark at 5°C. 
 
The cellular uptake and distribution was monitored by a fluorescence microscope 
(Axioplan-2, Zeiss, Jena, Germany) equipped with CY2 (green fluorescence), CY3 (red 
fluorescence) and UV (blue fluorescence) filters. 
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2.2.2    Proliferation Assay 
The Tetrazolium salt WST-1 and Crystal violet assay  
WST-1 cell proliferation assay 
96-well plates were coated with 0.2% gelatine for 6 hours at 37° C. After one wash with 
PBS, 2.0 x 104 cells in medium A were seeded in each well. The plates were incubated for 
12 hours. Since the doubling time for Hep G2 cells is reported to be 50-60 hours,[302, 303] the 
cells were incubated for 48 hours after treatment. A control plate with same number of cells 
was used to determine the background absorbance in case of WST-1 assay and the in case of 
the Cv assay to determine the cell number. The test compounds were introduced in 
concentrations of 1, 0.5 and 0.1 mM (4 wells for each concentration) and incubated in a 
humified atmosphere containing 5% CO2. After treatment, the cells were washed twice with 
medium A, then once with medium C. Each well was then supplied with 100µl of the 
medium C, 10µl/well of WST-1 reagent was added and the plates were incubated at 37°C. 
The cleavage of WST-1 to formazan by metabolically active cells at 0, 60 and 90 minutes 
was quantified by scanning the plates at 415nm against a reference wavelength at 655nm in 
a microtiterplate reader.[304] 
Crystal violet cell quantification assay 
After the WST-1 assay, the cells were fixed with 4% paraformaldehyde for 5 minutes at 
room temperature and later washed three times with PBS and three times with 0.1% Triton x 
100 buffer in PBS. 100µl of crystal violet [0.04% crystal violet in 4% (v/v) ethanol] was 
then added to each well and the plates were gently agitated for one hour at room 
temperature. After treatment with crystal violet the cells were washed 7 times with distilled 
water with two minute shaking intervals. Finally, 100µl of 1% SDS (sodium-n-dodecyl 
sulphate) was added to each well and the plates were incubated at room temperature with 
vigorous shaking, for 40 minutes. At the end, the absorbance was measured at 570 nm 
against a reference wavelength at 655nm.[305] 
Statistical Analyses 
All data are presented as mean values +standard errors of the mean (SEM). Depending on 
the mode of distribution, statistical procedures were performed by the Mann-Whitney Rank 
Sum test or by the Student’s t-test using the Sigmastat 3.10 for windows. A P value of 0.05 
or less was choosen for statistical significance. 
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2.2.3   Receptor Binding Studies 
The  binding studies were carried out  by Dr. E. Garcia-Garayoa  in  collaboration  with 
Prof. Dr. Bläuenstein of the Centre for Radiopharmaceutical Science, Paul Scherrer 
Institute, Switzerland. 
Materials 
Cell line 
HT-29 cell line (human colon adenocarcinoma) was obtained from European Collection of 
Cell Culture (ECACC), Salisbury, England. 
 
Chemicals  
The following chemicals were from Gibco BRL Life Technologies AG, Basel, Switzerland; 
McCoy’s 5A +GLUTAMAX-I  cell culture media 
Fetal calf serum (FCS) 
Antibiotic/antimycotic solution 
Bovine serum albumin (BSA) 
Trypsin-EDTA 
Soybean Trypsin inhibitor 
 
The following chemicals were from Sigma, Buchs, Switzerland; 
HEPES (N-2-Hydroxyethypiperazine-N´-2-ethanesulfonic acid) 
Chymostatin 
Bacitracin 
Neurotensin(8-13) 
 
The following chemicals were from Merck, Dietikon, Switzerland; 
HCl 
NaCl 
MgCl2
NaOH 
KCl 
 EGTA (Ethylene glycol-bis(β-aminoethylether)-N, N, N´, N´-tetraacetic acid) was from 
Fluka, Buchs, Switzerland. 
[125 I]Tyr3-NT was from Amersham, Zurich, Switzerland. 
The radiotracer 99m Tc-NT-II [retro-Nα-carboxymethylhistidine-NT(8-13)] was synthesised 
in the lab. 
 
Apparatus  
NaI gamma counter (Packard Canberra Cobra II Auto-Gamma) was used. 
 
Method 
The binding studies were carried out according to a reported method.[297] 
Cell Culture 
The HT-29 cells were maintained in McCoy’s 5A-GLUTAMAX-I media at 37°C in a 
humified incubator under an atmosphere containing 7.5% CO2 and passaged weekly. The 
culture media was supplemented with 10% FCS, 100 IU/ml penicillin, 100µg/ml 
streptomycin and 0.25 µg/ml amphotericin B. 
 
Binding assays  
Intact HT-29 cells at confluence were used for the binding assays. A day before the assay, 
106 cells/0.4ml (equivalent to 0.3 mg protein) were seeded in 48 well plates. For 
experiments, a  special binding buffer containing protease inhibitors (50 mM HEPES, 125 
mM NaCl, 7.5 mM KCl, 5.5 mM MgCl2, 1 mM EGTA, 5g/L bovine serum albumin, 2 mg/L 
chymostatin, 100 mg/L soyabean trypsin inhibitor, 50 mg/L bacitracin, pH 7.4) was used.  
 
Cells were incubated for 1 hour at 37°C with 2 kBq/well of 99mTc-NT-II [retro-Nα-
carboxymethylhistidine-NT(8-13)] and variable concentrations (0.01-30,000 nM) of the test 
compounds. The cells were then washed twice with cold binding buffer and afterwards 
solubilised with 1N NaOH at 37°C (0.4ml/well). The activity was determined in a γ-counter. 
Each experiment was performed in triplicate. 
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Results 
3.1    Syntheses and Characterization 
All bioconjugates were synthesized on solid phase using Fmoc strategy (scheme 3.1). The 
peptide sequences were synthesized either on automatic peptide synthesizers or manually. 
Wang resin preloaded with the first amino acid (with the C-terminal attached to the resin by 
a linker) was used. 
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Scheme 3.1: SPPS of fluorescently labelled metallocene-NLS bioconjugates with Fmoc strategy. 
 
In all cases, acid labile linker was used so as to obtain free acid group at the C-terminal 
upon acid cleavage (scheme 3.2). 
 
H
N
O
O
O
R
TFA
Peptide
 
Scheme 3.2: Wang resin with an acid labile linker. 
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 Ferrocene and cobaltocenium carboxylic acids were used as metal labels. Although both 
metal complexes resemble more or less in size and other properties, cobaltocenium 
carboxylic acid has cationic character as compared to the neutral ferrocene carboxylic acid 
(scheme 3.3). Both could be easily coupled to the peptides on the solid phase. However, 
cleavage conditions for ferrocene bioconjugates had to be modified to prevent the oxidative 
decomposition of the ferrocene moiety. 
Fe Fe
O
Co+ Co
O
(1) Ferrocene (FcH) (2) Ferrocene carboxylic acid, FcC(O)-
(4) Cobaltocenium carboxylic acid, CcC(O)-(3) Cobaltocenium (CcH)
OH
OH
+
 
Scheme 3.3: Metallocene carboxylic acids. 
 
Fluorescein isothiocyanate (FITC) was used as the fluorescent label and placed 
orthogonally on the side chain of the terminal Lysine. It was added manually in the last step 
of synthesis so as to minimise its exposure to harsh conditions of synthesis. The removal of 
Methytrityl (Mtt) group from Lysine side chain, with the help of dilute acid, is fully 
compatible with other acid labile protecting groups.  
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H
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N
H
CH C
O
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R
O
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S
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COOH
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Scheme 3.4: Removal of Mtt group and labelling with FITC. 
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 The coupling with FITC is also very efficient and simple washings are sufficient to 
remove most of the impurities. The HPLC chromatograms of some crude bioconjugates 
showed 98% purity. Therefore, labelling with FITC on solid phase is probably one of the 
cleanest and easy-to-handle methods. 
 
In case of platinum containing compounds K2PtCl4 was used for platination. The poor 
solubility of K2PtCl4 in DMF was a problem but it could be dissolved in a mixture of 9:1 
DMF/H2O in few hours on an ultrasonic bath maintained at 50°C. K2PtCl4 was handled with 
care and all the steps of synthesis were carried out in the dark. The ligands were the 
aminoethylglycine (BB) and diaminopropionic acid (DAP) (scheme 3.5). 
 
H2N
H
N
O O
NH2
H2N
(1) (2)
OH OH
 
Scheme 3.5: Ligands used for platination: aminoethylglycine (BB) and diaminopropionic acid (DAP).  
 
The ligands were coupled (with TBTU and HOBt) to the peptide and the amino groups 
were deprotected (with 20% piperidine) prior to platination. At least 40 hours were required 
for complexation. The change of colour of the resin indicated successful complexation. 
Afterwards the resin was washed with water in addition to CH2Cl2 and MeOH. The metal 
peptide bioconjugate was cleaved from the resin by a mixture of 95%TFA and 5% water in 
2 to 3 hours. 
 
All the bioconjugates were characterized by spectroscopic studies, HPLC and 
electrochemistry. The mass of each compound was determined by mass spectrometry 
MALDI-TOF or ESI. The 1H-NMR spectra were also measured for all bioconjugates. One 
of the remarkable characterising feature is the signals arising from the cyclopentadienyl 
rings of the metallocenes, around 6 ppm (intensity 5:2:1:1) for the cobaltocenium group and 
around 4 ppm (intensity 5:2:2) for the ferrocene group. The FITC signals were identified in 
the aromatic region of the proton NMR spectra. The purity of the bioconjugates was 
analysed by RP-HPLC and subsequent purifications were carried out by preparative RP-
HPLC using different isocratic conditions for different compounds. Since all the metal 
containing bioconjugates are electrochemically active, their redox potentials were 
determined.  
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 The successfully synthesized bioconjugates are listed in the table 3.1. One letter codes 
are used to denote the amino acids. CcC(O)- and FcC(O)- are used to denote the 
cobaltocenium and ferrocene carboxylic acids. Pt indicates Platinum, BB stands for 
backbone (aminoethylglycine) and DAP for diaminopropionic acid. NLS stands for nuclear 
localisation signal, NLSmca for methoxycoumarin substituted NLS, NLSscr for the scrambled 
sequence of NLS, NT for neurotensin, pNT for pseudo neurotensin and TAT denotes the 
transctivaor of transcription peptide.  
 
Table 3.1: List of synthesized bioconjugates 
 
Comp. No. Abbreviation Sequence 
1 CcC(O)-NLS CcC(O)-PKKKRKV 
2 FcC(O)-NLS FcC(O)-KPKKKRKV 
3 CcC(O)-NLSmca CcC(O)-PKKKRKmcaV 
4 Pt-BB-NLS Pt-BB-PKKKRKV 
5 Pt-DAP-NLS Pt-BB-PKKKRKV 
6 K-NLS KPKKKRKV 
7 K(FITC)-NLS K(FITC)-PKKKRKV 
8 CcC(O)-K-NLS CcC(O)-KPKKKRKV 
9 FcC(O)-K-NLS FcC(O)-KPKKKRKV 
10 CcC(O)-K(FITC)-NLS CcC(O)-K(FITC)-PKKKRKV 
11 FcC(O)-K(FITC)-NLS FcC(O)-K(FITC)-PKKKRKV 
12 CcC(O)-K(FITC)-V CcC(O)-K(FITC)-V 
13 FcC(O)-K(FITC)-V FcC(O)-K(FITC)-V 
14 NLSsrc KKVKPKR 
15 CcC(O)-NLSsrc CcC(O)-KKVKPKR 
16 FcC(O)-NLSsrc FcC(O)-KKVKPKR 
17 K-NLSsrc KKKVKPKR 
18 K(FITC)-NLSsrc K(FITC)-KKVKPKR 
19 CcC(O)-K-NLSsrc CcC(O)-KKKVKPKR 
20 FcC(O)-K-NLSsrc FcC(O)-KKKVKPKR 
21 CcC(O)-K (FITC)-NLSsrc CcC(O)-K(FITC)-KKVKPKR 
22 FcC(O)-K(FITC)-NLSsrc FcC(O)-K(FITC)-KKVKPKR 
23 K-TAT KGRKKRRQRRR 
24 K(FITC)-TAT K(FITC)-GRKKRRQRRR 
25 CcC(O)-K-TAT CcC(O)-KGRKKRRQRRR 
26 FcC(O)-K-TAT FcC(O)-KGRKKRRQRRR 
27 CcC(O)-K(FITC)-TAT CcC(O)-K(FITC)-GRKKRRQRRR 
28 FcC(O)-K(FITC)-TAT FcC(O)-K(FITC)-GRKKRRQRRR 
29 pNT KKPYIL 
30 FcC(O)-pNT FcC(O)-KKPYIL 
31 CcC(O)-pNT CcC(O)-KKPYIL 
32 Pt-BB-pNT Pt-BB-KKPYIL 
33 NT RRPYIL 
34 CcC(O)-NT CcC(O)-RRPYIL 
35 FcC(O)-NT FcC(O)-RRPYIL 
36 Pt-BB-NT Pt-BB-RRPYIL 
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 3.1.1    NLS Bioconjugates 
Wang resin preloaded with Fmoc-Val-OH (0.63mmol/g) was used for the synthesis of all 
the NLS (126-132) bioconjugates. The synthesis was carried out in an eppendorf automatic 
peptide synthesizer. The metal labels were coupled manually in the lab. The synthesized 
bioconjugates were comprehensively characterized. 
 
At the very beginning, it was investigated whether a metal carboxylic group could be 
coupled to the N-terminal of a peptide on the solid support. Therefore CcC(O)-NLS (1) was 
synthesized and characterized. It also led to optimisation of conditions. For cobaltocenium 
bioconjugates the purity of the metal label is very important. Besides longer activation time 
(5-10 minutes) for cobaltocenium carboxylic acid and longer coupling times (atleast 40 
minutes) were necessary.  
 
 
Fig. 3.1: ESI (pos.) spectrum of bioconjugate 1 showing characteristic peaks of mono, di and trications. 
 
For the ferrocene containing bioconjugate 2, problems were encountered when 
conventional cleavage mixture (95% TFA, 2.5% TIS and 2.5% H2O) was used to cleave the 
bioconjugate from the resin. The coupling did not pose any greater challenge than as for the 
cobaltocenium carboxylic acid. However the cleavage conditions had to be modified using 
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 10% phenol in the cleavage mixture to protect ferrocene from oxidation. The 1H-NMR 
spectrum of compound 2 is given in Figure 3.2. 
 
 
Fig. 3.2: 1H-NMR spectrum of FcC(O)-NLS (2) in D2O at room temperature. The characteristic peaks are 
indicated. 
 
In case of compound 3, a Lysine prelabelled with methoxycoumarin (mca) was used at 
position 131 of NLS(126-131) The objective was to synthesize a fluorogenically labelled 
metal-peptide conjugate to monitor the compound in cells. This is a fairly straightforward 
and very simple approach. However, due to incompatibility of this label with the 
microscopic facilities available, later another fluorescent label namely Fluorescein 
isothiocyanate (FITC) was used for labelling of all other compounds.  
 
 
Fig. 3.3:  ESI (pos.) spectrum of crude bioconjugate 3. 
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 First the metal-peptide bioconjugates with an additional lysine residue were synthesized 
and characterized. The metallocene carboxylic acids were coupled to the N-terminal of the 
peptide sequence. After cleavage of the bioconjugates from the resin the HPLC of most 
crude compounds showed 98-99% purity indicating the efficiency and cleanliness of the 
method. The HPLC chromatogram of CcC(O)-K-NLS (8) is depicted in Figure 3.4. 
 
 
Fig. 3.4: HPLC chromatogram of compound 8; RP-HPLC using method A, see experimental. 
 
The electrochemical behaviour of the metal-peptide bioconjugates was also analyzed by 
measuring their square wave or cyclic voltammograms. The ferrocene bioconjugates 
showed a reversible wave with a redox potential in the range of 150 to 280 mV. Whereas 
the cobaltocenium bioconjugates showed a reversible wave at a high scan rate. Figure 3.5 
depicts the cyclic voltammogram of ferrocene bioconjugate (9) exhibiting a reversible wave. 
 
 
Fig. 3.5: Cyclic voltammogram of compound 9 measured in acetonitrile with TBAPF6 as supporting 
electrolyte at room temperature. 
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 Fluorescein isothiocyanate (FITC) was used in order to visualise the metallocene-NLS 
conjugates (10-11) inside the cells. The FITC labelling was carried out as the last step 
before the final cleavage of the peptide from the resin to ensure minimum of side reactions. 
After coupling of the metallocene moiety to the peptide as for CcC(O)-K-NLS, the lysine 
side chain was deprotected by removal of its “Mtt” group using dilute TFA. Reaction with 
FITC yielded the CcC(O)-K(FITC)-NLS conjugate (10) and FcC(O)-K(FITC)-NLS 
conjugate (11) on the solid support, which are bright dark orange in colour. All the 
compounds bearing FITC were stored and handled in dark. After cleavage and HPLC 
purification, the 1H-NMR spectra clearly show the fluorescein signals in the aromatic 
region, in addition to the signals corresponding to the cyclopentadiene rings of the 
metallocenes and the peptide as well. Figure 3.6 depicts the comparison of the 1H-NMR of 
the peptide with the metal labelled peptide as well as the two FITC labelled ferrocene and 
cobaltocenium bioconjugates of NLS(126-132). 
 
 
Fig. 3.6: 1H-NMR spectra of FITC labelled compounds 10 and 11 in comparison with the unlabelled  metal 
bioconjugate 8 and that of peptide 6 in D2O at room temperature. The cyclopentadiene signals can be clearly 
observed around 6 ppm and 4 ppm for cobaltocenium and ferrocene bioconjugates respectively. The FITC 
signals can be seen in the aromatic region.  
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 The MALDI-TOF spectrum of Ferrocene bioconjugate (11) with characteristic peaks is 
represented below; 
 
 
Fig. 3.7: MALDI-TOF mass spectrum of bioconjugate 11 showing characteristic peaks. 
 
The HPLC chromatograms of the crude compounds 10 and 11 are depicted in Figure 3.8.  
 
 
               A                                                                                 B   
Fig. 3.8: HPLC chromatograms of bioconjugates 10 (A) and 11 (B) using method A, see experimental. 
 
As controls, a fluorescent NLS conjugate without the metal group (K(FITC)-NLS) 7 as 
well as the truncated peptides, CcC(O)-K(FITC)-V (12) and FcC(O)-K(FITC)-V (13), were 
also prepared by solid phase synthesis. The purity of the synthesized compounds was 
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 checked by RP-HPLC. Though lipophilic due to the cyclopentadienyl rings, the 
bioconjugate is soluble in water. The HPLC chromatogram of crude  bioconjugate 12 
analyzed using method A (see experimental for details) is depicted in Figure 3.9. 
 
 
Fig. 3.9: HPLC chromatogram of bioconjugate 12. 
 
The mass of the bioconjugates was also determined by MALDI-TOF mass spectrometry. 
The mass spectrum of bioconjugate 13 is shown in Figure 3.10. 
 
 
Fig. 3.10: MALDI-TOF spectrum of bioconjugate 13 showing characteristic peaks. 
 
In addition to the metallocene bioconjugates, the platinum bioconjugates of the nuclear 
localisation signal, 4 and 5 with aminoethylglycine and diaminopropionic acid ligands 
respectively, were also successfully synthesized on the solid phase and comprehensively 
characterized.  
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 3.1.2    NLSscr Bioconjugates 
The NLSscr is the scrambled sequence of the nuclear localiszation signal (KKVKPKR). All 
the NLSscr bioconjugates (14-22) were also synthesized on Wang resin. The square wave 
voltammogram of CcC(O)-K-NLSscr (19) is depicted in Figure 3.11A and shows an E½ of -
1.38 V vs. FcH/FcH+ which is very similar to the bioconjugate 8 which contains the 
unscrambled sequence. Figure 3.11B shows the squarewave voltammogram of CcC(O)-
K(FITC)-NLSscr. 
 
A      B 
Fig. 3.11: Square wave voltammograms of bioconjugates 19 and 21. 
 
The metal-NLSscr bioconjugates (21 and 22) were also labelled with FITC. As control the 
scrambled sequence of NLS labelled with FITC was synthesized. The 1H-NMR spectra of 
all compounds were measured. Figure 3.12 depicts the 1H-NMR of the unlabelled 
bioconjugate 17 and that of the double labelled (with ferrocene and FITC) bioconjugate 22. 
Again characteristic peaks are visible corresponding to the FITC moiety as well as the 
cyclopentadienyl rings of the metallocene.  
 
Fig. 3.12: 1H-NMR spectra of the unlabelled peptide (17) and that of the FITC labelled metal peptide 
bioconjugate (22) measured in D2O at room temperature.  
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 The purity of all bioconjugates was also analyzed by RP-HPLC and the respective 
chromatograms of the crude FITC labelled bioconjugates, the metal-free (18) 
Cobaltocenium (21) and ferrocene(22) bioconjugates are represented in Figure 3.13. 
 
 
           A                                                        B                                                         C 
Fig. 3.13: HPLC chromatograms of bioconjugates 18 (A), 21 (B) and 22 (C) using method A, see 
experimental. 
 
The following figure shows the MALDI-TOF spectrum of the bioconjugate 21. 
 
 
Fig. 3.14: The mass spectrum of bioconjugate 21 with characteristic peaks 
 
 
3.1.3    TAT Bioconjugates 
For the solid phase synthesis of the TAT sequence (KGKKRRQRRR) Wang resin preloaded 
with Fmoc-Arg(Pbf)-OH was used. All the metal labelled bioconjugates as well as the metal 
and FITC labelled bioconjugates were successfully synthesized and comprehensively 
characterized.  
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 The HPLC chromatograms of the crude CcC(O)-K-TAT (25) and FcC(O)-K-TAT (26) 
showed high purity as show in Figure 3.15A and B.  
 
 
            A                                                                               B 
 
Fig. 3.15: HPLC chromatograms of crude bioconjugate 25 (A) and bioconjugate 26 (B) using method A, see 
experimental.  
 
The 1H-NMR spectra also shows all the characteristic signals arising from the FITC and 
the cyclopentadienyl rings as presented in Figure 3.16. 
 
 
 
Fig. 3.16: 1H-NMR spectra of the peptide 23, the metal containing TAT peptide 25 and the FITC labelled 
Ferrocene-TAT bioconjugate 28 in D2O at room temperature. 
 
 
The electrochemical behaviour of the bioconjugates was also determined by measuring 
the cyclic or square wave voltammograms of the compounds. Figure 3.17A depicts the 
cyclic voltammogram of ferrocene bioconjugate 26 showing a reversible wave at 199 mV 
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 vs. FcH/FcH+. Whereas, the cobaltocenium bioconjugate (27) showed an E½ at -1.38 V vs. 
FcH/FcH+ in square wave voltammetry, Figure 3.17B  
 
 
               A                                                                                      B 
 
Fig. 3.17: Cyclic voltammogram of 26 (A) and the square wave voltammogram of 27 (B) in acetonitrile with 
TBAPF6 as supporting electrolyte. 
 
3.1.4    NT Bioconjugates 
The metal-neurotensin bioconjugates were also synthesized by solid phase synthesis. In 
addition, the NT(8-13) sequence was slightly modified that is the Arg8-Arg9 motif was 
replaced with Lys-Lys and the sequence is designated as pseudo NT (pNT). All the 
bioconjugates were characterized and their purity was determined by RP-HPLC. 
 
Bioconjugate 30 containing a ferrocene moiety exhibited a typical cyclic voltammogram 
as depicted in Figure 3.18 showing a reversible peak at 218 mV vs. FcH/FcH+. 
 
 
Fig. 3.18: Cyclic voltammogram of bioconjugate 30. 
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 In addition to the metallocene bioconjugates, the platinum conjugates of the neurotensin 
and pseudoneurotensin were also synthesized and characterized. The mass was determined 
using MALDI-TOF spectrometry as depicted below;  
 
 
Fig. 3.19: Mass spectrum of bioconjugate 32 showing characteristic isotopic pattern of platinum. 
 
The 1H-NMR of the two metallocene-peptide bioconjugates are compared with the metal 
free neurotensin fragment as depicted in Figure 3.20 and show the characteristic signals of 
the cyclopentadienyl rings of the respective metallocenes.  
 
 
Fig. 3.20: 1H-NMR spectra of the peptide 33 and the cobaltocenium-NT (34) and ferrocene-NT (35) in D2O at 
room temperature. 
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 RP-HPLC was used to check the purity of the compounds. The HPLC chromatograms of 
crude metallocene bioconjugates CcC(O)-NT (34) and FcC(O)-NT (35) are shown below in 
Figure 3.21 indicating a very high purity.  
 
 
 
               A                                                                                        B 
 
Fig. 3.21: HPLC chromatograms of crude bioconjugates 34 (A) and 35 (B) using method A, see experimental. 
 
 
The cobaltocenium bioconjugate 34 was tested for its electrochemical behaviour and it 
exhibited an E½ at -1.31 V vs. FcH/FcH+ as depicted in Figure 3.22.  
 
 
Fig. 3.22: Square wave voltammogram of 34 in acetonitrile with TBAPF6 as supporting electrolyte. 
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3.2    Cellular Uptake and Nuclear Localisation 
An immortalized human liver cancer cell line (Hep G2) was used for cellular uptake studies. 
Hep G2 cells were chosen, because they have relatively large nuclei. However, membrane 
translocation in this cell line is known to be rather difficult.[306] The cells were incubated with 
the test compounds in various concentrations for 24 h at 37°C in a humified incubator under 
an atmosphere containing 5% CO2. The cells were washed twice with medium A in order to 
remove any adhereing metal-peptide bioconjugate. After the first washing step with PBS, the 
cells were treated according to the protocols. The experiments with live cells and fixed cells 
were carried out in parallel. Because recent reports indicate potential artificial redistribution 
of cell penetrating peptides into the nucleus upon fixation,[226, 307] it was essential to monitor 
the uptake and distribution of compounds in live cells. In addition, a complete duplicate of 
experiments was carried out with fixation of the cells with paraformaldehyde. This was done 
not only for the ease of handling, observation and photography, but also for the sake of 
comparison of the uptake and distribution in live and fixed cells in order to determine 
potential differences.  
 
 
3.2.1 Experiments with Live Cells 
 
3.2.1.1 NLS Bioconjugates 
Cells incubated with Cobaltocenium bioconjugate (10) in a concentration of 1mM, showed 
three kinds of fluorescence; homogenous green fluorescence in the cytoplasm, and some 
dotted fluorescence in the cytoplasm and homogenous stronger fluorescence in the nuclei 
(Figure 3.2.1 A). Figures 3.2.1 C and D depict the co-localisation of the compound in the 
endosomes and the nucleus, respectively. The results indicate that the CcC(O)-K(FITC)-NLS 
(10) is readily taken up by the cells. The dot-like cytoplasmic distribution of compound 10 
(Figure 3.2.1 C) overlapping with that of the endosome marker FM 4-64 indicate an active 
transport via endocytosis. The bioconjugate is probably internalised via endocytosis, released 
into the cytoplasm and then accumulated in the nucleus. The integrity of the cell membrane 
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 was confirmed throughout the experimental procedure by verifying that the cells excluded 
propidium iodide (Figure 3.2.1 B). 
 
  
     A      B 
  
     C      D 
 
Fig. 3.2.1: Cellular uptake and nuclear localization of the cobaltocenium bioconjugate 10 (A); Integrity of 
cells after  treatment  with  propidium iodide (B);    Localisation  in  endosomes, cells after  incubation  
with FM 4-64 (5µM) for 15 minutes (merged image, C); Merged image depicting endosomes and nucleus; 
CY3 and UV filters (D). Double Fluorescence microscopy, magnification 630x. Representative pictures of 
three independent experiments. 
 
The ferrocene-NLS bioconjugate 11, in a concentration of 500µM, was found to be 
localised in most nuclei (Figure 3.2.2 A). Fluorescence microscopy showed homogenous 
green fluorescence intracellularly being stronger in the nuclei. Some point-like fluorescence 
was also observed which seemed apparently extracellular although some small fluorescence 
might be located inside the cells. Figure 3.2.2 B depicts the endosomal and the nuclear 
staining in the same cells. Using double fluorescence microscopy, the endosomal marker FM 
4-64 revealed that this bioconjugate was not co-localised in the endosomes (Figure 3.2.2 A). 
The same result was observed with the lower concentration (100µM) of this compound 
although less nuclear localisation was observed (see appendix for pictures) indicating a 
concentration-dependent uptake and nuclear translocation. 
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     A      B 
 
Fig. 3.2.2: Localisation of bioconjugate 11 in the nuclei, merged image with CY2, CY3 and UV filters (A); 
Merged image depicting the endosomes and nuclei using CY3 and UV filters (B); Double Fluorescence 
microscopy, magnification 400x. Representative pictures of three independent experiments. 
 
 
In contrast to metal-NLS bioconjugates, in case of the control compounds that is the metal-
free K(FITC)-NLS (7), the truncated peptides, CcC(O)-K(FITC)-V (12) and FcC(O)-
K(FITC)-V (13), an overall low and scattered fluorescence is observed with no or extremely 
weak fluorescence in the nuclei. For cells incubated with the non-metal containing conjugate 
7 (Figures 3.2.3 A and B) very low fluorescence is seen in the cytoplasm and the nuclei.  
 
  
     A      B 
 
Fig. 3.2.3: Distribution of metal-free bioconjugate 7, green fluorescence (CY2 filter) (A); Light microscopy 
(B); magnification 630x. Representative pictures of three independent experiments. 
 
On the other hand, the truncated peptides 12 and 13 do not accumulate in the nuclei as 
observed by fluorescence microscopy. Most probably, these dipeptides entered the cells by 
diffusion but were not sufficiently accumulated to be visible intracellularly. In case of 
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 CcC(O)-K(FITC)-V, the bioconjugate seems to adhere extracellulary on the membranes. 
Almost no fluorescence is seen intracellularly (Figures 3.2.4 A and B).  
 
  
  A       B 
 
Fig. 3.2.4: Distribution of truncated bioconjugate 12, green fluorescence (CY2) (A); Light microscopy (B); 
magnification 630x. Representative pictures of three independent experiments. 
 
Similarly very low fluorescence was observed in the cytoplasm and none at all in the 
nuclei of the cells treated with FcC(O)-K(FITC)-V. In addition, bright dot like fluorescence 
was observed extracellularly (Fig. 3.2.5 A and B). 
 
  
  A       B 
 
Fig. 3.2.5: Localisation of bioconjugate 13, merged image, CY2, CY3 and UV filters (A); Merged image 
depicting the endosomes, CY2 and CY3 filters (B); Double Fluorescence microscopy, magnification 400x. 
Representative pictures of three independent experiments. 
 
For all the metallocene-NLS and control compounds, some dot-like fluorescence is 
observed extracellularly and on the outer membrane, although to a varying degree (mostly for 
the control compounds, much less for the metallocene bioconjugates). It seems that these 
compounds adhere on the cell surface, a characteristic of basic cell penetrating peptides.  
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3.2.1.2 NLSscr Bioconjugates 
The role of the NLS upon cellular uptake and nuclear localisation could be determined by 
comparing the wild type NLS with the scrambled NLS. For this purpose, the scrambled 
sequence of the NLS (KKVKPKR) was used. Boffa et al have shown that this scrambled 
sequence is unable to target the nuclei of the cells. In this context it is necessary to note that 
the nuclear localisation function of the NLS is essentially dependent on the presence of Lys 
128.[308] 
 
Therefore, the ferrocene (22) and cobaltocenium conjugates (21) of the scrambled NLS 
sequence were synthesized. Both were similarly labelled with FITC for monitoring the 
uptake. FITC labelled metal-free scrambled peptide (18) was synthesized as a control. All the 
three compounds, 18, 21 and 22, showed similar behaviour: they were not localised in the 
endosomes, not distributed in the cytoplasm and no nuclear localization was observed in the 
concentrations tested (500µM and 100µM). Some bright green spots were seen extracellularly 
which is probably due to the tendency of these compounds to adhere to the cell membrane. 
 
For the metal-free scrambled peptide 18, the fluorescence was mostly extracellularly 
observed (Figures 3.2.6 A and B). This is probably due to adhering of the cationic peptide on 
the cell surface. 
 
  
  A        B 
 
Fig. 3.2.6: Distribution of bioconjugate 18, merged image green, red and blue fluorescence (A); Merged 
image depicting the endosomes, CY2and CY2 filters (B); Double Fluorescence microscopy, magnification 
400x. Representative pictures of three independent experiments. 
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 CcC(O)-K(FITC)-NLSscr (21), was also unable toenter the cells. Figures 3.3.7 A and B, 
depict the endosomes and the nuclei. Some bright spots were visible extracellularly. 
 
 
  
  A       B 
 
Fig. 3.2.7: Distribution of bioconjugate 21, merged image green, red and blue fluorescence (A); Merged 
image depicting the endosomes, CY2 and CY3 filters (B); Double Fluorescence microscopy, magnification 
400x. Representative pictures of three independent experiments. 
 
 
Similarly in case of the Ferrocene bioconjugate of the scrambled NLS, 22, no fluorescence 
was noted in either cytoplasm or in the nuclei while bright spots were visible extracellularly. 
(Figures 3.2.8 A and B).  
 
 
  
  A       B 
 
Fig. 3.2.8: Distribution of bioconjugate 22, merged image green, red and blue fluorescence (A); Merged 
image depicting the endosomes, CY2 and CY3 filters (B); Double Fluorescence microscopy, magnification 
400x. Representative pictures of three independent experiments. 
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 3.2.1.3                  TAT Bioconjugates 
TAT is a sequence of 10 amino acids known as the viral transactivator of transcription. This 
Arginine rich cationic peptide (GRKKRRQRRR) functions as a carrier peptide and carries the 
cargos inside the cells across the cell membrane. 
 
The TAT peptide was labelled with the cobaltocenium and ferrocene (bioconjugates 27 and 
28 respectively) at the N-terminal. An additional Lysine was used for FITC labelling. As 
control, metal-free peptide 24 was also synthesized. All the three compounds were the tested 
using Hep G2 cells for cellular uptake and nuclear localisation.  
 
The FITC labelled peptide (24) alone was not observed intracellularly in a concentration of 
100µM. No fluorescence was noted in the cytoplasm or in the nuclei. Because some green 
fluorescence was observed extracellularly, the peptide seems to attach to the cell surface. 
(Figures 3.2.9 A and B).  
 
  
  A       B 
  
  C       D 
Fig. 3.2.9: Localisation of bioconjugate 24, merged image green, red and blue fluorescence (A); 
bioconjugate 24, merged image depicting the endosomes, CY2 and CY3 filters (B); Localisation of 
bioconjugate 27, merged image CY2, CY3 and UV filters (C); bioconjugate 27, merged image depicting 
the endosomes, CY2 and CY3 filters (D); Double Fluorescence microscopy, magnification 400x. 
Representative pictures of three independent experiments. 
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 The CcC(O)-K(FITC)-TAT bioconjugate, 27 (100µM concentration), does not seem to 
gain access to either the intercellular compartments or the nuclei. Bright dot like fluorescence 
outside the cells indicates adhering of the compound on the cell surface (Figures 3.2.9 C and 
D). 
 
In contrast, the ferrocene bioconjugate (28) at tested concentration of 10µM, seems to 
accumulate inside the cytoplasm of the cells as homogenous green fluorescence is observed 
intracellularly (Figure 3.2.10 A). However, the compound does not gain entry in the nuclei 
(Figure 3.2.10 B). The hydrophobic ferrocene moiety helps the internalisation of the peptide 
most likely by endocytosis and the escape from the endosomes seems to occur partially 
because a co-localisation of the compound in the endosomes is observed (Figure 3.2.10).  
 
  
  A       B 
 
Fig. 3.2.10: Distribution of bioconjugate 28, merged image CY2, CY3 and UV filters (A); bioconjugate 28, 
merged image depicting the endosomes, CY2 and CY3 filters; Double Fluorescence microscopy, 
magnification 400x. Representative pictures of three independent experiments. 
 
 
3.2.2   Experiments with Fixed Cells 
 
We also performed experiments using 2% paraformaldehyde for the fixation of the cells 
(20 minutes). After washing three times, the nuclei were stained with Hoechst dye for 5 
minutes. For technical reasons the endosomal and nuclear staining was extremely difficult to 
carry out at the same time. Therefore, in one experiment cells were either stained with nuclear 
dye or with the endosomal marker. At the end, the coverslips were mounted in DAKO’s 
Fluorescent mounting medium and stored at 4 °C in the dark. 
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 3.2.2.1    NLS Bioconjugates 
Identical results were obtained for cellular uptake and nuclear localisation for fixed or live 
cells. In case of the cobaltocenium bioconjugate (10) homogenous fluorescence is observed in 
the cytoplasm while stronger fluorescence is noted inside the nuclei (Figures 3.2.11 A and B). 
The endosomal staining indicates localisation of the bioconjugate in the endosomes but not 
extensively (Figures 3.1.11 C and D). Most probably the endosomes were permeable and 
opene after the time of treatment. 
 
 
  
  A       B 
  
  C       D 
Fig. 3.2.11: Localisation of bioconjugate 10 after incubation with 5µM of the endosomal marker, FM 4-64 
for 15 minutes or with Hoechest dye for nuclear staining for 5 minutes, merged image, CY2 and UV filters 
(A); bioconjugate 10, merged image depicting the endosomes, CY2 and CY3 filters; The cells were fixed 
with 2% paraformaldehyde and mounted in DAKO’s fluorescent mounting medium. Double Fluorescence 
microscopy, magnification 630x. Representative pictures of three independent experiments. 
 
Similarly, in case of the the ferrocene-labelled bioconjugate, 11 three kinds of fluorescence 
was observed. The bioconjugate was observed to be homogenously distributed in the 
cytoplasm and accumulated in the nuclei as shown by the strong green fluorescence in the 
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 nuclei and weaker, but homogenous green fluorescence in the cytoplasm. Some bright dot like 
fluorescence was also observed extracellularly (Figures 3.2.12 A and B).  
 
  
  A       B 
 
Fig. 3.2.12: Localisation of bioconjugate 11, merged image, CY2 and UV filters (A); nuclear localization of 
bioconjugate 11 (B); The cells were fixed with 2 % paraformaldehyde and mounted in DAKO’s 
fluorescent mounting medium.  Double Fluorescence microscopy, magnification 630x. Representative 
pictures of three independent experiments. 
 
The bioconjugate was co-localised with the endosomal marker (FM 4-64) (Fig. 3.2.13 A 
and B). 
 
  
  A       B 
 
Fig. 3.2.13: Localisation of bioconjugate 11 in the endosomes after incubation with 5µM of the endosomal 
marker FM 4-64 for 15 minutes, merged image, CY2, CY3 and UV filters (A); bioconjugate 11, CY2  
filter; The cells were fixed with 2 % paraformaldehyde and mounted in DAKO’s fluorescent mounting 
medium. Double Fluorescence microscopy, magnification 630x. Representative pictures of three 
independent experiments. 
 
 
The control compound, the metal free peptide 7, (Figures 3.2.14 A-D) very little 
internalisation is seen. Bright spots are visible extracellularly indicating adherance to the cell 
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 surfaces or localisation among the cells. Due to its highly charged nature, the peptide seems to 
clump together therefore, dot-like fluorescence is observed extracellularly. 
 
  
  A       B 
  
  C       D 
 
Fig. 3.2.14: Localisation of bioconjugate 7, after incubation with 5µM of the endosomal marker FM 4-64 
for 15 minutes, CY2 and CY3 filters (A); Distribution of bioconjugate 7, CY2 filter (B) Localisation of 
bioconjugate 7, merged image, CY2 and UV filters (C); Distribution of bioconjugate 7 (D); The cells were 
fixed with 2% paraformaldehyde and mounted in DAKO’s fluorescent mounting medium. Double 
Fluorescence microscopy, magnification 630x. Representative pictures of three independent experiments.. 
 
The truncated peptides CcC(O)-K(FITC)-V (12) and FcC(O)-K(FITC)-V (13), used as 
controls, do not gain access to the nuclei. They are not localised in the endosomes. 
Extracellular bright fluorescence is observed in both cases (Figures 3.2.15 A-D).  
 
  
  A        B 
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  C       D 
 
Fig. 3.2.15: Cells after treatment with bioconjugate 12 and incubation with 5µM of the endosomal marker 
FM 4-64 for 15 minutes, CY2 and CY3 filters (A); Distribution of bioconjugate 12, CY2 filter (B) 
Localisation of bioconjugate 13, merged image, CY2 and UV filters (C); Distribution of bioconjugate 12 
(D); Double Fluorescence microscopy, magnification 630x. Representative pictures of three independent 
experiments. 
 
 
 
3.2.2.2         NLSscr Bioconjugates 
 
In case of the control, the metal-free peptide 18, few bright spots are observed outside the 
cells. The compound is neither visible in the cytoplasm nor in the nuclei (Figure 3.2.16). 
 
  
  A       B 
 
Fig. 3.2.16: Localisation of bioconjugate 18, merged image, CY2 and UV filters (A); Distribution of 
bioconjugate 18, CY2 filter (B); The cells were fixed with 2 % paraformaldehyde and mounted in 
DAKO’s fluorescent mounting medium. Double Fluorescence microscopy, magnification 630x. 
Representative pictures of three independent experiments. 
 
The metal labelled peptides 21 and 22 (with cobaltocenium and ferrocene respectively), do  
not gain access to the nuclei and no fluorescence is observed in the cytoplasm as well (Figures 
3.2.17 A-D). The peptide seems to clump together and adhere to the cell surface.  
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  A       B 
  
  C       D 
Fig.3.2.17: Localisation of bioconjugate 21, merged image, CY2 and UV filters (A); Distribution of 
bioconjugate 21, CY2 filter (B); Localisation of bioconjugate 22, merged image, CY2 and UV filters (C); 
Distribution of bioconjugate 22, CY2 filter (D); The cells were fixed with 2 % paraformaldehyde and 
mounted in DAKO’s fluorescent mounting medium. Double Fluorescence microscopy, magnification 630x. 
Representative pictures of three independent experiments. 
 
Some yellow spots are seen inside the cells indicating that some of the compounds might 
be trapped in the endosomes upon internalisation (Figures 3.2.18 A-D). 
 
  
  A       B 
89 
   
  C       D 
Figure 3.2.18 : Localisation of bioconjugate 21 and endosomes after incubation with the endosomal 
marker FM 4-64 (5µM) for 15 minutes,  merged image, CY2 and CY3 filters (A); Distribution of 
bioconjugate 21, CY2 filter (B); Localisation of bioconjugate 22, and endosomes after incubation with the 
endosomal marker FM 4-64 (5µM) for 15 minutes, merged image, CY2 and CY3 filters (C); Distribution 
of bioconjugate 22, CY2 filter (D); Double Fluorescence microscopy, magnification 630x. Representative 
pictures of three independent experiments. 
 
 
3.2.2.3    TAT Bioconjugates 
The TAT bioconjugates showed a different behaviour as compared to the NLS bioconjugates. 
The Ferrocene and cobaltocenium bioconjugates of TAT were synthesized and tested in a 
similar way as that of NLS under similar conditions. 
 
The control, metal-free peptide 24, was not found to be localised in the nuclei (Figure 
3.2.19 A and B). However, in some cells scattered fluorescence is seen intracellularly (Figures 
3.2.19 C and D). 
 
  
  A       B 
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  C       D 
 
Fig. 3.2.19: Localisation of bioconjugate 24 and nuclei after nuclear staining with Hoechst dye 33342 for 5 
minutes,  merged image, CY2 and UV filters (A); Distribution of bioconjugate 24, CY2 filter (B); 
Localisation of bioconjugate 24 and endosomes after incubation with the endosomal marker FM 4-64 
(5µM) for 15 minutes, merged image, CY2 and CY3 filters (C); Distribution of bioconjugate 24, CY2 filter 
(D); The cells were fixed with 2 % paraformaldehyde and mounted in DAKO’s fluorescent mounting 
medium. Double Fluorescence microscopy, magnification 630x. Representative pictures of three 
independent experiments. 
 
 
After fixation of the cells, the cobaltocenium bioconjugate (27) is found to be localised 
intracellularly. Weak fluorescence is observed in the cytoplasm, but not in the nuclei (Figures 
3.2.20 A and B). Some very bright spots are also observed outside the cells indicating 
adherence of the peptide on the cell surface. 
 
  
  A       B 
 
Fig. 3.2.20: Localisation of bioconjugate 27 and endosomes after incubation with the endosomal marker 
FM 4-64 (5µM) for 15 minutes,  merged image, CY2 and CY3 filters (A); Distribution of bioconjugate 27, 
CY2 filter (B); The cells were fixed with 2 % paraformaldehyde and mounted in DAKO’s fluorescent 
mounting medium. Double Fluorescence microscopy, magnification 630x. Representative pictures of three 
independent experiments. 
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 The ferrocene bioconjugate 28 seems to be internalised by the cells as indicated by the 
strong fluorescence in the cytoplasm. The bioconjugate, however, does not gain access to the 
nuclei (Figure 3.2.21). However, the bioconjugate is unable to enter the nuclei. It can not be 
proved whether this bioconjugate is localised with the endosomes.  
 
   
           A                B 
 
Figure 3.2.21 : Localisation of bioconjugate 28 and endosomes after incubation with the endosomal 
marker FM 4-64 (5µM) for 15 minutes,  merged image, CY2 and CY3 filters (A); Distribution of 
bioconjugate 28, CY2 filter (B); The cells were fixed with 2 % paraformaldehyde and mounted in 
DAKO’s fluorescent mounting medium. Double Fluorescence microscopy, magnification 630x. 
Representative pictures of three independent experiments. 
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 3.3     Proliferation Assay 
 
WST/CV assay 
For the screening of the compounds for their potential cytotoxic effects, the WST-1 assay, 
which is an easy, non-radioactive, spectrophotometric quantification of cell growth and 
viability was used. The WST-1 assay is a direct measurement of the cell viability. The 
tetrazolium salt WST-1 is cleaved to water soluble formazan dye by cellular enzymes (scheme 
3.3.1). An expansion in the number of viable cells results in an increase in the overall activity 
of mitochondrial dehydrogenases in the sample which will in turn lead to an increase in the 
formation of the formazan dye. This increase in the formazan dye can be quantified by 
measurement of the absorbance on a microtiterplate reader and correlates directly to the 
number of metabolically active cells in the culture. 
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Scheme 3.3.1: Cleavage of the tetrazolium salt WST-1 to formazan (EC=electron coupling reagent) 
 
The crystal violet cell quantification assay[305] was done after the WST-1 assay to 
determine the remnant number of adherent cells in order to correct the differences in cell 
numbers seeded in different wells. Crystal violet is a triphenylmethane dye that stains the 
membranes of viable cells. [305] 
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 To begin with, the Hep G2 standard population curve was drawn using different cell 
populations and their treatment with crystal violet (Figure 3.3.1) in order to determine the 
optimal number of cells required for the assays. 
 
Standard population curve for Hep G2 by Crystal Violet Assay 
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Fig. 3.3.1: Standard population curve for Hep G2 cells as determined by crystal violet cell quantification assay. 
After trypsinisation, the cells in suspension were first fixed with 4% paraformaldehyde for 5 minutes, diluted and 
centrifuged. After one washing the pellet was resuspended in 2 ml of Crystal violet solution and shaken for 1 
hour. Following dilution, the cells were again centrifuged. The pellet was resuspended in distil water and 
centrifuged, this step of washing was repeated 5 times. Finally the pellet was resuspended in a fixed volume of 
water and the cells counted. Different dilutions containing different number of cells were made and taken in a 
96-well plate (5 wells for each dilution). The cells were then treated with 1 %SDS solution for 30 minutes. The 
absorbance was measured on the ELISA reader at 570 nm against a reference wavelength at 655nm.  
 
 
The standard population curve also shows that a linear relationship exists between the 
number of cells and the increase in the absorbance. The minimum number of cells for 
satisfactory measurement of absorbance was estimated to be around 20,000 cells per well. The 
doubling time of Hep G2 cells is 50-60 hours.[302, 303] Therefore, for all experiments 20,000 
cells were seeded and treated with the test compounds after 12 hours and the assay was 
carried out after 48 hours. 
 
Similarly, another experiment was carried out to determine the optimal time of incubation 
with WST-1 for Hep G2 cells. A fixed number of cells were seeded in 12 wells of a 96-well 
plate and incubated with WST-1 reagent at 37°C and measurements were recorded every 30 
minutes for 4 hours. At the end the readings were further corrected by quantification of 
adherent cells by CV assay (Figure 3.3.2). It was observed that the maximum absorbance was 
achieved after one hour of incubation with WST-1 reagent after which a plateau was reached.  
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 Therefore, one hour was taken as the optimal time for incubation of Hep G2 cells with 
WST-1 in all experiments.  
 
WST-1/Crystal violet Standard curve for Hep G2 cells
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Fig. 3.3.2: Standard curve showing the optimal time of incubation of Hep G2 cells with WST-1 reagent. 5x104 
cells were seeded in 12 wells and incubated with 10 µl of WST-1 reagent at 37°C for 4 hours. Readings were 
taken every 30 minutes at 415 nm against a reference wavelength at 655 nm. The cells were then fixed with 4% 
PFA in PBS and after one washing, were treated with Crystal violet for 1 hour. After several washings the cells 
were treated with 1 % SDS for 40 minutes and the absorbance was measured at 570 nm against a reference at 
655 nm. 
 
 
Determination of the optimum number of Hep G2 cells and the optimal time of incubation 
with WST-1 reagent, permitted to proceed further with the actual cytotoxic screening of the 
synthesized compounds. The metal-peptide bioconjugates, not labelled with FITC, were 
screened for cytotoxic effects in the same concentrations as were used for the uptake studies. 
It should be noted that Vinblastine sulphate was used as the positive control in same 
concentrations as for the test compounds and was found to be cytotoxic in all the tested 
concentrations. Untreated cells represent the negative control and will be simply denoted as 
control in later descriptions.  
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Metallocene-NLS (wild type & scrambled) Bioconjugates  
 
The proliferation rates are presented in Figure 3.3.3 as percentage of the control with + SEM. 
The compounds K-NLS, CcC(O)-K-NLS and FcC(O)-K-NLS, in all tested concentrations 
(0.1, 0.5 and 1mM) revealed no statistically significant difference in the proliferation of the 
Hep G2 cells when compared to the control. Similarly, in case of K-NLSscr and FcC(O)-K-
NLSscr no statistically significant difference in cell proliferation was found with respect to the 
control. In contrast, CcC(O)-K-NLSscr exhibited a slightly significant difference compared 
with control in concentrations of 1mM and 0.5mM, indicating a stimulatory effect of this 
compound on the proliferation of the Hep G2 cells.  
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Fig. 3.3.3: Hep G2 proliferation rates after treatment with the metallocene-NLS bioconjugates (percentage of the 
control). Data represent the mean +SEM. The histogram and error bars represent mean of four values and the 
standard error mean respectively. (****p<0.001). 
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Platinum-NLS Bioconjugates  
 
The two platinum-NLS bioconjugates were also tested for their antiproliferative effects, 
which are presented in Figure 3.3.4. The results are presented as percentage of the control. 
Both compounds had no significant effect on the proliferation of Hep G2 cells in 
concentration of 0.1mM as compared to the control and Pt-BB-NLS had no significant effect 
in 0.5mM concentration as well.  
 
Pt-DAP-NLS was found to be cytotoxic in 0.5 and 1 mM concentrations. Pt-BB-NLS also 
showed antiprolifertiave effect in a concentration of 1 mM as indicated by the significant 
difference with respect to the control. 
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Fig. 3.3.4: Hep G2 proliferation rates after treatment with the Pt-NLS bioconjugates (percentage of the control). 
Data represent mean +SEM. The histogram and error bars represent mean of four values and the standard error 
mean respectively. (***p<0.005, *p<0.05) 
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Metallocene-TAT Bioconjugates  
 
The metallocene-TAT bioconjugates (not labelled with FITC) were tested for their cytotoxic 
effects (Figure 3.3.5). The results are presented as percentage of the control. K-TAT is non 
cytotoxic in all the tested concentrations as compared to the control. FcC(O)-K-TAT and 
CcC(O)-K-TAT are non toxic in 0.1 mM concentration. However, both these compounds are 
toxic when used at 0.5 and 1mM concentrations as indicated by the significant difference 
when compared to the control.  
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Fig. 3.3.5: Hep G2 proliferation rates after treatment with the metallocene-TAT bioconjugates (percentage of the 
control). Data represent +SEM. The histogram and error bars represent mean of four values and the standard 
error mean respectively. (***p<0.005, **p<0.01, *p<0.05) 
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 3.4    Receptor Binding Studies 
The affinity of various neurotensin bioconjugates to NTR1 receptor subtype of the 
neurotensin receptor in human colon adenocarcinoma HT-29 cells was determined. These 
studies were carried out in collaboration with Prof. Dr. P. Bläuenstein by Dr. E. Garcia-
Garayoa at the Centre for Radiopharmaceutical Science, Paul Scherrer Institute, Villingen, 
Switzerland. 
 
99mTc-NT-II [retro-Nα-carboxymethylhistidine-NT(8-13) at a concentration of 2 kBq/ml 
was used as the radiotracer. 99mTc-NT-II was selected since it is based on the sturcture 
NT(8-13) and shows a high affinity for NT receptors (Kd 0.5 nM). The affinity was even 
higher than that obtained for 125I-NT (Kd 1.6 nM).[297] The synthesized NT bioconjugates 
inhibited the binding of 99mTc-NT-II showing typical sigmoid curves (Figure 3.4.1). 
 
 
Figure 3.4.1:  Log-dose competitive inhibition of binding of 99mTc-NT-II by various concentrations of 
different unlabeled NT and pNT bioconjugates. Each point represents the mean ± SD of triplicate 
determinations. (Picture kindly provided by Dr. Garcia-Garayoa) 
 
The results of the inhibition studies yielding the respective IC50 of various neurotensin 
bioconjugates is summarized in table 3.4. The IC50 is the concentration needed to displace 
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 50% of the radiotracer from the receptor. Thus a lower IC50 indicates a better affinity to the 
receptors since a lower concentration is needed to displace the radiotracer from the receptor. 
Higher the IC50 lower is the affinity. An IC50 similar or lower than that of the NT(8-13) is 
the criterion for good affinity for a given compound.  
 
Table 3.4: Binding properties of NT and pNT neurotensin bioconjugates. Data are from 
atleast 3 experiments. 
 
Comp. 
no. 
Sequence Bioconjugate IC50 (nM) 
 RRPYIL NT(8-13) 1.8 + 1.5 
29 KKPYIL pNT 27.5 + 15.1 
30 FcC(O)-KKPYIL FcC(O)-pNT 238.1 + 72.3*† ‡ 
32 Pt-BB-KKPYIL Pt-BB-pNT 148.4 + 19.2*† ‡ 
34 CcC(O)-RRPYIL CcC(O)-NT 2.3 + 0.4 
35 FcC(O)-RRPYIL FcC(O)-NT 21.0 + 18.9 
36 Pt-BB-RRPYIL Pt-BB-NT 6.8 + 2.2 
 
All the experiments were performed using 99mTc-NT-II [NT-II= retro-Nα-carboxymethyl 
histidine-NT(8-13)] as radiotracer (Kd = 0.5 nM). 
* P<0.001 vs NT(8-13), † P<0.001 vs pNT (29), ‡ P<0.001vs. the corresponding metal 
bioconjugate, one-way ANOVA followed by Tukey’s post test.  
 
Replacement of Arg8-Arg9 with Lys-Lys in pNT (29) leads to a decrease in affinity with 
an IC50 approximately 15 times higher than that of the NT(8-13) although it was not 
statistically significant. A notable loss of affinity was observed in the two metal-NT 
bioconjugates, FcC(O)-pNT and Pt-BB-pNT, in which the arginines were replaced with 
lysines. The compounds showed IC50 of 238.1+72.3 and 148.4+19.2 respectively.  
 
The CcC(O)-NT bioconjugate exhibited an IC50 (2.3+0.4 nM) comparable to the native 
NT(8-13) indicating a good affinity for the NTR1 receptors. Whereas, affinity for FcC(O)-
NT is almost 10 times lower. The platinum bioconjugate, Pt-BB-NT, also exhibited an 
improved IC50 (6.8+2.2nM) in case when the unmodified sequence of neurotensin was used.  
The affinity was only 3.5 times lower that the NT(8-13) and around 21 times better than the 
Pt-BB-pNT bioconjugate. 
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 Discussion 
Recently, Peptide and protein-based drugs have rapidly become extensively investigated 
therapeutic agents. The global pharmaceutical industry is now paying great attention to the 
preclinical and clinical development of such drugs. In this regard, a comprehensive 
knowledge of the absorption and distribution properties beyond physicochemical properties, 
including the chemical and metabolic stability at the absorption site, passage through 
biomembranes and active uptake, is essential. Binding phenomenon and receptor-mediated 
cellular uptake are further complicating factors, in addition to generalised elimination and 
proteolysis as well as exsorption and receptor-mediated endocytosis at the cellular level.  
 
Syntheses of the peptide bioconjugates 
Bioorganometallic conjugates of bioactive peptides may lead to novel applications in 
therapy and diagnosis based on the unusual characteristics of the organometallic moieties as 
well as on the natural or modified biological activities of these peptides. Efficient and easy 
synthesis procedures are crucial for the success of such bioconjugates.  
 
The first objective was to successfully synthesize the metal-peptide bioconjugates and to 
optimise the conditions for syntheses. Moreover, the characterization of these bioconjugates 
should be possible with normal routine techniques such as NMR, HPLC and MS. All the 
bioconjugates, presented in this thesis, were synthesized using the modified strategy (e.g. 
using Fmoc instead of Boc protecting groups) of the famous Merrifield synthesis on a solid 
support. The solid support is in the form of inert insoluble resin beads that are functionalised 
with a linker on which the peptide synthesis is carried out. The elegance of method is the 
incorporation of the metal moiety on the solid phase either by covalent bonding or by simple 
complexation. The high yields and purity of the synthesized bioconjugates indicate the 
efficiency of the method even in the case of fluorescence labelling on the solid support. 
Purification of Cobaltocenium monocarboxylic acid 
Cobaltocenium carboxylic acid was synthesized according to a reported method.[299] During 
this reaction, a mixture of mono and dicarboxylic acids of cobaltocenium were obtained. 
After purification as described in the literature, the cobaltocenium monocarboxylic acid was 
always  contaminated  with cobaltocenium  dicarboxylic acid. The first synthesis of 
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 CcC(O)-NLS (1) gave poor yields because of an impurity in the starting material. Therefore, 
for purification the soxhlet’s apparatus was used. The very pure cobaltocenium 
monocarboxylic acid was thus collected in fractions. 
Choice of Fluorescent label 
The objective was to label the metallocene-peptides with a fluorescent marker. This 
objective had to be met within reasonable cost, ease and efficiency of synthesis and 
compatibility with the procedures of synthesis and technical applicability. Fluorescein 
isothiocyanate (FITC) was chosen as the fluorescent marker of choice. The FITC label was 
added to a lysine side chain manually. The synthesis procedures had to be optimised to 
allow this orthogonal substitution of the fluorescent label during the solid phase synthesis. 
Labelling with FITC  
The lysine that was to be labelled with the FITC tag was chosen with an extremely acid 
labile side chain protecting group that could be removed without disturbing the other 
protecting groups. This removal should not cleave the peptide which is also linked to an 
acid labile resin. Therefore, Fmoc-lysine(Mtt)-OH was used since the “Mtt” group 
(methyltrityl group)can be removed with 1% TFA. In the first attempt, the first lysine from 
the C-terminal was chosen for fluorescence labelling at the end of entire synthesis. The 
reaction gave very poor yield of the final bioconjugate. There were two reasons for this 
difficulty of synthesis, firstly the proximity of the target lysine with the resin and secondly 
the steric hindrance of the neighbouring bulky groups which protect the target lysine side 
chain amino group in a kind of pocket. Another simpler strategy was therefore used in 
which a supplementary lysine was added as the carrier of the fluorescent label at the end of 
the desired peptide sequence. The synthesis of various FITC labelled bioconjugates was thus 
achieved with success in very good yields.  
Labelling with metallocenes  
For both cobaltocenium and ferrocene carboxylic acids longer activation times of 10 
minutes were used as compared to the normal activation time of 1 minute for the amino 
acids. This was especially important in the case of cobaltocenium carboxylic acid which 
was used as a PF6 salt. 
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 The sensitivity of ferrocene to oxidative conditions led to problems in the solid phase 
synthesis of ferrocene-peptides when TFA cleavage of the peptide was carried out. 
Ferrocene carboxylic acid itself was rather stable to TFA in concentrations up to 50% for 
several hours. However, ferrocene conjugated to a peptide sequence could not withstand 
even 1 % TFA. To overcome this problem, various strategies were tried namely different 
resins, different side chain protecting groups and different cleavage conditions and 
combinations of these. None of these yielded 100% satisfactory results except for one route 
in which Tentagel HMB resin was used and the final ferrocene-peptide was cleaved from 
the resin with 2% hydrazine giving a ferrocene-peptide hydrazide. Later, upon 
recommendation of Prof. Dr. H.-B. Kraatz, phenol was added in the acid cleavage cocktail 
for ferrocene compounds. The phenol seems to protect the ferrocene from oxidation during 
acid cleavage. Thus all the ferrocene-peptide bioconjugates were successfully synthesized 
with a cleavage mixture containing 85 % TFA, 10 % phenol and 5 % TIS.  
Peptide Sequences 
A problem with Fmoc-Arginine(Pbf)-OH, due to its poor solubility and difficult coupling 
was realised when an arginine was found missing in a couple of peptide sequences as 
indicated by mass spectrometry. Therefore, Fmoc-Arginine(Pbf)-OH was used in 6 eq. and 
prolonged coupling times of 45-50 minutes were used. Another point where care had to be 
taken during the solid phase synthesis of the peptides was the coupling of the amino acid 
following the proline residue which is an imine acid. Longer coupling times were used for 
the amino acid following proline in order to increase the efficiency of synthesis and to 
minimise side products. 
Characterization of the bioconjugates 
The synthesized bioconjugates were comprehensively characterised by nuclear magnetic 
resonance (NMR) spectroscopy, mass spectrometry, reverse phase HPLC and 
electrochemistry. Some of the physicochemical characterizing information of the 
bioconjugates can be used for a preliminary prediction of their behaviour in physiological 
conditions such as stability and solubility in aqueous media, lipophilicity and redox 
behaviour. 
 
Reversed-phase liquid chromatography is one such technique that helps to determine the 
hydrophobic parameters of a given substance.[309] In case of peptides, the hydrophobicity of 
103 
 the component amino acids is a key to the final three dimensional structure and biological 
activity of peptides, proteins and enzymes. The hydrophobicity or lipophilicity can be 
measured from the octanol/water partition co-efficient (Log P) which is one of the best 
predictors for the biological transport properties of peptides.[310-312] Estimation of the Log P 
values for some peptides has been used for the quantitative structure activity prediction or 
for structural parameters.[313, 314]However, the unusual properties of peptides such as the 
conformational flexibility, presence of ionizable species, possibility of multiple 
intramolecular hydrogen bonds, and active transport mechanisms should not be overlooked.  
 
The retention times of various synthesized bioconjugates in RP-HPLC give a simple but 
a rough indication of the lipophilicity of these compounds although a direct correlation with 
the biological behaviour should not be drawn. It is only a cautious reasoning of the 
biological effects observed. The retention times for the fluorescently labelled/unlabelled 
NLS and NLSscr bioconjugates with/without metal are summarised in table 4.1. 
 
Table 4.1: Retention times of various NLS and NLSscr conjugates determined by RP-HPLC. 
Bioconjugate Rt (minutes) Bioconjugate Rt (minutes) 
K-NLS 6.9 K-NLSscr 6.7 
Cc(O)-K-NLS 8.1 CcC(O)-K-NLSscr 7.4 
FcC(O)-K-NLS 9.7 FcC(O)-K-NLSscr 9.1 
K-(FITC)-NLS 10.6 K(FITC)-NLSscr 10.1 
Cc(O)-K(FITC)-NLS 11.2 CcC(O)-K(FITC)-NLSscr 10.7 
FcC(O)-K(FITC)-NLS 12.2 FcC(O)-K(FITC)-NLSscr 12.0 
Pt-BB-NLS 9.4 Pt-DAP-NLS 7.8 
 
 
It is obvious from this table that the ferrocene bioconjugates show higher retention times 
as compared to the cobaltocenium bioconjugates which bears a positive charge. In addition, 
the aromatic structure of the FITC imparts further lipophilicity to the bioconjugates as the 
retention times are higher than as for the unlabelled bioconjugates. The metal and FITC free 
peptides are polar due to the cationic lysine and arginine residues. The metallocenes despite 
imparting lipophilicity to the bioconjugates, do not abolish the solubility of these 
compounds in water or phosphate buffered saline. Moreover, close look at the Pt 
bioconjugates reveal that when the ligand is backbone (BB), an additional -CH2- group 
leads to an increase in the retention time by at least 1.5 minutes as compared with the 
diamiopropionic acid ligand. The same tendency was observed in case of the NLSscr 
bioconjugates. The retention time for the FITC labelled bioconjugates was approximately 3 
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 minutes longer than the unlabelled bioconjugates. The retention times for TAT and the NT 
bioconjugates exhibited a similar trend (see experimental). 
 
The redox potentials of the ferrocene bioconjugates are listed in Table 4.2. Although 
conflicting reports exist in literature about the effects of the redox potential on the activity 
of ferrocene derivatives, it is known that ferrocene is able to sense the slight changes in the 
structure. This is also observed in case of the synthesized bioconjugates. However it is not 
possible to deduce a regular pattern. 
 
Table 4.2: E½ values of various Ferrocene bioconjugates. 
Bioconjugate E½ (mV) FcH vs. FcH+
FcC(O)-NLS 247 
FcC(O)-K-NLS 239 
FcC(O)-K(FITC)-NLS 166 
FcC(O)-NLSscr 252 
FcC(O)-K-NLSscr 279 
FcC(O)-K(FITC)-NLSscr 279 
FcC(O)-K-TAT 199 
FcC(O)-K(FITC)-TAT 237 
 
For the cobaltocenium bioconjugates it is interesting to note that addition of one more 
lysine changed the redox potential by approximately 300mV whereas the side chain 
substitution of FITC had almost no effect on the E½ values. The redox potentials of 
cobaltocenium bioconjugates are summarised in table 4.3.  
 
Table 4.3: E½ values of various Cobaltocenium bioconjugates. 
Bioconjugate E½ (V) FcH vs. FcH+
CcC(O)-NLS -1.08 
CcC(O)-K-NLS -1.38 
CcC(O)-K(FITC)-NLS -1.37 
CcC(O)-NLSscr -1.09 
CcC(O)-K-NLSscr -1.38 
CcC(O)-K(FITC)-NLSscr -1.35 
CcC(O)-K-TAT -1.32 
CcC(O)-K(FITC)-TAT -1.38 
 
It is difficult to draw a parallel between the redox and the biological behaviour of the 
bioconjugates. Further detailed studies might lead to better insight in this phenomenon. 
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 Biological Studies 
Targeted delivery of diagnostic probes and therapeutics intracellularly is of great importance 
for the improvement of disease detection and treatment if one considers that the biological 
target is generally strictly localized, for example DNA in the nucleus. Transport of any 
compound into the nucleus of an intact cell is limited by at least three major membrane 
barriers namely the cell membrane, the endosomal membrane (in case mode of 
internalization is endocytosis) and the nuclear membrane.  
 
The cellular uptake or internalisation of a given substance in intact living cells through the 
cell membrane into the cytoplasm can take place by either passive diffusion i.e. direct 
translocation in an energy-independent manner or via endocytosis. Low molecular weight 
compounds, including many drugs, may enter cells by passive diffusion. However, P-
glycoproteins usually pump them out of the cells before they gain access to the nucleus. In 
case of uptake by endocytosis, the distribution of the substance in the cytoplasm and/or its 
delivery to the nucleus depends on its escape from the endosomes in sufficiently non-
degraded form. The release from the endosomes is a complex process, which partly depends 
on the physicochemical properties of the endocytosed material.[315] 
 
Cellular uptake and nuclear localisation of metallocene-TAT bioconjugates 
Recently the cell penetrating peptides (CPPs) have been extensively investigated for 
delivery of substances across the cell membrane. The cell penetrating peptides are defined 
by their ability to cross the cell membrane and reach cytoplasmic and/or nuclear 
compartments after internalisation. These include large peptides and even proteins that can 
translocate through the plasma membrane as part of a physiological process. Among these 
CPPs, TAT peptide is the earliest discovered peptide. TAT translocates freely across the cell 
membrane. The shortest sequence capable of translocation is TAT(48-57). When carrying a 
cargo the translocation across the cell membrane and cellular distribution of the TAT 
peptide is highly dependent on the cargo. TAT peptide is internalised by endocytosis[316] and 
in many cases the inability to escape from the endosomes is observed. Moreover slight 
changes in the peptide sequence or charge result in impairment of the translocation across 
the cell membrane.[317] In a recent study, TAT was shown to effect only cytosolic delivery 
and no nuclear localisation was observed.[317] In addition, it was noted that the cationic 
charge of the peptide is not the only factor mediating cellular uptake. The distribution of the 
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 cationic charges more amphipathically or addition of hydrophobic moieties can enhance 
membrane crossing. TAT peptide is characterised by low cargo efficiency as compared with 
other CPPs. However the advantage is that it posses less membrane permeablising 
effects.[318]  
 
The cellular uptake and nuclear localisation of metallocene-TAT bioconjugates was 
monitored by fluorescence microscopy in live Hep G2 cells. The Hep G2 cells have 
relatively large nuclei, but membrane translocation in this cell line is known to be rather 
difficult.  
 
We observed that the control bioconjugate, K(FITC)-TAT (0.1mM) was not internalised 
by the Hep G2 cells. Similarly, the cobaltocenium-TAT bioconjugate (0.1mM) was also 
unable to translocate across the cell membrane. It is suggested that a small cargo in the form 
of a fluorescence-labelled lysine bound to the TAT peptide, which results in membrane 
translocation impairment. The addition of a lipophilic group in the form of cobaltocenium 
also did not improve the transport across the membrane. This is most likely due to the 
positive charge on the cobaltocenium moiety, which may be indicated by our finding that 
the neutral ferrocene bioconjugate of TAT (0.1mM) was localised in the cytoplasm.  
 
A          B          C   
Fig. 4.1: Cellular distribution of K(FITC)-TAT (A), CcC(O)-K(FITC)-TAT (B) and FcC(O)-K(FITC)-TAT 
 
The uptake most probably takes place by endocytosis as seen by some co-localisation 
with the endosomal marker (FM 4-64). This bioconjugate was not totally trapped in the 
endosomes, but was found to be distributed in the cytoplasm. The ferrocene moiety 
facilitates the escape of the bioconjugate from the endosomes and results in the cytoplasmic 
distribution of the bioconjugate. This is a very interesting observation because escape from 
the endosomes is considered to be one of the major limiting factors for the use of TAT 
peptide for cellular delivery.[317]  
 
107 
 Moreover, the parallel control experiments with metallocene-TAT bioconjugates with 
fixation of the cells with paraformadehyde resulted in artificial redistribution of the 
K(FITC)-TAT and CcC(O)-K(FITC)-TAT bioconjugates in the cytoplasm. This is probably 
due to the cell permeablising effects of the bioconjugates. Some of the CPPs have shown to 
be cytotoxic in higher concentrations and indicate complex mechanisms of entry which 
involves pathways such as direct translocation by inducing pores in the membrane or 
through miscelle formation, in addition to endocytosis.[203] For this reason, the metallocene-
TAT bioconjugates were tested for their effects on the proliferation of Hep G2 cells and will 
will be discussed later in the cytotoxicity part. 
 
Cellular uptake and nuclear localisation of metallocene conjugates of NLS and NLSscr
The transport in and out of the nucleus is a highly controlled process. Endogenously, the 
nuclear localisation or export signals are responsible for most of this trafficking. The 
transport across the nuclear membrane is mediated through the nuclear pore complexes 
(NPC) that form kind of aqueous channels,[231] although the docking of any substance along 
the pore depends on hydrophobic interactions with the NPC amino acid residues. Generally, 
small molecules, up to 30 kDa, can diffuse through the NPC in an energy-independent 
manner,[319] while larger molecules gain entry by active transport with carrier peptides such 
as the nuclear localisation signals (NLS). However, the actual passage of a substance, small 
or large is not random and it greatly depends on the physicochemical properties of that 
substance such as the net charge, lipophilicity, the orientation and the possibility for 
hydrogen bonding. As such, some small molecules like the histones are actively 
transported,[320] whereas some larger proteins can diffuse through the pores. Similarly, in the 
case of large proteins, some are more efficiently transported than others.[236] Moreover, the 
transport into the nuclei is also dependent on the permeability of the nuclear pore complexes 
at a given stage in cell cycle as well as the ratio of these pore complexes available for 
entry.[240]  
 
A part of the present research focuses mainly on the metallocene-NLS conjugates. The 
SV 40 T antigen nuclear localisation signal was chosen to effect nuclear delivery. The NLS 
transports the cargo into the nucleus through the nuclear pore complexes.[234] However, 
inefficient entry into the cells[321] or inability to escape endosomes[252] has been reported.  
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 Furthermore, to determine the role of the NLS peptide, upon cellular uptake and nuclear 
localisation the scrambled sequence of the NLS (KKVKPKR) was used. This sequence was 
reported by Cutrona et al.[322] and was shown to be unable to target the nuclei of the cells. It 
was reported that the nuclear localisation function of the NLS is essentially dependent on 
the presence of Lys 128.[308, 323] 
 
Incorportion of the metallocene moiety was devised to impart the necessary lipophilicity 
to the NLS for crossing the cell membrane via direct translocation through the lipid bilayer. 
Both ferrocene and cobaltocenium were used as metal labels, because they resemble in size 
and other properties with the exception of one positive charge on the cobaltocenium. 
Another reason for choosing cobaltocenium was the fact that ferrocenes are reported to be 
cytotoxic and therefore the isostructural cobaltocenium that is non toxic might serve as a 
model to monitor the uptake. Both ferrocene and cobaltocenium bioconjugates were tested 
for their effects on proliferation of Hep G2 cells and the results are discussed later in the 
cytotoxicity part. The metallocene conjugates of the truncated peptides as well as the metal 
free NLS sequence were used as controls. Once distributed in the cytoplasm, the NLS in 
principle should carry the metallocene as well as the FITC marker into the nucleus. The 
fluorescence label should enable the tracking of the bioconjugate in various cellular 
compartments. 
 
The internalisation of metallocene-NLS conjugates and their nuclear localization was 
monitored by fluorescence microscopy in live Hep G2 cells. Throughout the live cell study, 
the integrity of the cell membrane was checked by the ability of the cells to exclude 
propidium iodide. Recent investigations on other cationic peptides like Arg-rich or Tat 
sequences demonstrate that fixation of the cells causes artificial redistributaion of those 
peptides in the cytoplasm and in the nucleus, leading to false-positive results.[226] Therefore, 
live cell microscopic imaging was used to follow the cellular uptake and nuclear localisation 
of the bioconjugates. However, parallel experiments with fixation of cells were also carried 
out to determine whether the SV 40 NLS also gives these artifactual results upon fixation. 
 
The metallocene-NLS bioconjugates were efficiently taken up by the cells and were also 
translocated in the nuclei of Hep G2 cells. A concentration-dependent uptake was observed 
as lessuptake was observed with lower concentrations of the bioconjugates. Co-staining 
with the endosomal marker, FM 4-64, was carried out to get an insight into the mode of 
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 internalisation of these bioconjugates. In case of the cobaltocenium-NLS bioconjugate some 
co-localisation with the endosomal marker was observed but not extensively. The same 
observation was made in case of the ferrocenium-NLS bioconjugate. It is suggested that, to 
some extent, the bioconjugates entered the cells in an endocytosis-independent pathway. 
There is also the possibility that the uptake is via endocytosis but the endosomes were 
permeable and the bioconjugates rapidly escaped from the endosomes and were 
homogenously distributed in the cytoplasm or accumulated in the nuclei. Although 
conflicting reports exist concerning the internalisation of NLS conjugates, the majority of 
studies indicate an uptake by endocytosis. However, the possibility of an additional 
endocytosis-independent pathway has not been ruled out.  
 
A    B    C    D  
Fig.4.2: Cellular distribution and nuclear localisation of CcC(O)-K(FITC)-NLS (A), FcC(O)-K(FITC)-NLS  
              (B) K(FITC)-NLS (C) and CcC(O)-K(FITC)-NLSscr
 
Experiments with control compounds show that the ease of cellular uptake is a property 
that is particular to the presence of the metallocene moiety in the NLS conjugates. The 
fluorescently labelled NLS alone was unable to enter the cells. Due to its highly cationic 
composition, it has tendency to clump and adhere to the cell membrane as was observed in 
fluorescence microscopy. Similarly in case of the metallocene-dipeptides, no significant 
cellular uptake was observed and no nuclear localisation at all. Although small amounts 
may have entered the cells by passive diffusion but not in sufficient amounts to accumulate 
in the cytoplasm or to gain access to the nuclei. In addition, it might be efficiently 
eliminated from the cells by exsorption or P-glycoproteins.  
 
Ferrocene and cobaltocenium conjugates of NLSscr sequence, both labelled with FITC 
were studied along with a metal free, FITC labelled scrambled peptide. These conjugates 
not only did not gain entry into the nuclei but also were unable to enter the intact cells. 
These compounds had the tendency to clump together and adhere on the outer cell surface, 
which can be seen as bright fluorescence outside the cells.  
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 These results suggest the correct peptide sequence is essential for the internalisation of 
these compounds and for nuclear distribution as well. In addition, the unique combination of 
metallocene and NLS seems necessary for the effects observed. The metal moiety is 
suggested to help the NLS to gain entry into the cells and the NLS is then responsible for 
shuttling into the nuclei. This seems plausible, as attempts have already been made to 
combine hydrophobic such as the fusion peptide of GP41 and NLS sequence in order to gain 
entry into the cells, escape the endosomes and to target the nucleus.[249] The positively 
charged cationic peptides interact with the anionic cell membrane and adhere very tightly to 
the surface. A hydrophobic handle would facilitate the anchoring and internalisation of the 
carrier. For the metallocene-NLS bioconjugates, it may be concluded that the metallocene 
moiety plays a role in the cellular uptake although the charge does not lead to any drastic 
consequences upon the uptake. This is contrast to the TAT bioconjugates where the 
positively charged cobaltocenium was not internalised in the cells. This shows that in case 
of TAT peptide changes in charge have an impact on the membrane translocation properties 
of this peptide. 
 
The successful synthesis of the first metallocene conjugates to the SV 40 nuclear 
localization signal peptide was accomplished by SPPS. The metallocene moiety is highly 
stable under physiological conditions making it ideally suitable for the study of 
bioconjugates in cell culture media. The metallocene-NLS conjugates significantly 
accumulate in the nuclei of Hep G2 cells. Moreover, the organometallic moiety is essential 
for the uptake of the conjugates and release of the conjugate into the cytoplasm. It is known 
that, NLS-assisted nuclear delivery is only possible from the cytoplasm. Therefore, the 
escape of the compound from the endosomes is essential for subsequent translocation of any 
NLS bioconjugate into the nucleus. Metal-enhanced cellular uptake and peptide-mediated 
nuclear delivery is demonstrated herein for an organometallic species. A hydrophobic 
moiety seems to plays an important role in improving the uptake of the hydrophilic carrier 
peptide NLS. It is potentially highly useful because the metallocene moiety is relatively 
small, robust and easy to handle. The cyclopentadienyl rings of metallocenes although 
imparting enough lipophilicity, do not interfere in the biological functioning of the nuclear 
localisation signal.  
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 Cytotoxicity studies 
Over the years much debate has been going on the antitumour activity of ferrocene 
derivatives but the site or mechanism of action still remains an ambiguity. The cytotoxicity 
of metallocenes such as ferrocene have been postulated to be due to its direct or indirect 
interactions with the DNA. Although many studies have been undertaken to determine the 
subcellular and subnuclear target as well as the mechanism of action of these metallocene 
derivatives, no attempt so far has been made to monitor the cellular uptake and nuclear entry 
of these compounds. On the other hand, the metallocene dihalides have been extensively 
studied and recently the subcellular distribution of some metallocene dihalides has been 
reported.[324] By using the fluorescently labelled conjugates enhanced cellular uptake and 
nuclear localisation was observed. Once selectively delivered into the nuclei of live cells, 
the next question is: are these metallocene bioconjugates toxic? If DNA damage (direct or 
by OH. radical generation) is the mechanism of cytotoxicity of the metallocenes, then it 
should be enhanced by direct delivery into the nucleus of a cell.  
 
Therefore, the metallocene-NLS bioconjugates (not labelled with FITC) were screened in 
a WST-1 assay for cytotoxicity. This assay depends on the measurements of absorbance of 
the soluble formazan dye that is generated by the cleavage of the tetrazolium salt (WST-1) 
by mitochondrial dehydrogenase in metabolically active cells. In case of K-NLS, CcC(O)-
K-NLS and FcC(O)-K-NLS in all the tested concentrations (0.1, 0.5 and 1mM) no 
statistically significant difference was observed in the proliferation rate of the Hep G2 cells, 
as compared with the control. Similarly, in case of K-NLSscr and FcC(O)-K-NLSscr no 
statistically significant difference was found with respect to the control in all tested 
concentrations. However, in case of CcC(O)-K-NLSscr a slightly significant difference was 
found in comparison with control in concentrations of 0.5 and 1mM, indicating a 
stimulatory effect of this compound on the proliferation of the Hep G2 cells. This is not 
extraordinary since an early report by Motohashi with Ferronece mustards also 
demonstrated an increase in tumour growth by some of the compounds.[117]  
 
None of the compounds were found to be cytotoxic in the tested concentrations. It may 
be concluded that the neutral ferrocene bioconjugate (FeII) or the cationic cobaltocenium 
bioconjugate are non toxic even when they are localised in the nuclei. Some reports have 
established the lack of activity for ferrocene derivatives.[115-118] Recently, it has been 
suggested that only the ferrocenium cation is responsible for reacting with dioxygen leading 
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 to generation of OH. radicals, which are in turn responsible for the antitumour activity of 
ferrocenium derivatives. This phenomenon is suggested to occur extracellularly and the 
cytotoxic effects observed are a result of attack of radicals on the cell membrane lipids.  
 
The metallocene-TAT bioconjugtes were tested for cytotoxicity in the WST-1 assay for 
cell viability. It was observed that both the metallocene-TAT bioconjugates are cytotoxic in 
concentrations higher than 100µM. It was observed that the combination of metallocene and 
TAT peptides have the antiproliferative effects since the peptide alone is not toxic even in 
high concentrations. The uptake detected at higher concentration is ascribed to membrane 
perturbation and the toxic effects of the labelled peptides. [325] It is possible that addition of 
one more positive charge in case of the K-TAT results in unfavourable parameters that 
abolish the membrane interactions of the peptide prior to its translocation into the cell. The 
other problem is extensive clumping of this peptide which definitely results in less 
availability for uptake. It is also very likely that the toxic effects of the metallocene-TAT 
bioconjugates are due to disruption of the cellular membrane since almost the same toxic 
effects are observed in both cases of ferrocene and cobaltocenium conjugates. The former is 
translocated inside the cells and the later not. Therefore, an intercellular mechanism of 
toxicity cannot be suggested. The observed cytotoxicity may also be due to the production 
of membrane impermeable degradation products of the metallocene-TAT bioconjugates. It 
has been shown that a large portion of the internalized CPP is degraded. This mechanism is 
not likely to be an endosomal degradation of material taken up through classical 
endocytosis, as it is not sensitive to cholorquine, brefeldin-A or potassium depletion and can 
be competitively inhibited.[318]  
 
A tremendous amount of research had been carried out and is still going on in the field of 
platinum analogues for their antitumour activity. One of the major limitations with platinum 
anticancer drugs is the inherent or acquired resistance of cancer cells, among many others. 
The major site of action of platinum compounds is DNA. In other words the target of 
platinum compounds is the nucleus. Therefore, a carrier like NLS that selectively carries the 
platinum analogue into the nucleus will most likely enhance the cytotoxicity of these 
compounds. Thus, in the series of metal-NLS bioconjugates, the platinum(II) complexes of 
the SV40 nuclear localisation signal were also synthesized on the solid phase. The solid 
phase synthesis of platinum analogues of small peptides and their cytotoxicity has been 
reported.[192, 193] These compounds did not show an improved cytotoxicity as compared with 
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 cisplatin most probably because they are unable to reach their nuclear target that is the 
DNA. 
 
The bioconjugates were stable in aqueous media so that the toxicity tests in culture media 
could be carried out. However, the bioconjugates were dissolved just prior to the tests. The 
WST-1 assay was carried out to determine the antiproliferative effects of the platinum-NLS 
bioconjugates. Both conjugates have a cytotoxic effect in concentrations higher than 0.1µM. 
It may be noted here that for proper functioning of the NLS, it has to be located in the 
cytoplasm. As remarked earlier, NLS does not translocate very easily through the cell 
membrane. Therefore, the true potential of the antitumour activity of platinum compounds 
can not be estimated. It may be possible that the observed effect is due to slow diffusion of 
the bioconjugates into the cells. It seems necessary to facilitate the cellular uptake of the 
bioconjugates with external means like digitonin or with the help of some carrier. Once 
inside the cell, it would then be possible to determine the true cytotoxicity potential of the 
Pt-NLS bioconjugates. It is expected that in case of resistant cell lines, despite the 
sequestration of platinum in the lysosomal vesicles, the NLS will result in enhanced nuclear 
delivery of the platinum where it can bind with the DNA.  
 
Moreover, the Pt-NLS bioconjugates were tested in the yeast assay for cytotoxicity and 
genotoxicity (data not shown in this thesis, work done in collaboration). Both Pt-NLS 
bioconjugates were cytotoxic in both yeast strains.  
 
Receptor binding studies on metallocene bioconjugates of NT and pNT 
The metallocene moieties can impart lipophilicity to the peptides they are attached to 
without extensively compromising their biological function. This lipophilicity may in turn 
enable the peptide to cross various biological membranes such as the blood brain barrier. 
The blood brain barrier presents a major limitation in the therapeutic application of 
compounds intended for a central effect such as pain management and various neurological 
pathologies. Certain small regulatory peptides such as the neurotensin play important 
functions in the central nervous system as well as in the periphery. In certain diseases like 
cancer where the neurotensin receptors are overepressed, it can indirectly induce 
proliferation. Active research is going on to exploit the various biological activities of 
neurotensin for therapeutic purposes. In addition the neurotensin receptors that are 
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 specifically overexpressed in certain cancers might also be exploited for tumour detection 
by radio-imaging as well as for the selective delivery of anticancer agents to tumour 
sites.[289-291]  
During the course of present research the metal conjugates of neurotensin were 
synthesised and tested for their binding efficiency to the NTR1 receptors in an 
adenocarcinoma cell line. In addition to the wild type NT sequence (RRPWIL) another 
slightly modified sequence, the pseudo neurotensin in which the arginines were replaced by 
lysines, were also synthesized and tested. The metal-free peptides were also tested for their 
affinity to the receptors in order to determine the effect of the amino acid residue mutation.  
 
Replacement of Arg8-Arg9 with Lys-Lys in pseudo neurotensin resulted in a decrease in 
the affinity with an IC50 approximately 15 times higher than the wild type NT(8-13) 
sequence. This decrease was, however, not statistically significant. The cobaltocenium 
bioconjugate of NT showed almost comparable affinity to the receptors, while in case of the 
platinum bioconjugate there was only a slight effect on the affinity. However, in case of the 
ferrocene bioconjugate the affinity was 12 times lower compared with the wild type NT(8-
13) but this decrease was not statistically significant. The pseudo neurotensin bioconjugates 
all showed statistically significant drop in the affinities as compared to the two metal-free 
peptides as well as the respective metal-NT bioconjugates. This is understandable because 
the guanidino groups of arginines are involved in specific interactions with the receptors. 
The metals were placed at the N-terminal since a free N-terminal is not a prerequisite for 
binding whereas a free C-terminal is important. 
 
The comparative binding of some of these bioconjugates like the cobaltocenium-NT 
bioconjugate shows that further exploitation such as determination of the agonist or 
antagonistic effects of these bioconjugates at the NTR1 receptors could be imagined. 
Moreover, the metallocene bioconjugates especially the cobaltocenium-NT bioconjugate 
may facilitate the crossing of the blood brain barrier (BBB) membranes while retaining the 
binding affinity. One major limitation for NT analogues is their inability to cross the 
BBB[264] in therapy as antipsychotics and analgesics. Lastly, cytotoxic metals derivatives 
such as the platinum can be specifically delivered to the tumour tissues that overexpress NT 
receptors ensuring selectivity. The bioconjugates were also tested for their cytotoxic effects 
in a yeast assay (data not shown in this thesis, work done in collaboration). 
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 Conclusion 
A multitude of challenges is associated with satisfactory cellular uptake and nuclear 
targeting. Practically all macromolecules and small molecules whose physicochemical 
properties do not allow passive diffusion are impermeable to cell membrane. Application of 
peptide vectors capable of transporting such molecules into the cells or even into the 
nucleus in the form of covalent conjugates is proving to be a useful way to circumvent this 
problem. 
 
During the course of the present research, various metal bioconjugates of bioactive 
peptides namely NLS, TAT and NT were successfully synthesized by solid phase peptide 
synthesis. All the bioconjugates were comprehensively characterised. This is the first 
reported SPP Synthesis of metallocene-NLS, -TAT and -NT bioconjugates. 
 
The metallocene-NLS bioconjugates show enhanced cellular uptake and nuclear 
localisation. This seems to be a property conferred only due to the presence of the 
metallocene moiety. The bioconjugates did not inhibit proliferation of Hep G2 cells even in 
high concentration. The results indicate a good potential for these compounds to be used as 
vectors for directed nuclear delivery.  
 
The results with the TAT peptide conjugates indicate that the ferrocene moiety facilitates 
endosomal escape of the conjugate. Whereas positively charged cobaltocenium-TAT 
bioconjugate is not translocated into the cells. Toxicity of these bioconjugates is observed at 
higher concentrations as indicated by the inhibition of proliferation of Hep G2 cells. The 
study may impart a further understanding of the behaviour of TAT peptide in cell membrane 
translocation. 
 
The metal conjugates of NT may be used to facilitate the crossing of the BBB and in the 
case of toxic metals may be used for selectively targeting the tumours that overexpress the 
neurotensin receptors. 
 
Based on these results an insight into the biological behaviour of bioorganometallic 
peptide conjugates has been gained. The metal conjugates show a potential for the 
improvement of cellular uptake of the carrier peptides. They may as well be further 
investigated for the selective delivery to targets as in case of NT conjugates. 
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1) Cellular distribution of compound 11 at a concentration of 0.1mM, CY2 & CY3 
filters, green and red fluorescence, merged image. 
2) Cellular distribution of compound 11 at a concentration of 0.1mM, CY2, CY3 and 
UV filters; green, red and blue fluorescence, merged image. 
3) Cellular distribution of compound 11 at a concentration of 0.1mM, CY3 & UV 
filters; red and blue fluorescence, merged image. 
4) Cellular distribution of compound 13 at a concentration of 0.1mM, CY2 filter, green 
fluorescence. 
5) Cellular distribution of compound 13 at a concentration of 0.1mM, CY2 & CY3 
filter, green and red fluorescence, merged image. 
6) Cellular distribution of compound 13 at a concentration of 0.1mM, CY3 filter, red 
fluorescence. 
7) Cellular distribution of compound 18 at a concentration of 0.1mM, CY2 & CY3 
filters, green and red fluorescence, merged image. 
8) Cellular distribution of compound 18 at a concentration of 0.1mM, CY2, CY3 and 
UV filters; green, red and blue fluorescence, merged image. 
9) Cellular distribution of compound 18 at a concentration of 0.1mM, CY3 & UV 
filters; red and blue fluorescence, merged image. 
10) Cellular distribution of compound 21 at a concentration of 0.1mM, CY2 & DAPI 
filters, green and blue fluorescence, merged image. 
11) Cellular distribution of compound 21 at a concentration of 0.1mM, CY2, CY3 and 
UV filters; green, red and blue fluorescence, merged image. 
12) Cellular distribution of compound 21 at a concentration of 0.1mM, CY3 & UV 
filters; red and blue fluorescence, merged image. 
13) Cellular distribution of compound 22 at a concentration of 0.1mM, CY2 & CY3 
filters, green and red fluorescence, merged image. 
14) Cellular distribution of compound 22 at a concentration of 0.1mM, CY2, CY3 and 
UV filters; green, red and blue fluorescence, merged image. 
15) Cellular distribution of compound 22 at a concentration of 0.1mM, CY3 & UV 
filters; red and blue fluorescence, merged image. 
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16) Cellular distribution of compound 24 at a concentration of 50µM, CY2 & CY3 
filters, green and red fluorescence, merged image. 
17) Cellular distribution of compound 24 at a concentration of 50µM, CY2, CY3 and 
UV filters; green, red and blue fluorescence, merged image. 
18) Cellular distribution of compound 24 at a concentration of 50µM, CY3 & UV filters; 
red and blue fluorescence, merged image. 
19) Cellular distribution of compound 27 at a concentration of 50µM, CY2 & CY3 
filters, green and red fluorescence, merged image. 
20) Cellular distribution of compound 27 at a concentration of 50µM, CY2, CY3 and 
UV filters; green, red and blue fluorescence, merged image. 
21) Cellular distribution of compound 27 at a concentration of 50µM, CY3 & UV filters; 
red and blue fluorescence, merged image. 
22) Cellular distribution of compound 28 at a concentration of 50µM, CY2 & CY3 
filters, green and red fluorescence, merged image. 
23) Cellular distribution of compound 28 at a concentration of 50µM, CY2, CY3 and 
UV filters; green, red and blue fluorescence, merged image. 
24) Cellular distribution of compound 28 at a concentration of 50µM, CY3 & UV filters; 
red and blue fluorescence, merged image. 
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 List of synthesized bioconjugates 
 
Comp. No. Abbreviation Sequence 
1 CcC(O)-NLS CcC(O)-PKKKRKV 
2 FcC(O)-NLS FcC(O)-KPKKKRKV 
3 CcC(O)-NLSmca CcC(O)-PKKKRKmcaV 
4 Pt-BB-NLS Pt-BB-PKKKRKV 
5 Pt-DAP-NLS Pt-BB-PKKKRKV 
6 K-NLS KPKKKRKV 
7 K(FITC)-NLS K(FITC)-PKKKRKV 
8 CcC(O)-K-NLS CcC(O)-KPKKKRKV 
9 FcC(O)-K-NLS FcC(O)-KPKKKRKV 
10 CcC(O)-K(FITC)-NLS CcC(O)-K(FITC)-PKKKRKV 
11 FcC(O)-K(FITC)-NLS FcC(O)-K(FITC)-PKKKRKV 
12 CcC(O)-K(FITC)-V CcC(O)-K(FITC)-V 
13 FcC(O)-K(FITC)-V FcC(O)-K(FITC)-V 
14 NLSsrc KKVKPKR 
15 CcC(O)-NLSsrc CcC(O)-KKVKPKR 
16 FcC(O)-NLSsrc FcC(O)-KKVKPKR 
17 K-NLSsrc KKKVKPKR 
18 K(FITC)-NLSsrc K(FITC)-KKVKPKR 
19 CcC(O)-K-NLSsrc CcC(O)-KKKVKPKR 
20 FcC(O)-K-NLSsrc FcC(O)-KKKVKPKR 
21 CcC(O)-K (FITC)-NLSsrc CcC(O)-K(FITC)-KKVKPKR 
22 FcC(O)-K(FITC)-NLSsrc FcC(O)-K(FITC)-KKVKPKR 
23 K-TAT KGRKKRRQRRR 
24 K(FITC)-TAT K(FITC)-GRKKRRQRRR 
25 CcC(O)-K-TAT CcC(O)-KGRKKRRQRRR 
26 FcC(O)-K-TAT FcC(O)-KGRKKRRQRRR 
27 CcC(O)-K(FITC)-TAT CcC(O)-K(FITC)-GRKKRRQRRR 
28 FcC(O)-K(FITC)-TAT FcC(O)-K(FITC)-GRKKRRQRRR 
29 pNT KKPYIL 
30 FcC(O)-pNT FcC(O)-KKPYIL 
31 CcC(O)-pNT CcC(O)-KKPYIL 
32 Pt-BB-pNT Pt-BB-KKPYIL 
33 NT RRPYIL 
34 CcC(O)-NT CcC(O)-RRPYIL 
35 FcC(O)-NT FcC(O)-RRPYIL 
36 Pt-BB-NT Pt-BB-RRPYIL 
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